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1 INTRODUCTION 
1.1 Atherosclerosis – a chronic inflammatory disease 
Atherosclerosis, previously considered merely a lipid deposit-driven narrowing of the 
vessel lumen, is nowadays appreciated as a chronic inflammatory disease of the 
arterial wall. The main clinical manifestations of atherosclerosis include coronary artery 
disease, stroke, and peripheral arterial disease which still represent the leading cause 
of death in Europe and North America.1  
During the development of atherosclerosis, plaque progression and vascular 
dysfunction are influenced and promoted by the immune system.2 Atherosclerotic 
lesions preferentially develop at sites of disturbed blood flow where the endothelium is 
locally activated. As lipoproteins and lipids in the vessel wall accumulate to a degree 
exceeding the capacity of clearance they are retained in the extracellular matrix of the 
vessel thereby activating endothelial cells (EC) (Figure 1 A).3 Upon activation EC 
express leukocyte adhesion molecules such as intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) which will lead to the 
adherence of circulating leukocytes.4 Subsequently, the adherent leukocytes respond 
to attractant stimuli, such as chemokines produced by the inflamed intima, and 
transmigrate across the endothelium along a chemokine gradient into the sub-
endothelial space further perpetuating lesional inflammation (Figure 1 B). Among those 
leukocytes are neutrophils, T cells, B cells, monocytes, and natural killer (NK) cells. 
Chronic hyperlipidemia and local inflammation contribute to enhanced endothelial 
dysfunction resulting in the infiltration and retention of lipoprotein particles in the 
nascent plaque.5 Retained lipoprotein particles such as low-density lipoprotein (LDL) 
might undergo chemical modification. Presumably, LDL particles are oxidized by anti-
microbial products of macrophages, such as reactive oxygen species (ROS), released 
into the developing atherosclerotic plaque. Excessive uptake of modified and natural 
lipid particles by macrophages leads to their cytosolic accumulation as droplets 
transforming the macrophage into foam cells, termed according to their morphologic 
appearance. Foam cells will undergo apoptosis, necroptosis, and necrosis due to the 
massive cholesterol scavenging forming the necrotic core of the plaque. The necrotic 
core and the uncontrolled release of inflammatory mediators from dying macrophages 
will attract further immune cells, thus perpetuating inflammation (Figure 1 C). Lesional 
macrophages derive from circulating monocytes and represent an elaborate source of 
pro-inflammatory mediators such as cytokines. This inflammatory response is further 
fueled by cell death of chronically overwhelmed macrophages further recruiting more 
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immune cells including monocytes and lymphocytes to the plaque.6, 7 Immune cells 
within the atherosclerotic lesion will release further cytokines which reduce smooth 
muscle cell (SMC) survival and proliferation.8  
 
 
Figure1. Evolution of atherosclerosis. 
(A) EC dysfunction and activation under pro-inflammatory conditions of hyperlipidemia leads to early 
platelet and leukocyte adhesion and increased permeability of the endothelium. (B) Monocytes that are 
recruited to the intima and subintima accumulate lipids and transform into macrophages or foam cells, 
which form fatty streaks. Continued mononuclear-cell influx, deposition of matrix components and 
recruitment of SMC give rise to the fibroproliferative progression of the plaques. (C) Apoptosis of 
macrophages and other plaque cells creates a necrotic core covered by a fibrous cap consisting of matrix 
and a SMC layer. Neovascularization can occur within the plaque and from the adventitia, and leakage of 
fragile vessels can lead to plaque hemorrhage. (D) Thinning and erosion of the fibrous cap in unstable 
plaques, for example, owing to matrix degradation by proteases, may ultimately result in plaque rupture, 
with release of debris, activation of the coagulation system and plaque thrombosis of the artery. This leads 
to arterial occlusion and myocardial infarction or stroke. Modified from: Weber, C., Zernecke A., and Libby 
P.
9
 
 
Thus, the abundance of SMCs and their capacity to produce collagen will be reduced in 
this pro-inflammatory environment. Furthermore, the release of proteases degrades 
matrix proteins such as collagen fibers contributing to the thinning of the fibrous cap. 
The fibrous cap is a layer of fibrous connective tissue and containing collagen, elastin, 
SMC, EC, and immune cells which protects contact of circulating platelets with plaque-
resident, pro-thrombotic material. During advanced atherosclerosis neovascularization 
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might occur promoting plaque hemorrhage by the leakage of fragile vessels thus 
contributing to the destabilization of the atherosclerotic lesion. Ultimately, the rupture of 
the destabilized plaque will be provoked leading to a release of highly-coagulant 
substances into the blood stream causing rapid thrombus formation and its life-
threatening clinical manifestations, namely myocardial infarction and stroke (Figure 1 
D).10  
1.2 The role of T cells in atherosclerosis 
Although monocytes/macrophages are the most abundant immune cells in the plaque, 
several studies have proven a pivotal role for T cells in the pathogenesis of 
atherosclerosis.11 Mice deficient for the recombinase activating gene 2 (RAG-2) do not 
harbor any T- and B cells as the gene re-arrangement of immunoglobuline (Ig)- and T 
cell receptor (TCR) depends on RAG-2. Atherosclerosis prone Rag2-/- mice display 
reduced atherosclerosis only under mildly elevated hypercholesterolemia.12, 13 If 
hypercholesterolemia is exaggerated by administration of a cholesterol-enriched, 
western-type diet, the innate immune system overrides effects caused by adaptive 
immune cells. 
Cluster of differentiation (CD) 4+ T cells are the predominant T cell subset in 
atherosclerotic lesions of Apolipoprotein E-deficient (Apoe-/-) mice and accelerate 
atherosclerosis as demonstrated by reconstitution of lymphocyte-deficient scid mice 
with CD4+ T cells.14, 15 However, subsets of CD4+ T cells contribute differently to 
atherosclerosis which will be discussed in detail below. 
CD8+ T cells have a controversial role in atherogenesis. In comparison to Apoe-/- mice, 
Apoe-/-Cd8-/- mice exhibit no alteration in lesion formation.16 However, antibody-
mediated depletion of CD8+ T cells in LDL receptor-deficient (Ldlr-/-) mice ameliorated 
atherosclerosis by the reduction of circulating Ly6Chi monocytes, which are considered 
to be main driving forces of atherogenesis.17 Furthermore, CD8+ T cells seem to 
contribute to vulnerable plaque formation by inducing apoptosis of lesional 
macrophages, SMC, and EC via their cytotoxic products, perforin and granzyme B 
when adoptively transferred into lymphopenic Apoe-/- mice.18 However, adoptive 
transfer of CD8+CD25+ T cells, a CD8+ subset that is considered anti-inflammatory and 
exerting suppressive effects, decreased atherosclerotic burden in Apoe-/- mice.19 In 
general, CD8+ T cells are considered pro-atherogenic, but their contribution to 
atherogenesis seems to depend on timing and the subset. 
Although T cell activation accelerates early progression of atherosclerosis, it is not 
required for its initiation, as shown using conditional ablation of dividing T cells in Apoe-
/- mice.20 Expression analysis of TCR from atherosclerotic lesions and spectratyping of 
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fragment lengths revealed a restricted heterogeneity of TCR variation in the 
atherosclerotic plaque suggesting an accumulation of oligo-clonal T cells.21 This 
strongly indicates the recognition of antigen via specific TCR. Antigen-presenting cells 
(APC) including B cells, dendritic cells (DC) and macrophages express major 
histocompatibility complex (MHC) II on their surface displaying antigen to CD4+ T cells, 
typically in secondary lymphoid organs. Recognition of cognate antigen by CD4+ T cells 
results in their activation und subsequent mode of action. Of note, in human 
atherosclerotic lesions APCs were shown to express MHCII-complexes, especially the 
variant HLA-DR, indicating a constant activation of T cells in atherosclerotic lesions.22 
However, atherosclerosis relevant antigens are largely unknown although current 
research aims to identify such antigens. Recent evidence suggests peptide moieties of 
apolipoprotein B (ApoB)-100 as major atherosclerosis-specific antigens.23 Additional 
candidate antigens contributing to an adaptive atherosclerosis-specific immune 
response are heat shock protein (HSP) 60 and HSP65.24 
As discussed above, CD4+ T cells come in different flavors and each subset 
contributes differently to atherosclerosis. Naïve CD4+ T cells are undergoing 
differentiation during their activation and each subset classically bears a hallmark 
transcription marker specific for their lineage. However, there is increasing evidence, 
also in atherosclerosis, that committed and lineage-restricted CD4+ subsets display a 
certain degree of plasticity. For instance, anti-inflammatory regulatory T cells (Treg) 
represented by Forkhead Box P3 (Foxp3) expression gain expression of the pro-
inflammatory and Treg-atypical cytokine interferon gamma (IFN) in the inflammatory 
milieu of the atherosclerotic lesion.25, 26 
T helper (Th) 1 cells are considered to be the prototypical pro-inflammatory and –
atherogenic T cells. They are characterized by IFNsecretion and the expression of 
the T-box transcription factor (T-bet), which fosters Th1 differentiation whilst 
suppressing Th2 differentiation.27 Deficiency of T-bet decreases atherosclerotic burden 
in mice accompanied by reduced IFNlevels and an enhanced, atheroprotective Th2-
mediated antibody response.28 Further studies identified significant IFN-expression in 
atherosclerotic lesions indicating Th1 cells as the most abundant CD4+ T cell subset. 
Deficiency of IFN or its receptor led to diminished atheroma development.29, 30 
However, atheroprotection based on IFN-deficiency was gender-biased and only 
conferred protection to male mice. IFNenhances recruitment of T cells and 
macrophages to the plaque, inhibits SMC infiltration and proliferation, reduces collagen 
production and increases the synthesis of extracellular matrix-degrading proteins 
thereby promoting a rather unstable plaque phenotype which is prone to rupture.31 
Additional cytokines associated with Th1 cells are interleukin (IL)-12 and IL-18. IL-12 is 
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typically produced by DC, macrophages, neutrophils and a subset of T cells. IL-12 
stabilizes the Th1 subset whilst reducing IL-4 production, a cytokine typically expressed 
by Th2 cells that in turn suppresses IFNproduction. Furthermore, IL-12 increases 
expression of MHCII, CD80, and CD86 on APCs thereby enabling an efficient immune 
response.32 Conversely, IL-12-deficiency impairs a Th1-mediated immune response 
and is atheroprotective.33 IL-18 acts synergistically with IL-12 by inducing Th1 
differentiation and IFN production in NK cells, T cells, macrophages, and in SMCs.34, 35 
In addition, IL-18 increases the expression of matrix metalloproteinases (MMP) which 
degrade extracellular matrix thereby rendering the atherosclerotic plaque vulnerable.36  
The role of Th2 cells in atherosclerosis is still controversial. The Th2 lineage 
transcription factor is trans-acting T cell-specific transcription factor (GATA-3) and Th2 
associated hallmark cytokines are IL-4, -5, and -13.37-39 IL-4 is repressing differentiation 
of pro-inflammatory Th1 cells and lack of IL-4 leads to increased atheroprogression.33 
However, this phenotype was very mild in Apoe-/- mice whereas Ldlr-/- mice deficient for 
IL-4 demonstrated reduced atherosclerotic plaque formation.37 Next to T cells a variety 
of plaque-resident cells are affected by IL-4 leading to increased lipid oxidation in the 
nascent lesions, recruitment of leukocytes by enhanced endothelial activation and 
cytokine secretion, increased macrophage activation to scavenge lipoproteins 
deposited in the arterial wall and concomitantly foam cell formation.40, 41 Furthermore, 
IL-4 induces atheroprotective M2-like macrophages via map kinase signaling 
pathways.42 Surprisingly, hypercholesterolemic Apoe-/- mice demonstrate pronounced 
Th2 responses as defined by enhanced IL-4 production in atherosclerotic lesions 
without positively influencing atheroprogression.43  
The cytokine IL-5 is considered anti-atherogenic and is pivotal for development of B1 
cells. This subclass of B cells is anti-atherogenic by their potent secretion of oxidized 
(ox)LDL-directed natural IgM antibodies. These antibodies support the clearance of 
oxLDL particles thus contributing to reduced foam cell formation.38  
IL-13 is also atheroprotective. Transplantation of Il13-/- bone marrow exacerbated 
atherosclerosis whereas injection of recombinant IL-13 limited plaque progression by 
reduced lesional macrophage content and a M2 macrophage skewed phenotype.39  
Overall, the influence of the Th2 lineage on atherosclerosis requires careful 
interpretation. The most frequently applied mouse models in atherosclerosis-related 
research, Apoe-/- and Ldlr-/- mice, were derived from the C57Bl/6 strain that intrinsically 
favors a Th1 driven immune response.44 
Recently, the Th17 subset of CD4+ T cells was discovered and categorized different 
from the Th1 and Th2 lineages.45, 46 IL-17 is the characteristic Th17 cytokine by which 
chronic inflammation and autoimmune diseases, such as arthritis and colitis, are 
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promoted.47, 48 Furthermore, murine Th17 cells are defined by expression of the lineage 
marker of retinoic acid receptor-related orphan receptor (ROR)-t. Th17 cells derive 
from naïve T cells in the presence of antigen and the cytokines TGFβ and IL-6.49 Th17 
cells are potent sources of IL17A, IL-17F, IL-21, IL-22, and IL-23.50 Although the 
presence of IL-17- and IFN-producing T cells in atherosclerosis was observed, their 
contribution to atherosclerosis is under debate.51 As Th17 cells are potent sources of 
the aforementioned cytokines they fuel the inflammatory component in 
atherosclerosis.52, 53 However, other reports detected anti-atherogenic features of the 
hallmark cytokine IL17.54, 55 
1.3 Tregs in atherosclerosis 
Tregs are important to sustain self-tolerance and play a pivotal role in the prevention of 
autoimmunity controlling the balance of an immune response, particularly those driven 
by T cells. They are generally defined as CD4+ T cells expressing high-levels of CD25, 
and Foxp3.56 Natural (n)Tregs derive from the thymus where they undergo selection 
against self-antigens expressed in the context of MHCII by medullary thymic epithelial 
cells (mTEC) and DC under the transcription factor autoimmune regulator (AIRE). 
During this process, called negative selection, the developing Treg needs to receive 
low to intermediate signals provided by the TCR and proper costimulatory signals.57, 58 
A strong TCR signal would lead to the deletion of the developing thymocytes since it 
represents a potential threat to the host immune system. Induced (i)Treg originate from 
peripheral naïve T cells during an ongoing immune reaction. In mice, nTregs are 
characterized by the expression of Neuropilin-1 and Helios.59 Nonetheless, this concept 
might need further careful evaluation. Neuropilin-1 may be a more reliable marker for 
nTreg as Helios expression was recently also reported by murine iTregs, however, 
Neuropilin-1 is not expressed by human Tregs.60, 61 
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Figure 2. Tregs employ several modes to act on other immune cells in atherosclerosis.  
By releasing IL-10 and transforming growth factor  (TGF) Tregs suppress Th1 and Th17 activation and 
proliferation. Accordingly, release of pro-inflammatory IFN is limited leading to reduced M1 macrophage 
polarization, SMC-, and EC activation. Activated endothelium fosters adhesion of platelets and leukocytes 
promoting progression of atherosclerosis. IFN inhibits Th2 differentiation and collagen synthesis 
enhancing inflammation and destabilizing the plaque. Treg-derived TGF can antagonize these IFN-
mediated effects and stabilizes the plaque. Furthermore, secretion of IL-10 can induce a switch of pro-
inflammatory M1 macrophages to a more anti-atherogenic M2 phenotype. Tregs support development of 
tolerogenic DC by secretion of TGF and IL-10 or interaction of cytotoxic-T-lymphocyte-associated protein 
4 (CTLA-4) with CD80/86. Amongst other pathways, Tregs can inhibit B cell activation via CTLA-4- or IL-
10-mediated mechanisms. Activated T effector (Teff) cells release IL-2 which they require as an autocrine 
survival factor for further activity. High expression of CD25, the IL-2 receptor a chain, on Tregs scavenges 
IL-2, thus depriving the microenvironment of this growth factor and ultimately dampening the pro-
inflammatory T cell responses. Red-shaded cells and red arrows are considered mainly pro-inflammatory 
and contribute to athero-progression. Conversely green-shaded cells and green arrows diminish 
inflammatory response and mitigate the course of the disease. Modified from Spitz, Winkels et al.
62
 
 
Tregs harbor a powerful anti-inflammatory arsenal and are versatile in the modes of 
action by which they prevent autoimmunity or tissue damage by host-derived immune 
cells. Conventional CD4+ T cells need to receive co-stimulatory signals via CD28 which 
binds to co-stimulatory molecules CD80/CD86 provided by APCs. Tregs constantly 
express CTLA-4, which is a co-inhibitory molecule also binding to CD80/CD86. Thus, 
Tregs prevent physically the activation of conventional T cells (Figure 2).63 
Furthermore, engagement of CTLA-4 with CD80/CD86 leads to their internalization 
further reducing their surface abundance and rendering the APC tolerogenic.64 The 
high expression of CD25 enables Tregs to deprive the micromilieu from the T cell 
autocrine growth factor IL-2 limiting growth and survival of effector T cells. 
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Furthermore, Tregs are potent sources of the anti-inflammatory cytokines IL-10, IL-35, 
and TGF which modulate and reduce the activation of APCs. Additionally, similar to 
CD8+ T cells, Tregs are equipped with the molecular machinery to produce and release 
granzyme B and perforin, which can negatively modulate function and survival of 
conventional T cells, B cells, and NK cells.65, 66  
Given the aforementioned anti-inflammatory features of Tregs they were also ascribed 
anti-atherogenic functions. A landmark paper by Ait-Oufella demonstrated that Tregs 
conferred atheroprotection. The authors observed decreased Treg development and 
abundance in hyperlipidemic Ldlr-/- reconstituted with CD80/CD86- or CD28-deficient 
bone marrow accompanied by increased atherosclerotic burden.67 However, CD28 and 
CD80/CD86 interactions pertain not only to Treg function and development as IFN-
producing T cells display markedly reduced activation in absence of either molecule. In 
hyperlipidemic mice, this can lead to complex, vulnerable atherosclerotic lesions.68  
Injection of an anti-CD25 antibody in hyperlipidemic mice reduced abundance of Tregs 
and concomitantly increased lesion size and infiltration of macrophages and 
conventional T cells.67 However, besides Tregs, also activated conventional T cells, NK 
cells, B cells, and DC express CD25, thus, pharmacological depletion of Tregs might 
also affect other immune cell subsets.69 Vice versa, the adoptive Tregs was 
atheroprotective in mice.70 However, Tregs were isolated by fluorescence activated cell 
sorting (FACS) and defined as CD4+CD25hi leaving this population contaminated by 
activated conventional T cells and only enriched for natural Tregs. 
A recent study provided by Klingenberg et al. indirectly confirmed the anti-atherogenic 
propensities of Treg. Hyperlipidemic Ldlr-/- mice were transplanted with bone marrow 
from transgenic mice expressing the diphtheria toxin receptor under control of the 
Foxp3 promotor. Treatment of the resulting bone marrow chimeric mice with diphtheria 
toxin induced cell death of all Foxp3+ Tregs resulting in their systemic ablation.71  
Tregs represent potent sources of the anti-inflammatory cytokine TGF. Nevertheless, 
TGF is also expressed by other circulating and plaque-resident cells, such as platelets 
and macrophages. Presence of TGF stabilizes the atherosclerotic lesion by increasing 
SMC survival and enhancing their capacity to synthetize collagen. Concomitantly, 
macrophages become foam cells to a lower extent (Figure 2).72, 73 Conversely, 
desensitizing T cells or DCs for TGF-mediated signals by overexpression of a 
dominant-negative TGF receptor induced increased atherosclerotic burden and 
pronounced T cell responses in atherosclerosis-prone mice.74, 75 As demonstrated for 
defective TGF signaling, deficiency of IL-10 increased atherosclerotic burden 
accompanied by increased macrophage and T cell infiltration.76, 77 In contrast, IL-10 
overexpression was atheroprotective, prevented a Th1-mediated immune response in 
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the atherosclerotic lesion and fostered the generation of IL-10-producing iTregs, called 
Tr1 cells.78  
Interestingly, the development of both Th17 and Tregs depends on the presence of 
TGF suggesting linkage between both cell types. During the progression of 
atherosclerosis Th17 cells dominate over Tregs further contributing to the pro-
inflammatory component of the chronic disorder.79 In notion of this phenomenon, a 
recent study demonstrated the vanishing of Tregs from atherosclerotic lesions in 
hyperlipidemic Ldlr-/- mice at later stages of atherosclerosis.80 However, further 
research will have to demonstrate whether Tregs emigrate from the atherosclerotic 
lesion, lose expression of their hallmark transcription factor Foxp3, or whether they 
undergo cell death.  
Although Tregs are anti-inflammatory and a plethora of data ascribes Tregs anti-
atherogenic propensities, there is only indirect evidence linking Treg numbers to 
atheroprogression and further research is required to formally demonstrate the role of 
Tregs in atherosclerosis.62 
1.4 Macrophages in atherosclerosis 
Macrophages are cellular key players in atherosclerosis and they are involved in 
plaque initiation, progression, but also in regression.81 Most macrophages derive from 
circulating monocytes which roll along the endothelium. Monocytes express chemokine 
(C-C motif) receptors (CCR)5 and CCR1 which enable them to sense chemokine (C-C 
motif) ligand (CCL)5 (aka RANTES) and CXCL1 deposited on the activated 
endothelium fostering their local arrest. Subsequently, VCAM-1 and ICAM-1 expressed 
on the endothelium interacting with lymphocyte function-associated antigen 1 (LFA-1) 
and very late antigen-4 (VLA-4) expressed by monocytes leads to firm adhesion. The 
chemokines CCL2, CX3CL1 (also known as fractalkine), and CCL5 secreted by 
activated EC, macrophages, and SMCs mediate transmigration of macrophages into 
the nascent atherosclerotic lesion via CCR2, CCR5, and CX3CR1, respectively.82 
However, lesional macrophage content is not only dependent on monocyte recruitment 
but there is substantial contribution by proliferation of plaque-resident macrophages.83, 
84 Once recruited to the intima, the macrophages will scavenge deposited lipoprotein 
particles and turn into foam cells. Macrophages express LDLR, however, increased 
cellular cholesterol content decreases LDLR expression, diminishing their capacity to 
scavenge ApoB-containing lipoproteins.85 Furthermore, macrophages express 
substantial amounts of scavenger receptors. These receptors are pattern recognition 
receptors (PRR) and a variety has been described to promote foam cell formation 
including scavenger receptor (SR)-A1, SR-B1, lectin-type oxLDLR 1 (LOX1), and 
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CD36.86 Deficiency for CD36 and SR-A1 reduced foam cell formation in hyperlipidemic 
Apoe-/- mice, but did not completely prevent it, suggesting other pathways being 
involved in foam cell formation.87 Indeed, macrophages exert pinocytosis in the intima 
to take up native and modified LDL particles in a receptor-independent fashion. The 
internalized lipoproteins are degraded in the late endosomal compartment where the 
cholesteryl esters are hydrolyzed to free cholesterol and free fatty acids. The free 
cholesterol will be transported to the endoplasmatic reticulum (ER) where the enzyme 
acetyl-coenzyme A:cholesterol acetyltransferase 1 (ACAT1) catalyzes esterification of 
free-cholesterol to cholesteryl fatty acid esters that will occur as lipid droplets in foam 
cells as defined by their microscopic appearance.88 
The oxidative and enzyme rich milieu of the nascent atherosclerotic lesion results in the 
generation of modified lipoproteins, particularly oxLDL. Macrophages scavenge 
significant amounts of oxLDL in vitro and demonstrate PRR expression, especially toll-
like receptor (TLR)2 and TLR4 which are both exerting pro-atherogenic functions.89-91 
PRR sense pathogen-associated molecular patterns (PAMP) exposed by infectious 
threats to activate the innate immune system. Furthermore, they can recognize danger-
associated molecular patterns (DAMP) provided by endogenous agents which display 
molecular similarities to PAMPs. Reactivity to agents of both families is pivotal by 
maintaining physiological homeostasis. Reactivity to PAMPs helps to clear the body 
from pathogens whereas DAMPs induce a sterile inflammatory response towards 
tissue damage involving the recruitment of phagocytes. In atherosclerosis, among 
others, cholesterol crystals and oxLDL represent such DAMPs triggering activation of 
innate PRR.24 
Besides passive diffusion of cholesterol from the cell membrane, macrophages 
increase expression of cholesterol efflux transporters such as ATP-binding cassette 
subfamily A member 1 (ABCA1) and ABCG1.92 Increased cholesterol levels activate 
the liver X receptor (LXR) which drives expression of the genes encoding for ABCA-1 
and ABCG-1. ABCA-1 mediates cholesterol efflux to Apolipoprotein A1 (ApoA1) 
whereas ABCG-1 mediates high-density lipoprotein (HDL)-directed efflux. Esterified 
cholesterol in macrophages is non-reactive, however, free cholesterol is toxic to cells. 
The increased accumulation of free cholesterol changes membrane fluidity and 
enhances inflammatory signaling in lipid rafts via TLR and subsequent nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFB) activation, but also inhibits 
further esterification of free cholesterol by ACAT1.93, 94 The increased accumulation of 
free-cholesterol and a misbalanced lipid metabolism of macrophages promote 
sustained ER stress which induces apoptosis.95 Furthermore, lipid-laden macrophages 
are less competent in uptake, or so called efferocytosis, of apoptotic cells and particles 
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from the local environment, leading to secondary necrosis. Due to membrane instability 
cellular components and lipids are released and further contribute to advanced 
atherosclerotic lesion development by necrotic core formation.96 Lesional macrophages 
phagocytosing cholesterol crystals demonstrate NACHT, LRR and PYD domains-
containing protein 3 (NLRP3) inflammasome activation resulting in the enhanced 
secretion of activated IL-1.97 IL-1 is a driving force in atherosclerosis and mice 
without IL-1 are protected from atherosclerosis.98 
1.5 Macrophage polarization in atherosclerosis 
Macrophages exist in different phenotypes and are classified according their distinct 
features based on in vitro generation. However, the paradigm of M1 and M2 
macrophages is nowadays under discussion as the phenotype of macrophages 
induced by immune-related ligands in vitro is not linkable to in vivo existing 
macrophage phenotypes in pathological conditions.99 However, for reasons of 
simplicity, I will continue to refer to the classical M1/M2 nomenclature in the following. 
M1 macrophages are classically activated in vitro by TLR4 agonists such as 
lipopolysaccharide (LPS) or by IFN and their presence was demonstrated in murine 
and human atherosclerotic lesions.100, 101 M1 macrophages are rich sources of 
inducible nitric oxide synthase (iNOS), CCL2, tumor necrosis factor(TNF), IL-1, IL-6, 
and IL-12. All these pro-inflammatory mediators recruit additional macrophages and T 
cells and activate the latter mentioned immune cells, EC, and SMC, respectively, thus 
further perpetuating inflammation.101 M1 macrophages contribute to plaque 
destabilization as they secrete significant amounts of matrix-degrading enzymes such 
as MMP2 and MMP9. Additionally, in vitro polarized M1 macrophages display 
significant reduction in ABCA-1 expression accompanied by decreased cholesterol 
efflux capacity.102 However, this in vitro generated data is not directly confirmable in 
vivo. Thus, these findings have to be interpreted carefully and in vitro generated data 
cannot necessarily be extrapolated to the actual disease progression.81  
M2 polarized macrophages are induced by Th2-related cytokines IL-4, IL-13, and IL-10, 
the latter also produced by Tregs (as discussed above).100, 103 Phenotypically, M2 
macrophages demonstrate expression of CD163, CD206 (also known as mannose 
receptor 1), resistin-like beta (Fizz1), and arginase 1.81 This subtype of macrophages 
harbors anti-inflammatory propensities by the production of TGF, IL-10, and IL-1 
receptor agonists. In addition, TGF can promote M2 macrophage differentiation 
representing an autocrine feed-forward loop.104 Furthermore, M2 macrophages 
produce collagen contributing to plaque stability. Accordingly, these macrophages are 
predominantly found in regressing plaques.105 
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The presence of both, M1 and M2 macrophages is increased during the progression of 
atherosclerosis in patients. However, the localization of M1 and M2 macrophages 
differed in human atherosclerotic plaques where M1 macrophages predominantly 
locate to rupture-prone shoulder regions whereas M2 macrophages are mostly 
abundant in the adventitia and in stable regions of the plaque.106 In mice, 
atherosclerotic lesions are initially dominated by M2 macrophages whereas the M1 
macrophage subset dominates during atheroprogression.107  
1.6 B cells and Immunoglobulins in atherosclerosis 
B cells are predominantly found in the adventitia and contribute to and regulate lesional 
inflammation.108, 109 Antibodies specific for plaque-restricted antigens such as oxLDL 
were detected in human atherosclerotic plaques.110 Further antigens that can be 
detected by antibodies in atherosclerosis are HSP60, HSP65, and in general antigenic 
motifs derived from lipid peroxidation motifs as found on the surface of oxLDL and also 
on apoptotic cells.24 The accumulation of oxLDL and apoptotic cells in atherosclerotic 
lesions represents potent innate immunity activators.  
The spleen is a large reservoir for B cells. Splenectomy of Apoe−/− mice induced 
pronounced atherosclerosis compared to sham-operated mice.111 Furthermore, 
transplantation of µMT-/- bone marrow which is B cell-deficient into Ldlr−/− mice 
aggravated atherosclerosis.112 However, pharmacological depletion of B cells with anti-
CD20-antibodies was atheroprotective in Apoe−/− and Ldlr−/− mice.113, 114  
This data suggests that B cell subsets contribute differently to atherosclerosis. In mice, 
there are two major subsets of B cells, B2 and B1 cells. Whereas (marginal and 
follicular) B2 cells are bone marrow-derived, B1 cells are most apparent in peritoneal 
and pleural cavities and seem to be of a different developmental origin.115, 116 Markers 
for B1a cells are CD19+B220lowIgMhiCD5+CD43+CD23- whereas B1b cells are CD5 
negative.117 IL-10-producing regulatory B cells (Bregs) represent another subset of B 
cells mediating an immune-modulatory function, however, their contribution to 
atherosclerosis by IL-10 seems negligible.118  Innate response activator (IRA) B cells 
express granulocyte-macrophage colony-stimulating factor (GM-CSF) by which they 
seem to foster expansion of mature DCs which in turn stimulate differentiation of naïve 
T cells into IFN-producing Th1 cells accompanied by a switch from IgG1 to IgG2c 
oxLDL-specific antibodies ultimately leading to pronounced atherosclerosis.119 
Interestingly, patients with symptomatic cardiovascular disease (CVD) have elevated 
numbers of splenic IRA B cells.119 
Although the role of B2 cells in atherosclerosis is controversial, the picture for B1 cells, 
particularly B1a cells, seems clearer. The exact contribution of B1b cells to 
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atherosclerosis however, needs to be defined. As outlined above (1.2), IL-5, a Th2-
associated cytokine, is necessary for B1a cell development and maintenance. 
Conversely, lack of IL-5 leads to pronounced atherosclerosis in hyperlipidemic mice.38 
Levels of circulating IgM antibodies recognizing oxLDL or malondialdehyde (MDA)-
modified LDL, another naturally-occurring oxidized form of LDL, are inversely 
correlated with the carotid intima–media thickness or the risk of developing a >50% 
diameter stenosis in the coronary arteries.120, 121 Natural IgM antibodies are germline-
encoded and mainly produced by B1 cells. The generation of natural IgM is 
independent of exogenous antigen presentation.122 
Transplantation of B1a cells isolated from sIgM−/− donor mice, which express but do not 
secrete IgM did not protect from pronounced atherogenesis suggesting B1a cell-
derived IgM responsible for the anti-atherogenic effects of B1a cells.123  Indeed, anti-
oxLDL-specific IgM antibodies, in particularly clone E06, prevent the binding of oxLDL 
to CD36 and SR-B1 on macrophages in vitro subsequently reducing oxLDL uptake and 
foam cell formation.124 
B2 cells express different subclasses of IgG which are IgG1, IgG2, IgG3, and IgG4 in 
humans and IgG1, IgG2a/c, IgG2b, and IgG3 in mice.117 Each of the IgG subtypes 
exhibits different fragment crystallizable gamma receptor (FcR) affinity and harbors 
different capacities to activate the complement system.125, 126 OxLDL-specific IgG 
antibodies were detected in atherosclerotic lesions, however, the correlation between 
circulating oxLDL-antibody titers and CVD risk remains controversial.110, 127 As 
mentioned before, the depletion of B cells lowered atherosclerotic burden and 
concomitantly titers of oxLDL-specific IgG antibodies and to a lesser extent those of 
IgM antibodies.113, 114 However, most information about IgG antibodies in 
atherosclerosis was derived from immunization approaches with HSP65 or oxLDL. 
Ldlr−/− mice administered a regular chow diet and immunized with HSP65 mounted high 
anti-Hsp65 IgG antibody titers and displayed aggravated atherosclerosis.128 Most likely, 
this effect was caused by damage of EC expressing the HSP65 homologue HSP60.129 
On the contrary, immunization with MDA-LDL induced increased amounts of specific 
antibodies and was atheroprotective in hyperlipidemic mouse models.130, 131 
Contrasting results were obtained in vitro, where plasma from mice with high IgG titers 
to MDA-LDL inhibited oxLDL uptake by macrophages whereas recombinant human 
MDA-LDL–specific IgG1, which is atheroprotective, promoted uptake of oxLDL by 
macrophages.132, 133 Whether these effects are actually representative of the processes 
occurring in vivo remains to be determined.  
The role of the allergy-mediating IgE was only indirectly tested in atherosclerosis. 
Apoe−/− mice deficient for the high-affinity FcεRI receptors contained smaller 
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atherosclerotic lesions accompanied by reduced macrophage and apoptotic cell 
content. Mechanistically, the binding of IgE induced activation of FcεRI which 
cooperates with TLR4 on macrophages inducing cytokine secretion and cell death.134 
Another Ig subclass is represented by IgA which confers mucosal protection against 
pathogens, however, substantial amounts are found in the circulation of humans. The 
mechanistic contribution of IgA to atherosclerosis is not resolved yet. However, 
epidemiologic studies correlate circulating IgA titers with myocardial infarction, CVD, 
and cardiac death in hyperlipidemic humans.135, 136 
1.7 An introduction to the CD27/CD70 dyad 
A functional T cell response requires not only ligation of the antigen-specific TCR by its 
cognate MHC:antigen complex but also proper signaling provided by costimulatory 
molecules. These signals are important during different stages of a T cell response, 
such as clonal expansion and during the function and survival of T cells in primary and 
secondary immune responses. Many studies revealed the effects of costimulatory 
molecules belonging to the Ig-like CD28 family or TNF receptor (TNFR) family. 
Activation of CD28 by its ligands CD80 and CD86 leads to T cell division and survival. 
The costimulatory axis CD40/CD154 exerts many different effects beyond its critical 
involvement in B cell help and subsequent switch of the antibody isotype. Most notable 
these interactions also contribute to cell activation and promote cytokine release. 
CD27 and CD70 are members of the TNFR family. The homology between murine und 
human CD27 and CD70, respectively, is 60-65% and their respective expression 
patterns between species are comparable.137-139 
CD27 is expressed on naïve T cells at steady state. In addition, CD27 is expressed on 
NK cells, activated B cells, and hematopoietic stem cells.139, 140 CD70 - the ligand of 
CD27 - is transiently expressed on T cells, B cells, and DCs upon activation thus 
reflecting recent antigenic priming.141 However, APC in the thymus including mTEC141 
and in the lamina propria142 express CD70 constitutively. Furthermore, NK cells were 
reported to express CD70.143 Expression of CD70 is induced by signaling via TLR, 
CD40-CD40L interactions, and signaling via antigen receptors.141, 144  
The exclusive expression pattern of CD27 and CD70 suggests important impacts of 
these molecules during the initiation of a T cell and B cell response not only at the 
priming site but also in the periphery where the T cell receives signals via CD27 ligating 
to CD70 on activated B cells, DCs, or through the interaction with other T cells.145 
CD27 forms stable dimers via disulfide-bonds which upon activation trimerize thus 
enabling interaction with the homotrimeric type II membrane bound CD70. The 
interaction of CD27 with CD70 leads to the cleavage of CD27 from activated T cells by 
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surface expressed metalloproteases displaying a first step of negative regulation.146, 147 
CD27 and CD70 are exclusive interaction partners and so far no other potential binding 
partner has been found. The ligation of both molecules elicits bidirectional signaling. 
CD27, like other members of the TNFR family, has an intracellular domain to which the 
TNFR-associated factor 2 (TRAF2) and TRAF5 bind relaying further signals to activate 
NFB pathways.148 Indeed, TRAF5 deficiency blocks CD27-mediated signaling.149 
Furthermore, coupling of TRAF2 to CD27 activates the c-Jun-N-terminal kinase (JNK)-
signaling cascade further contributing to inflammatory processes and potentially 
exerting anti-apoptotic effects.150 Moreover, CD27 can bind to apoptosis-inducing factor 
(Siva1) which is an intracellular mediator of apoptosis and, indeed, these interactions 
induce cell death.151, 152 However, as discussed below, CD27 costimulation contributes 
to cellular activation and survival, thus the exact function of this interaction remains 
undefined. 
Furthermore, CD70 also bears signaling activity. Suboptimally-activated B cells 
triggered with an agonistic CD70 antibody elicited phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) and mitogen-activated protein kinase (MEK) pathways 
resulting in enhanced proliferation and IgM production in vitro.153 Further studies 
substantiated signaling via CD70. Ligation of soluble CD27 to CD70 increased surface 
expression of other immune-regulatory molecules such as CD40L on CD4+ T cells 
whereas CD8+ T cells displayed enhanced CD25, CD70, and 4-1BB expression, which 
is also a costimulatory molecule of the TNFR family.154 
1.8 The CD27/CD70 dyad in T cell responses 
CD27 signaling plays an important role in Treg development as well as for antigen-
specific CD4+ and CD8+ T cell memory formation, which is reduced in virus-infected 
Cd27-/- mice rendering them more susceptible for a second infection.155, 156 However, 
CD27 is not a classical costimulatory molecule per definition such as CD28 since it 
does not influence the rate of cell division of antigen-primed T cells but seems to 
prolong T cell survival. Indeed, B-cell lymphoma-extra large (Bcl-xL), an anti-apoptotic 
molecule, is upregulated in T cells triggered in vitro by CD27 signaling.157 Additional in 
vitro experiments demonstrated enhanced T cell proliferation and cytokine production 
upon treatment with an agonistic anti-CD27-antibody and administration of growth 
factors such as phytohaemagglutinin or IL-2.158, 159 Furthermore, CD27 signaling was 
pivotal for the IL-2 production of antigen-primed CD8 T cells at the site of infection in 
non-lymphoid tissue regulating their survival and proliferation.160 Moreover, CD27 
costimulation promoted expression of the chemokine CXCL10 by primed CD8+ T cells 
further attracting T cells to the site of infection.161 In addition, CD27/CD70-driven 
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costimulation seems to influence T cell polarization. Human CD4+ T cells stimulated via 
CD27 displayed increased survival and enhanced expression of T-bet and the cytokine 
receptor IL-12 receptor 2 chain (typical for Th1 cells).157 Furthermore, the constitutive 
expression of CD70 induced conversion of naïve T cells into IFN-producing effector T 
cells which induced a patho-inflammatory condition increasing mortality of these 
transgenic mice.162, 163 
1.9 The CD27/CD70 dyad in B cell responses 
The CD27/CD70 dyad exerts important effects on the B cell compartment as well. 
CD70 surface expression is increased on activated human and murine B cells.164, 165 
However, in humans, CD27 is upregulated during T cell help in the germinal center 
reaction and is still highly expressed on memory B cells whereas in mice only splenic 
marginal zone B cells and a subset of B1 cells express CD27.164, 165 Hence, murine B 
cells express CD27 temporarily and spatially restricted suggesting involvement in the 
germinal center response. Proper CD27/CD70 signaling is needed for B cell 
proliferation and plays an important role during the process of Ig synthesis.166 
Insufficient CD70 triggering on B cells leads to an impaired germinal center formation 
thereby affecting the humoral immune response.167 However, B cells from Cd27-/- mice 
still undergo class switching and Ig maturation in aged mice, thus, other factors 
contribute and compensate for CD27 defects which are only present during early 
phases. In contrast, human CD27+ B cells produced a higher amount of Ig, IL-10, and 
displayed enhanced survival.168-170 In accordance, humans carrying mutations in the 
CD27 gene suffer from a severe immunodeficiency characterized by 
hypogammaglobulinemia, dysregulated lymphoproliferation and increased susceptibility 
for infections with Epstein-Barr virus (EBV).171-173 Costimulation of CD70 via CD27 
induced B cell proliferation but impaired terminal differentiation and Ig secretion of 
human and murine B cells although stimulation of CD70 via soluble CD27 resulted in 
increased Ig secretion.153, 166, 174 Thus, soluble and membrane bound CD27 interacting 
with CD70 exerts species-specific effects and seems to contribute to a germinal center 
reaction in mice whereas in humans, CD27 promotes terminal B cell differentiation and 
CD70 might downregulate humoral immunity. Interestingly, blocking CD27/CD70 
interactions in lymphocytic choriomeningitis virus (LCMV) infections enhanced the 
clearance of pathogens from the area of infection by enhanced production of 
neutralizing antibodies by B cells.175 
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1.10 Implications of the CD27/CD70 dyad in autoimmune 
disorders 
The co-stimulatory dyad CD27/CD70 plays important roles in several autoimmune 
disorders. 
Patients suffering from systemic lupus erythematosus (SLE) had higher numbers of 
circulating CD27high plasma cells which correlated with SLE disease activity index 
(SLEDAI) and titers of anti-double stranded deoxyribonucleic acid (anti-dsDNA) 
autoantibodies.176 Additionally, levels of serum sCD27 positively correlated with 
SLEDAI.177 Furthermore, SLE patients demonstrated enrichment of CD70+ CD4+ T cells 
among memory T cells. This population remained stable over time possibly involving 
these cells in SLE progression and susceptibility, however, excluding them as a 
biomarker for SLE prognosis.178 Interestingly, CD4+ T cells isolated from SLE patients 
and healthy controls substantially increased CD70 expression when incubated with 
DNA methylation inhibitors. These treated CD4+ T cells enhanced IgG production by B 
cells in in vitro co-cultures in a CD70-specific fashion.179 Downregulation of the 
transcription factor RFX1 increased CD70 overexpression by failed recruitment of 
transcriptional co-repressors to the CD70 promotor and decreased interactions with 
DNA methyltransferase 1 (Dnmt1) and histone deacetylase 1 (HDAC1) resulting in an 
active, hypomethylated CD70 promotor.180, 181 Similar observations were made in 
MRL/lpr mice with established lupus-like disease harboring splenic CD4+ T cells with 
enhanced CD70 expression which was again associated by decreased Dnmt1 
expression and a hypomethylated CD70 locus.182 
Similarly to SLE patients, CD4+ T cells from patients with rheumatoid arthritis (RA) 
display increased CD70 expression which concomitantly had elevated IFNand IL-17 
production.183 However, CD70 expression on CD4+ T cells did not correlate with 
disease severity, again, excluding its function as a biomarker. Nonetheless, CD70 
expression could contribute to lowering of the activation threshold of bystander naïve 
CD4+ T cells.181, 184 Moreover, pharmacological inhibition of CD70 with antibodies 
reduced disease burden and titers of anti-collagen autoantibodies in mice with 
collagen-induced arthritis, potentially demonstrating a new therapeutical strategy in 
RA.185 
As mentioned above, CD70 is constitutively expressed on APCs in the lamina propria 
of the intestine. This unique APC subset is involved in Th17 differentiation when 
stimulated with ATP in a germ-free environment via IL-6 and IL-23 production and 
controls the T cell response towards a listeria infection in the intestinal mucosa.142, 186 
These observations raised the possibility of CD27/CD70 involvement in intestinal 
associated pathologies, which are also influenced by the microbiome. Indeed, transfer 
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of naïve Cd27-/- CD4+ T cells into Rag-/- mice induced a less pronounced colitis, which 
is the murine model of inflammatory bowel disease. In addition, pharmacological CD70 
inhibition with antibodies not only protected against colitis when naïve wild-type CD4+ T 
cells were transferred, but also rescued mice from established colitis.187  
Besides the aforementioned pathologies, the CD27/CD70 axis plays a pivotal role in 
neuro-immunological disorders. Although patients suffering from multiple sclerosis 
display increased sCD27 levels in cerebrospinal fluid, the exact involvement of the 
CD27/CD70 dyad has to be elucidated.188 Murine models of multiple sclerosis, 
experimental autoimmune encephalomyelitis (EAE), were used to assess CD27/CD70 
implications. Immunization of myelin oligodendrocyte glycoprotein (MOG)-specific TCR 
transgenic mice with MOG peptide induced profound EAE accompanied by reduced 
Treg abundance when CD70 was constitutively expressed by B cells.189 Moreover, 
MOG-TCR transgenic mice immunized with MOG displayed exacerbated EAE when 
deficient for CD27 or CD70 based on a pronounced Th17 response which is 
considered a driving pathogenic force in EAE progression.190 These facts argue for a 
tempo-spatial context of CD27 and CD70 expression on the outcome of EAE in the 
investigated murine models. 
1.11 The role of CD27/CD70 interactions in tumor immunology 
Hematologic malignancies and solid tumors feature high CD70 expression.191-195 
Constitutive expression of CD70 might cause immune-evasive effects and thus 
positively propagate tumor growth. Indeed, as pointed already out in aforementioned 
sections, CD27/CD70 interactions drive the development of Tregs. Furthermore, recent 
work demonstrated abrogated expansion and differentiation of intratumoral iTregs in 
Cd27-/- mice resulting in decreased tumor growth and an effective anti-tumor immune 
response.196 Conversely, constant CD27/CD70 interactions promote IL-2 production 
and conventional CD4+ and CD8+ T cell survival which further nourishes Tregs resulting 
again in an immune-evasive and anti-inflammatory tumor micromilieu.196 Indeed, 
increased abundance of intratumoral Tregs is linked to a poor prognosis for cancer 
patients.197-199 Secondly, the constitutive expression of CD70 in combination with 
persistent antigen exposure causes exhaustion of effector T cells which was 
demonstrated in patients suffering from B cell non-Hodgkin’s lymphoma.200 Exhausted 
T cells are less active and cytotoxic and thus do not mount a resounding attack on the 
tumor. Furthermore, antibodies targeting CD70 could induce antibody-dependent 
cellular cytotoxicity and phagocytosis enabling the destruction of tumor cells by 
immune cells ultimately leading to tumor regression. Thus, blocking-CD70 antibodies 
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provide a promising therapeutical strategy in the treatment of aforementioned 
malignancies and several antibodies are currently clinically evaluated.201, 202 
Another therapeutical intervention represents the agonistic modulation of CD27 which 
could complement and amplify current anti-tumor strategies. Moreover, agonistic 
modulation of CD27 also represents a promising therapeutical strategy. As highlighted 
above, T cells demonstrate exhaustion in a variety of malignancies leading to a 
reduced cytotoxic activity and propagated tumor growth. The re-activation of T cells 
facilitates recognition of tumor cells by T cells and their destruction. To test this 
hypothesis, mice with a transgenic human CD27 locus were challenged with colon 
carcinoma and T cell lymphoma.203 The administration of a humanized CD27-agonistic 
antibody successfully reduced tumor burden and induced resistance of those mice 
towards future tumor challenges. Causative for tumor regression was a highly effective 
anti-tumor cytotoxic CD8+ T cell response which was supported by a CD4+ T cell 
response.203 This particular agonistic CD27 antibody, CDX-1127 (varlilumab), is now 
investigated in clinical trials therapeutically targeting B-cell malignancies, melanoma, 
and renal cell carcinoma.199, 204 Of note, the antibody transiently influenced abundance 
of circulating CD27+ immune cells in cynomolgus monkeys and rhesus macaques. 
CD8+ T cells, Treg, and NK cells were transiently reduced in circulation whereas CD4 T 
cells were increased.203, 205 However, the successful regression in tumor burden 
outweighs potential off-target effects caused by a reduction in circulating immune cells. 
The CD27/CD70 dyad plays an important and complex role in tumor immunology. 
Targeting CD27/CD70 interactions in advanced cancer malignancies represents a 
promising therapeutical approach. Patients with advanced malignancies displaying high 
CD70 expression on tumor cells would benefit from a CD70 blocking antibody whereas 
the therapeutical, agonistic stimulation of CD27 reconstitutes the activity of exhausted 
cytotoxic CD8+ T cells. Subsequently, these cells can mount a cytotoxic anti-tumor 
immune response leading ultimately to the regression of tumor burden. Both 
therapeutical strategies modulate the patients’ immune system to respond to the tumor 
without the need for treatment with chemotherapeutic agents that can have severe side 
effects. These novel approaches, however, aim to complement and amplify existing 
anti-tumor strategies. 
1.12 The role of CD27/CD70 costimulation in atherosclerosis 
The role of T cells and B cells in atherosclerosis and the imminent role of interactions 
between CD27 and CD70 on these and other cell types strongly suggest the detailed 
investigation of this costimulatory dyad in the field of atherosclerosis. Little is known 
about CD27 and CD70 function in atherosclerosis. A recent study demonstrated 
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chronic CD70 overexpression in B cells to be atheroprotective.206 This group 
engineered mice harboring B cells to overexpress CD70 backcrossed to ApoE*3-
Leiden mice and administered a high cholesterol/fat diet. The continuous triggering 
CD27 on T cells led to an increase in the presumably pro-atherogenic Th1 subset. 
Surprisingly, this transgenic CD70 overexpression exerts rather atheroprotective 
effects which are probably due to an increased rate of apoptosis among the pro-
atherogenic Ly6C+ monocytes. As atherosclerosis is largely monocyte-driven it is likely 
that loss in monocytes ameliorates atherosclerosis. However, the mouse model used in 
this study suffers additional side effects. Constitutive overexpression of CD70 in B cells 
results in exhaustion of the T cell pool, due to excessive and continuous activation and 
thus does not provide conclusive evidence regarding the precise roles of CD27 and 
CD70 in atherosclerosis. 
1.13 Rationale 
CD27 and CD70 interactions play important roles in various auto-immune disorders 
and advanced malignancies. In respect of the limited knowledge of the involvement of 
CD27 and CD70 interactions in atheroprogression, the here proposed studies aim to 
specify the influence of costimulation via CD27/CD70 on atherosclerosis at early and 
late timepoints of atherogenesis. Particularly, athero-prone Apoe-/- mice will be crossed 
to either Cd27-/- or Cd70-/- mice to investigate the impact of a global deficiency in one of 
these costimulatory molecules on the generation of atherosclerosis. Furthermore, 
transplantations of bone marrow derived from CD27- or CD70-Apoe compound mutant 
mice will help to understand the contribution of each molecule by the hematopoietic 
component. In addition to atherosclerosis-specific parameters such as plaque size and 
plaque phenotype other organs and tissues will be analyzed to examine whether and 
how the different T cell subsets and memory types are influenced by a deficiency in 
one of the costimulatory molecules. Furthermore, in vitro based assays will be 
performed to elucidate the function of immune cells isolated and generated from CD27- 
or CD70-compound mutant mice and their potential contribution to atherosclerosis. 
 
The research presented here will provide novel insights in the complex field of adaptive 
T cell immunity and in particular the effects exerted by CD27 and CD70 in 
atherogenesis. The most promising approaches to treat atherosclerosis employ 
different vaccination regimen thereby very specifically influencing the adaptive immune 
system and long-term T cell homeostasis. As the CD27/CD70 dyad plays an imminent 
role in the interaction of T cells and B cells, it is important to understand pathways 
elicited by CD27 and CD70 in immune responses and also upon immunization to 
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modulate and improve potential vaccination therapies. Furthermore, CD27/CD70 
interactions and modulation of both molecules needs to be understood in cancer 
therapy to gauge potential vascular harmful offside effects. 
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2 MATERIALS AND METHODS 
2.1 General equipment 
2.1.1  Table 1: General equipment used for this thesis 
Equipment Modell Source 
Autoclave VX150 Systex, Linden, Germany 
Balance 
BP2100S 
R160P 
Sartorius, Goettingen, Germany 
Centrifuges 
5415R 
5810 
Eppendorf, Hamburg, Germany 
Multifuge 3S-R Heraeus 
Multifuge 40R Heraeus 
Thermo Scientific, Waltham, 
MA, USA 
Galaxy Mini Star VWR, Radnor, PA, USA 
Cryotome CM3050S Leica, Wetzlar, Germany 
Flow cytometer 
FACS Canto II 
FACS Aria III 
BD Biosciences, San Jose, CA, 
USA 
Heating block SBH130DC 
Stuart, Staffordshire, United 
Kingdom 
Incubator Binder CB150 Binder, Tuttlingen, Germany 
Laminar Flow Hood 
Bdk UVF 6.18 S 
Weisstechnik, Sonnenbuehl, 
Germany 
Herasafe (Heraeus) Thermo Scientific 
Luminex xMAP 
instrument 
MAGPIX Luminex, Austin, TX, USA 
Microplate reader Tecan GENios 
Tecan Group, Maennedorf, 
Switzerland 
Microscopes 
DMLB 
DM6000 
SP8 3X 
Leica 
Microtome RM2155 Leica 
pH-meter HI2211 pH/ORP meter 
Hanna Instruments, 
Voehringen, Germany 
Plate shaker Titramax 101 
Heidolph, Schwabach, 
Germany 
qPCR system 
7900 HT Fast Real-Time 
PCR System 
ViiA 7 Real-Time PCR 
System 
Thermo Scientific 
Spectrometer ND1000 Nanodrop Peqlab VWR, Radnor, PA, USA 
Thermal cyclers 
MyCycler 
Bio-Rad T100 
Bio-Rad, Hercules, CA, USA 
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Tube Rotator MACS Mix Tube Rotator 
Miltenyi, Bergisch-Gladbach, 
Germany 
Vortex REAX top Heidolph 
Water purification 
system 
Milli Q Direct Q 16 
Merck Millipore, Billerica, MA, 
USA 
 
All solutions were prepared with Millipore water (Milli Q Direct Q 16, Merck Millipore, 
Billerica, MA, USA), if not stated otherwise.  
2.2 Human specimen 
2.2.1 Gene expression of CD27 and CD70 in human plaques 
CD27 and CD70 gene expression data was taken from an existing database and 
analyzed as described previously.106, 207 In short, human carotid endarterectomy (cea) 
specimens were obtained from the Maastricht Pathology Tissue Collection. 
Atherosclerotic lesions were classified according to the Virmani criteria.208 Segments 
considered as stable harbored fibrous cap atheromata or a pathological intimal 
thickening whereas segments designated ruptured displayed intra-plaque hemorrhage 
and/or a thrombus encroaching the lumen. Sections were considered stable or ruptured 
if they were flanked at both sides by a similar plaque type within the same 
endarterectomy specimen. Only endarterectomy specimen containing stable and 
ruptured plaque segments (n = 20, respectively) within the same specimen were 
applied for a microarray analysis to determine mRNA expression by Illumina Human 
Sentrix‐8 V2.0 BeadChip technology (Illumina, Inc., San Diego, USA). All use of tissue 
and patient data was in agreement with the “Code for Proper Secondary Use of Human 
Tissue in the Netherlands”. Patients suffering from acute inflammatory disorders 
(sepsis etc.) were excluded. The patient cohort was 72.55±6.36 and 72.38±7.89 (stable 
vs. ruptured) years old and 100% vs 95.8% male (stable vs. ruptured). 
2.2.2 Human carotid endarterectomy specimens and tissue processing 
For (immune-) histological analysis, CEA specimens were obtained from the vascular 
surgery department of the Academic Medical Center in Amsterdam and immediately 
fixed in 10% formalin and processed for paraffin embedding. All use of tissue was in 
agreement with the “Code for Proper Secondary Use of Human Tissue in the 
Netherlands”. 
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2.2.3 Histological staining of CEA sections 
To determine the plaque phenotype, consecutive sections (4μm) were stained with 
standard hematoxylin and eosin (H&E) and elastin von Gieson (EVG).  
For CD27-positive T cell visualization, sections were boiled in 1 M solution of 
Tris(hydroxymethyl)aminoethamine (Tris) with a 0.1 M ethylenediaminetetraacetic acid 
(EDTA) (pH 8.0, Lab Vision, Fremont, USA) and blocked with Lab VisionTM Ultra V-
Block (Thermo Scientific). Next, specimens were incubated with monoclonal rabbit anti-
human CD3 (dilution: 1:1000; Immunologic BV, Duiven, The Netherlands) antibody. 
BrightVision poly-horseradish peroxidase-anti-rabbit IgG (Immunologic BV) was used 
as secondary antibody and visualized by ImmPACTTM AMEC Red Substrate (Vector 
Laboratories, Burlingame, USA). Furthermore, staining for CD27-positive cells was 
performed using monoclonal mouse anti-human CD27 (LifeSpan BioSciences, Inc., 
Seattle, USA) antibody. BrightVision poly-alkaline phosphatase-anti-mouse IgG 
(Immunologic BV) was used as secondary antibody and visualized by Vector® Blue 
Substrate (Vector Laboratories, Burlingame, USA). Sections stained solely for CD3 
were counterstained with hematoxylin or with nuclear red for CD27, respectively.  
2.3 Mice 
Cd27-/- mice155 and Cd70Cre/Cre mice190 were crossed with Apoe-/- mice (stock No. 
002052, The Jackson Laboratory, Bar Harbor, Maine, USA) mice to generate Cd27+/-
Apoe-/- mice or Cd70+/CreApoe-/- mice, respectively. Cd70Cre/Cre mice are CD70-deficient 
as exon 1 of the CD70 locus was replaced by a DNA sequence coding for the Cre 
recombinase.156 To simplify matters, Cd70Cre/Cre mice will be referred to as Cd70-/- mice 
throughout this thesis. Heterozygous mice were intercrossed and Cd27+/+Apoe-/- and 
Cd27-/-Apoe-/- or Cd70+/+Apoe-/- and Cd70-/-Apoe-/- littermates, respectively, were used. 
Housing and breeding of mice followed institutional guidelines. All animal experiments 
were approved by the local ethical committee for animal experimentation. 
2.3.1 Genotyping 
Newly weened mice were marked by individual ear notches and holes produced by an 
ear punch device. A tail biopsy of 1-2 mm length was taken for genotypic analysis of 
mice.  
The tail biopsy was incubated overnight at 56°C in 250 µl tissue lysis buffer (see 2.8) 
supplemented 1:100 with proteinase k solution (Qiagen, Hilden, Germany). 
Subsequently, automatic DNA isolation was performed with the QIAxtractor (Qiagen) 
2 MATERIALS AND METHODS 
 
26 
according the manufacturer’s instructions. The isolated DNA was kept at 4°C and 
applied for polymerase chain reaction (PCR).  
 
Following PCR mastermixes were prepared for CD27, CD70 and Apoe genotyping 
reactions: 
 
Stock concentration   Volume in µl 
Dnase-/Rnase-free H2 O  -     12.75 
GoTaq Flexi buffer   5x     5 
MgCl2     25 mM     2 
dNTP mix    10 mM each    0.5 
forward Primer   10 µM     1.25 
reverse Primer   10 µM     1.25 
GoTaq DNA Polymerase  5 U/µl     0.25 
Genomic DNA    100 ng/µl    2 
 
GoTaq Flexi DNA polymerase and GoTaq Flexi buffer were obtained from Promega 
(Promega, Fitchburg, WI, USA). Dnase-/Rnase-free H2O, primer, magnesium chloride 
(MgCl2), and the deoxynucleotide triphosphate (dNTP, containing deoxyadenosine/-
guanosine/-cytidine/-thymidine triphosphate) mix were obtained from Sigma (Sigma 
Aldrich, St. Louis, USA). 
Two mastermixes each were prepared for CD27 and CD70 genotyping containing 
either wildtype- or mutant allele-detecting primer.  
The PCR program for CD27 DNA detection was composed of an initial step at 94°C for 
2 min followed by 35 cycles of each 30 sec at 94°C, 30 sec at 60°C, and 1 min at 72°C. 
Subsequently, the samples were incubated at 72°C for 5 min and 21°C for 5 min. 
 
Primer sequences for CD27 genotyping: 
CD27 wildtype forward  5' CAA ACT CTG GTC CTC TGG AG 3' 
CD27 wildtype reverse  5' AGG GCA GTG CTA TCC CTA TC 3' 
CD27 mutant forward   5' CGT CTG TCG AGA AGT TTC TG 3’ 
CD27 mutant reverse   5' AGA AGA AGA TGT TGG CGA CC 3' 
 
The amplified PCR products were each electrophoretically separated applying the 
QIAexcel Advanced System (Qiagen) according to the manufacturer’s instructions. 
Expected results are a wildtype product at 390 base pair (bp) length and a mutant 
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product at 680 bp length. DNA samples from heterozygous mice would yield a product 
at 390 bp and 680 bp length. 
Also for CD70 and Apoe genotyping two mastermixes were prepared with the common 
CD70 or Apoe forward primer and either the wildtype reverse primer or the mutant 
reverse primer. The PCR program was composed of an initial step at 94°C for 5 min 
followed by 35 cycles of each 30 sec at 94°C, 30 sec at 60°C, and 1 min at 72°C. 
Subsequently, the samples were incubated at 72°C for 5 min and 21°C for 5 min. 
 
Primer sequences for CD70 genotyping: 
CD70 common forward  5' ACA GGC CTG CTT CAG TTT GT 3' 
CD70 wildtype reverse  5' TGC TTT AGC GCT TTC TCT CC 3' 
CD70 mutant reverse   5' TCA AGT GTA TGG CCA GAT CG 3' 
 
Expected results for CD70 are a wildtype product at 406 bp length and a mutant 
product at 472 bp length. DNA samples from heterozygous mice would yield a product 
at 406 bp and 472 bp length. 
 
Primer sequences Apoe genotyping: 
Apoe common forward  5’ GCC TAG CCG AGG GAG AGC CG 3’ 
Apoe wildtype reverse  5’ TGT GAC TTG GGA GCT CTG CAG C 3’ 
Apoe mutant reverse   5’ GCC GCC CCG ACT GCA TCT 3’ 
 
Expected results for Apoe are a wildtype product at 150 bp length and a mutant 
product at 245 bp length. DNA samples from heterozygous mice would yield a product 
at 150 bp and 245 bp length. 
2.3.2 Surgical procedure 
Mice were administered a normal chow diet and at the age of 18 and 28 weeks, mice 
were euthanized i.p. with Ketamine/Xylazine and blood was obtained via cardiac 
puncture. Spleen, abdominal aorta, liver, aortic root, and lymph nodes were harvested 
after perfusion of the arterial tree with sodium nitroferricyanide(III) dehydrate (Sigma 
Aldrich) followed by 1% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) 
perfusion (Sigma Aldrich). Parts of the tissue were stored in RNAlater (Life 
Technologies, Carlsbad, USA) for 24 h at room temperature and afterwards at -80°C. 
Hearts were isolated and frozen in Tissue-tek (Sakura Finetek, Torrance, USA). The 
aortic arch and its main branch points were excised, fixed overnight in 1% PFA in PBS, 
and embedded in paraffin.  
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2.3.3 Bone marrow transplantation 
Bone marrow cells were isolated from femurs and tibiae of Cd27+/+Apoe-/- and Cd27-/-
Apoe-/- or Cd70+/+Apoe-/- and Cd70-/-Apoe-/- and a single-cell suspension was prepared, 
followed by lysis of red blood cells (see 2.8). The bone marrow from the donor mice 
was stored at 5x107/ml in Roswell Park Memorial Institute 1640 (RPMI1640) (Life 
Technologies) medium containing 10% fetal bovine serum (FBS) (Life Technologies) 
and 10% dimethylsulfoxid (DMSO) (Sigma Aldrich) in liquid nitrogen until further use. 
Six to seven-week-old recipient Apoe-/- mice (Jackson laboratory) received drinking 
water containing antibiotics (polymyxin B sulfate, 6000 U/ml and neomycin, 100 µg/ml, 
Life Technologies) from 1 week prior to the bone marrow transplantation until 4 weeks 
after. Recipient mice were lethally-irradiated with 6 Gy (0.5 Gy/min; MU15F/225 kV; 
Philips, Eindhoven, The Netherlands) on two consecutive days. Following the second 
round of irradiation recipient mice were reconstituted intravenously with 1.5x106 thawed 
and washed bone marrow cells from either Cd27+/+Apoe-/- and Cd27-/-Apoe-/- or 
Cd70+/+Apoe-/- and Cd70-/-Apoe-/- mice, respectively. Recipient mice were allowed to 
recover for 6 weeks and received a cholesterol-rich diet (HFD) containing 16% fat and 
0.15% cholesterol (Western type diet 4021.13, Hope Farms, The Netherlands) for 7 
weeks until their sacrifice was performed as described above.  
2.4 Protein assays 
2.4.1 Flow cytometry 
Aortas were digested with an enzymatic cocktail (Collagenase I, 450 U/ml; collagenase 
XI, 250 U/ml; hyaluronidase, 120 U/ml; deoxyribonuclease (DNase) I, 120 U/ml; all 
Sigma Aldrich) in PBS containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) (Thermo Scientific) for 30 min at 37°C as previously described.209 Single 
cell suspensions of the aortic lysates were prepared by filtering the aortic tissue 
through a 50 µm cell strainer (BD Biosciences). Aortic lysates were washed with 1x 
PBS and resuspended in 100 µl 1x PBS/staining mix (maximum 2 staining panels were 
applied due to low abundance of leukocytes). Cell suspensions were prepared from 
harvested spleens and lymph nodes by tearing the tissues apart. Single cell 
suspensions were prepared by meshing the tissue through a 70 µm cell strainer (BD 
Biosciences). Splenic cells were erylysed (6 ml for a whole spleen) for 3 min on ice, 
washed and filtered through a 70 µm cell strainer. Freshly-drawn blood was incubated 
with red blood cell lysis buffer (5 ml for 1 ml blood) for 10 min at room temperature and 
subsequently washed. If the pellet was still containing too many red blood cells, 
another lysis step was performed (3 ml, 3 min, wash). Wash steps were performed with 
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1x PBS. Pellets from lymph nodes were resuspended in 1 ml PBS and pellets from 
whole spleens in 6 ml PBS. Blood leukocytes were resuspended in 100 µl/staining mix. 
Subsequently, 100 µl of cell suspension were stained with a viability dye (Live/Dead 
fixable Aqua/Violet/Near-Infrared; Life Technologies) to discriminate between living and 
dead cells according the manufacturer’s instruction concomitantly with Fc-Block (anti-
CD16/32-antibody, functional grade, clone:93, 1:100, eBioscience, San Diego, CA, 
USA). 1x PBS was used for Live/Dead staining as protein components of buffers, such 
as bovine serum albumin (BSA) FACS buffer, could reduce staining efficacy thus 
producing false negative results. Single cell suspensions were incubated (20 min, dark, 
room temperature) and washed with FACS buffer to remove remnant Live/Dead dye. 
Subsequently, cells were incubated for 20 min on ice with 50 µl of antibody mixes with 
antibodies from BD Biosciences, eBioscience, Biolegend (San Diego, CA, USA), or 
Novus Biologicals (Littleton, CO, USA). An extended list of antibodies applied in 
staining panels can be found below. An additional washing step was performed after 
antibody-staining with FACS buffer to remove unbound antibodies. In case intracellular 
stainings were performed the Foxp3/Transcription Factor Staining Buffer Set was used 
according the manufacturer’s instructions (eBioscience). To determine the level of 
apoptosis, stainings were performed for fluorochrome-conjugated Annexin V 
(Biolegend) and simultaneous exclusion of dead cells determined by Live/Dead 
staining (Life Technologies) according the manufacturer’s protocol. Apoptosis stainings 
were analyzed immediately. Other stainings were fixed with 1% PFA in FACS buffer 
and analyzed within the following days. Single cell suspensions were analyzed using a 
FACS Canto II (BD Biosciences) and data were analyzed using Flowjo v.10 (Flowjo, 
LLC, Ashland, USA). 
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2.4.2 Table 2: Antibodies used for flow cytometry 
Antigen Source and reactivity Clone Dilution Source 
CD45 
APCe780 
Rat-anti-mouse (IgG2b, ) 30-F11 1:400 eBioscience 
CD4 V500 Rat-anti-mouse (IgG2a, ) RM4-5 1:200 BD Biosciences 
CD8a e450 Rat-anti-mouse (IgG2a, ) 53-6.7 1:200 eBioscience 
Foxp3 PE 
Rat-anti-
mouse/rat/pig/canine/bovine 
(IgG2b, ) 
FJK-16s 1:40 eBioscience 
CD3 FITC 
Armenian Hamster-anti-
mouse (IgG) 
45-2C11 1:200 eBioscience 
CD25 APC Rat-anti-mouse (IgG1, ) PC61.5 1:300 eBioscience 
CD44 APC 
Rat-anti-mouse/human 
(IgG2b, ) 
IM7 1:1000 eBioscience 
Ki-67 FITC 
Rat-anti-
mouse/rat/canine/human 
(IgG2a, ) 
SolA15 1:100 eBioscience 
BCL-2 PE Rat-anti-mouse (IgG1, ) 10C4 1:40 Biolegend 
CD70 PE Rat-anti-mouse (IgG2b, ) FR70 1:100 eBioscience 
-TCR e450 
Armenian Hamster-anti-
mouse (IgG) 
H57-597 1:200 eBioscience 
TCR APC 
Armenian Hamster-anti-
mouse (IgG) 
eBioGL3 1:200 eBioscience 
CD11b 
PerCp-Cy5.5 
Rat-anti-mouse (IgG2b, ) M1/70 1:300 eBioscience 
F4/80 BV510 Rat-anti-mouse (IgG2a, ) BM8 1:300 Biolegend 
CD27 PE-
Cy7 
Armenian Hamster-anti-
mouse/rat/human (IgG) 
LG.3A10 1:300 Biolegend 
ABCA-1 PE Rabbit polyclonal 1:200 
Novus 
Biologicals 
ABCG-1 
FITC 
Rabbit polyclonal 1:200 
Novus 
Biologicals 
APC =Allophycocyanin, PE=Phycoerythrin, FITC = Fluorescein Isothiocyanate, PerCp 
= Peridinin chlorophyll, Cy = Cyanine 
2.4.3 Plasma preparation and lipid analysis 
Plasma was isolated by centrifugation (500 x g, 15 min, 4°C) of EDTA-anticoagulated 
blood. Plasma cholesterol concentration was determined using a colorimetric assay 
(Roche, Basel, Switzerland). In brief, the plasma samples were diluted 1:5 with 0.9% 
saline on ice. For a calibration of the machine a standard (Roche/Hitachi; 152 mg/dl 
accordingly 3.95 mmol/l) was serially diluted 1:2, 1:4, 1:8, 1:16 and 1:32 with 0.9% 
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saline on ice. Subsequently, 2 µl of each standard, sample and blank (0.9% saline) 
were transferred to a flat bottom microtiterplate (BD Biosciences) on ice. To increase 
the range of the standard 2 µl and 4 µl undiluted standard was added to the respective 
wells.  After adding 200 µl reagent CHOD-PAP (Roche) to each well the microtiter-plate 
was gently mixed. Following incubation at room temperature for 30 min absorbance at 
505 nm wavelength was measured using a 96-well plate reader (Tecan GENios). For 
calculating the cholesterol content of the sample the following equation was used: 
 
Sample (mean) x standard-concentration (mmol/l) 
Concentration (mmol/l) =   
Standard (mean) 
 
Lipoproteins were isolated by sequential ultracentrifugation from 60 µl of plasma at d < 
1.006 g/ml [very LDL (VLDL)], 1.006 ≤ d ≤ 1.063 g/ml [intermediate-density lipoprotein 
and LDL], and d > 1.063 g/ml [HDL] in an Optima LE 80K ultracentrifuge (Beckman, 
Brea, CA, USA). Cholesterol concentration in the respective lipoprotein fraction was 
determined enzymatically using a colorimetric assay (Roche). Hematologic analysis 
was performed with a ScilVet abc Plus+ (ScilVet, Viernheim, Germany). 
2.4.4 Plasma analysis 
Murine plasma was analyzed for cytokine levels, general Ig levels and oxLDL-reactive 
Ig using multiplex bead-based assays (eBioscience) and enzyme-linked 
immunosorbent assays (ELISA). 
2.4.4.1 Anti-oxLDL-Ig ELISA 
The abundance of antibodies detecting oxLDL in plasma of Cd70+/+Apoe-/- and Cd70-/-
Apoe-/- mice was detected via ELISA. In brief, a 96-well polystyrene microplate (Costar 
3690, Corning, Corning NY, USA) was incubated with 50 µl per well of 10 µg/ml oxLDL 
in PBS pH 7.4 at 4°C overnight. Wells were washed twice with PBS, blocked 1h at 
room temperature with 1% gelatin (Sigma Aldrich) in PBS and washed twice with PBS. 
Subsequently, 50 µl of pre-diluted mouse plasma (1:20, 1:200, 1:1000) in 0.1% 
gelatin/Tris-buffered saline (TBS) were added per well and incubated for 2 h at room 
temperature. After incubation, wells were washed thrice with 0.05% PBS-Tween (PBS-
T) and 50 µl of the biotinylated anti-mouse IgG-antibodies listed below were added 
(each antibody was diluted 1:25000 in 0.1% gelatin/TBS): 
 Biotin-SP-conjugated Goat anti-mouse IgG1, 
 Biotin-SP-conjugated Goat anti-mouse IgM, µ chain, 
 Biotin-SP-conjugated Goat anti-mouse total IgG, 
2 MATERIALS AND METHODS 
 
32 
 Biotin-SP-conjugated Goat anti-mouse total IgG2b, 
 Biotin-SP-conjugated Goat anti-mouse total IgG3, 
 Biotin-SP-conjugated Goat anti-mouse total IgG2a, 
All antibodies were obtained from Jackson ImmunoResearch Labs and handled 
according the manufacturer’s data sheets. Subsequent to incubation for 1 h at room 
temperature with biotinylated antibodies, wells were washed thrice in 0.05% PBS-T and 
50 µl of streptavidin conjugated to horse radish peroxidase (HRP, 1:1000 in 0.1% 
gelatin/TBS) were added (1 h ,room temperature, dark). After washing with 0.05% 
PBS-T (4x), 50 µl 3,3',5,5'-Tetramethylbenzidin (TMB) substrate (1-Step Ultra TMB 
ELISA substrate, Thermo Scientific) were added for 2-10 min depending of titers. The 
substrate is converted into blue product in presence of HRP activity. The addition of 1 
M hydrochloric acid (HCL) stopped the reaction and changes the substrate to a yellow 
color. Absorbance was analyzed with an ELISA-well plate reader (Tecan GENios) at 
450 nm wavelength with reference wave length set at 570 nm.  
2.4.4.2 TGF1 ELISA 
TGF1 concentration was determined in murine plasma employing a specific ELISA 
(Thermo Scientific). The manufacturer’s protocol was followed. In brief, a 96-well plate 
was coated with a monoclonal antibody detecting murine TGF1. Murine plasma 
samples and control regimen were incubated in duplicates on the 96-well plate followed 
by incubation with a biotinylated antibody detecting TGF1. Several washing steps 
were performed between each incubation step. Subsequently, a streptavidin-HRP 
conjugate was added and colorimetric conversion of a substrate based on the 
enzymatic activity of HRP was analyzed with an ELISA well plate reader (Tecan 
GENios) at 450 nm wavelength with reference wave length set to 570 nm.  
Of note, total TGF was analyzed after activation of latent TGF with acidic treatment, 
since concentrations of active TGFalone are below the detection limit in murine 
plasma. 
2.4.4.3 Bead Arrays 
Murine plasma from 18-week-old Cd27+/+Apoe-/-, Cd27-/-Apoe-/-, Cd70+/+Apoe-/-, Cd70-/-
Apoe-/- and from 28-week-old Cd27+/+Apoe-/-and Cd27-/-Apoe-/- mice was analyzed for T 
helper cytokine abundance with the mouse Th1/2/17/22 13-plex kit FlowCytomix 
Multiplex Kit (eBioscience) which allows for the simultaneous detection of IL-13, IL-1, 
IL-2, IL-22 IL-5, IL-21, IL-6, IL-10, IL-27, IFN, TNF, IL-4, and IL-17. Levels of 
circulating Ig subclasses (IgA, IgG1, IgG2a, IgG2b, IgG3, IgM) from 18-week-old 
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Cd70+/+Apoe-/- and Cd70-/-Apoe-/- mice were assessed with the mouse Ig isotyping 6-
plex kit (eBioscience). Both assays are bead-based and follow a similar principal as a 
sandwich ELISA. Analysis was performed with a flow cytometer (BD FACS Canto II, 
BD Biosciences). In brief, fluorescently-marked polystyrol beads were pre-coupled with 
antibodies specifically detecting the respective analyte(s) of interest. A single bead 
population was only coupled with one specific capturing antibody. A mixture of different 
bead populations was incubated with plasma samples for 2 h. The bead-bound-analyte 
from the plasma sample was detected by a biotinylated detection antibody. Subsequent 
1h incubation with streptavidin conjugated PE binding to the biotinylated analyte-bead-
complex allowed for quantification of the respective analyte. The bead samples were 
acquired with a BD FACS Canto II (BD Biosciences). Up to 20 bead sets could be 
analyzed in one fluorescent channel as the beads are distinguishable by size (4 µm 
and 5 µm) and different intensities of the fluorochrome labeling the bead populations. 
Here, beads were labeled with a fluorochrome emitting in the far-red channel at 690 nm 
wavelength. First beads were separated by size by displaying size (front scatter) and 
granularity (side scatter). Gating on the size-separated bead populations allowed for 
further discrimination in fluorescence intensity by displaying fluorescence emitted in the 
APC channel. Mean fluorescence intensities (MFI) of each bead population for 
fluorescence emitted in the PE channel were acquired and standard curves based on 
the MFI obtained from standard cytokine beads were used for quantification of sample 
analyte concentration. Flow cytometer data was analyzed with the FlowCytomix Pro 3.0 
analysis software to obtain plasma cytokine or Ig concentrations.  
During the course of this thesis the manufacturer replaced the bead array technology 
analyzed by flow cytometry with the ProcartaPlex immunoassays using Luminex xMAP 
technology for the multi-analyte detection. Here, we applied the ProcartaPlex mouse 
Th1/Th2/Th9/Th17/Th22/Treg cytokine panel (17 plex) to simultaneously analyze 
plasma concentration of IL-12, IL-23, IL-27, GM-CSF, IFNTNFIL-1, IL-10, IL-13, 
IL-17A, IL-18, IL-2, IL-22, IL-4, IL-5, IL-6, and IL-9. Plasma was obtained from 
Cd27+/+Apoe-/-, Cd27-/-Apoe-/-, Cd70+/+Apoe-/- or Cd70-/-Apoe-/- bone-marrow 
transplanted Apoe-/- mice. The xMAP technology is also a bead-based technique which 
applies beads which are internally labeled with fluorescent dyes to produce a specific 
spectral address. The beads are magnetized thus allowing for convenient washing 
steps in a 96-well plate. The beads are coupled with antibodies which will capture the 
specific analyte which in turn will be bound by a biotinylated detection antibody. 
Quantification will follow the binding of streptavidin-PE-conjugates to the detection 
antibody. Again, MFI of each bead population for fluorescence emitted in the PE 
channel were acquired and standard curves based on the MFI obtained from standard 
2 MATERIALS AND METHODS 
 
34 
cytokine beads were used for quantification of sample analyte concentration. The 
samples were analyzed with the Luminex platform MAGPIX (Luminex). Data was 
analyzed with the xPONENT software controlling the MAGPIX platform (Luminex). 
2.4.5 Histochemistry (morphometry and histology) 
Hearts were cut in 8 µm-thick serial sections beginning from the onset of the aortic 
valves until the valves disappeared. Serial sections were stained with Oil Red O 
(Sigma to determine lipid depositions and analyzed with a Leica DM6000 microscope 
(Leica Microsystems) equipped with a computerized morphometry system (LAS 4.6 
analysis, Leica Microsystems). In brief, air-dried cryostat sections were pre-incubated 
with 60% 2-propanol (10x dipping) and subsequently kept 15 min in the Oil Red O-
working solution (180 ml Oil red O-stock solution and 120 ml distilled water filtered 1 h 
after mixing to remove precipitated salts). Excess Oil Red O solution was washed away 
by dipping 10 x in 60% 2-propanol. The sections were rinsed 5 min in tap water and 
counterstained with hemalaun in distilled water for 30 s followed by rinsing 5 min in tap 
water. Oil red O-stained sections were embedded in Immu-Mount (Thermo Scientific). 
H&E-stained sections were classified as initial or advanced according the histological 
criteria determined by Virmani et al.208 A picrosirius red staining was applied to 
visualize collagen content in atherosclerotic lesions. Phosphomolybdic acid (0.2%, 
Merck, Darmstadt, Germany) was used to block unspecific binding and sections were 
analyzed using brightfield light microscopy. Tissue sections with insufficient quality 
were excluded from further analysis, which influences the individual parameter group 
size.  
2.4.6 Immunohistochemistry 
Selected murine tissue cryosections were fixed in ice-cold acetone prior to incubation 
with antibodies against CD68 (AbD Serotec), alpha smooth muscle actin (-SMA), 
CD3, CD4, Foxp3, ICAM-1, and VCAM-1. The primary antibody binding of non-
fluorescent conjugated antibodies was detected either by incubation with fluorochrome- 
(Alexa Fluor 488, Alexa Fluor 594, Cy3 or horse-radish peroxidase-conjugated 
secondary antibodies and diaminobenzidine (ABC kit, Vector Labs, Burlingame, USA). 
To amplify signal strength for -SMA staining, a primary antibody against -SMA 
conjugated with FITC and secondary antibody directed against FITC and conjugated 
with Alexa Fluor 488 were used. Tissue sections were counterstained with hematoxylin 
or 4’,6-Diamidino-2-phenylindol (DAPI, Life Technologies), respectively, mounted with 
DAKO fluorescent mounting medium (Dako, Agilent Technologies, Santa Clara, CA, 
USA), and images were recorded with a Leica DM6000 microscope equipped with a 
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DFC295 and DFC365FX camera (Leica). CD3-, CD4-, and Foxp3-stained cells were 
counted. CD68-, -SMA-, ICAM-1-, and VCAM-1-positive areas were analyzed by 
applying color threshold measurements. ICAM-1 staining in sections of the aortic sinus 
is specifically correlating with endothelium. However, SMC are also expressing VCAM-
1 besides EC. Thus, to specifically assess endothelial VCAM-1 staining, additional 
CD31 staining with a directly-conjugated antibody was performed. The CD31 positive 
area in the aortic root was subsequently assessed for VCAM-1 staining. The ICAM-1-
and VCAM-1-positive area was correlated to plaque endothelial length. Tissue sections 
with insufficient quality were excluded from further analysis, which influences the 
individual parameter group size.  
2.4.7 Confocal microscopy 
Selected tissue cryosections from Apoe-/- mice were fixed in ice-cold acetone prior to 
incubation with antibodies against CD4, Foxp3, -SMA, CD8, MAC3, CD68 (Abcam, 
Cambridge, United Kingdom), CD70, and CD27. The primary antibody binding was 
detected by incubation with fluorochrome-conjugated secondary antibodies (Alexa 
Fluor 488, Cy3; Abberior STAR 635 P). Tissue sections were counterstained with DAPI 
(Life Technologies) and mounted in DAKO fluorescence mounting medium. Confocal 
laser scanning microscopy was performed with a Leica SP8 3X microscope equipped 
with a 100xNA1.40 (Leica) oil immersion objective. Optical zoom was utilized where 
applicable. For fluorescence excitation, a UV laser (405 nm), and a tunable white light 
laser (488 nm, 552 nm, and 635 nm) were used to excite DAPI, Alexa Fluor 488, Cy3, 
Abberior Star 635p, respectively. Emitted fluorescence signal was sequentially 
detected using hybrid diode detectors spectrally set to minimize bleed-through between 
the sequentially recorded channels: 420-470 nm for DAPI, 515-540 nm for Alexa Fluor 
488, 590-660 nm for Cy3, and 655-750nm for Abberior STAR 635 P. Image processing 
was performed using Leica LAS X software, image deconvolution (CMLE algorithm) 
was conducted with the Huygens Professional 15.05 software package (Scientific 
Volume Imaging, The Netherlands). The obtained 3D datasets are presented as 
extended depth of field projections based on maximum intensity contrast. 
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2.4.8. Table 3: Primary antibodies used in immunohistochemistry 
Antigen Source and reactivity Clone Dilution Source 
CD3 
Armenian Hamster-anti-mouse 
(IgG1, ) 
145-2C11 1:100 BD Biosciences 
CD4 Rat-anti-mouse (IgG2a, ) RM4-5 1:100 BD Biosciences 
Foxp3 
Rat-anti-
mouse/rat/pig/canine/bovine 
(IgG2b, ) 
FJK-16s 1:50 eBioscience 
SMA 
Mouse-anti-
mouse/rabbit/human/pig 
(IgG2a) FITC conjugated 
1A4 1:1000 Sigma Aldrich 
CD8 Rat-anti-mouse (IgG2a) YTS105.18 1:100 
AbD Serotec, 
Puchheim, 
Germany 
MAC3 Rat-anti-mouse (IgG1, ) M3/84 1:200 BD Biosciences 
CD68 Rat-anti-mouse (IgG2a) FA-11 1:200 AbD Serotec, 
CD68 Rabbit-anti-mouse/human Polyclonal 1:200 Abcam 
CD27 
Armenian Hamster-anti-
mouse/rat/human (IgG) 
LG.3A10 1:100 eBioscience 
CD70 Rat-anti-mouse (IgG2b, ) FR70 1:100 eBioscience 
ICAM-1 
Armenian Hamster-anti-mouse 
(IgG) 
3E2B 1:100 
Thermo 
Scientific 
VCAM-1 Rat-anti-mouse (IgG1) 6C7.1 1:500 
Novus 
Biologicals 
CD31-PE Rat-anti-mouse (IgG2a, ) MEC13.3 1:300 BD Biosciences 
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2.4.9. Table 4: Secondary antibodies used in immunohistochemistry 
Source and Reactivity Conjugate Dilution Source 
Donkey-anti-rat Alexa Fluor488 1:300 Thermo Scientific 
Mouse-anti-FITC Alexa Fluor488 1:400 
Jackson 
ImmunoResearch, 
West Grove, PA, 
USA 
Goat-anti-armenian 
hamster 
Cy3 1:300 Thermo Scientific 
Goat-anti-mouse Alexa Fluor594 1:300 Thermo Scientific 
Goat-anti-rabbit Star 635P 1:300 
Abberior, 
Goettingen, 
Germany 
2.4.10 Western blot 
At day 7 bone marrow-derived macrophages (BMDM) were loaded with 15 µg/ml 
oxLDL for 48 h. Subsequently, BMDM were lysed using radioimmunoprecipitation 
assay (RIPA) buffer supplemented with a protease inhibitor cocktail (Complete Mini, 
Roche). Aliquots (30 μg) of total protein were then size-fractioned by sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (4-12% Tris-Glycine Mini Protein 
gels, Novex, Thermo Scientific) and transferred to nitrocellulose membranes. After 
blocking for 1h in Tris-buffered saline containing 0.1% Tween 20 and 3-5% skim milk, 
membranes were probed overnight at 4°C with primary antibodies against ABCA1 or 
ABCG1 (both from Abcam). Target protein expression was normalized to 
glycerinaldehy-3-phosphat-dehydrogenase (GAPDH) (Abcam) to correct for loading 
and band densities were analyzed using ImageJ software. 
2.5 Cell culture and functional assays 
Cell culture was performed under sterile conditions in a laminar flow hood. Cells were 
maintained in a carbon dioxide (CO2)-incubator at 37°C and a humidified 5% CO2 
atmosphere. FBS was incubated at 56°C for 30 min to inactivate the complement 
proteins and stored at -20°C until use. According to cell types specific media were 
used.  
2.5.1 CD4+ T cell isolation 
T cells were sorted isolated from spleen and lymph nodes. CD4+ T cells were 
negatively sorted using antibody-conjugated magnetic beads (Dynabeads Untouched 
Mouse CD4, Life Technologies) and dynal isolation buffer. In brief, an antibody-mix 
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was used to label non-CD4+ T cells. The addition of Fc-binding magnetic beads bound 
the labeled cells in the tube while separating untouched CD4+ T cells. Tregs were 
sorted by either flow cytometry sorting for CD3+CD4+CD25high cells (BD FACS Aria III, 
BD Biosciences) or using an untouched CD4 negative magnetic bead-sort followed by 
a CD25 positive magnetic bead sort according to the instructions of the manufacturer 
(Dynabeads Flowcomp Mouse CD4+CD25+ Treg cells kit, Life Technologies). T Cells 
were cultured in T cell medium (see 2.9). 
2.5.2 Treg suppression assay 
Sorted CD4+ T cells from Apoe-/- mice were stained with carboxyfluorescein 
succinimidyl ester (CFSE, Life Technologies). In brief, T cells were adjusted to 
1x106/100 µl in 37°C pre-warmed and stained with 3 µM CFSE for 15 min at 37°C in a 
water bath while shaking the tube every 2 min. Subsequently, the T cells were washed 
twice with T cell medium and adjusted to 1x106/ml. 5x104 CFSE-labeled T cells were 
co-cultured in a 1:1 ratio with anti-CD3/CD28 antibody-conjugated beads (Life 
Technologies) and varying concentrations of Tregs from Cd27+/+Apoe-/- or Cd27-/-Apoe-/- 
mice for 72 h. T cell proliferation was determined by CFSE dilution measured by flow 
cytometry. 
2.5.3 Treg chemotaxis assay 
For chemotaxis assays CD4+ T cells from either Cd27+/+Apoe-/- or Cd27-/-Apoe-/- mice 
were sorted (Dynabeads Untouched Mouse CD4, Life Technologies) and applied on 
top of a HTS transwell plate (5 µm pore size, Corning, New York, USA) containing in 
the lower compartment varying concentrations of murine CCL19 or CCL21 (R&D 
Systems, Minneapolis, USA). Cells were incubated for 2 h and migration was assessed 
by determining the absolute number of migrated cells using CountBright beads (Life 
Technologies) and flow cytometry (BD FACS Canto II, BD Biosciences).  
2.5.4 L929-conditioned medium 
L929 is a murine fibrosarcoma cell-line that secretes macrophage-colony stimulating 
factor (M-CSF) into the medium, a growth factor for macrophage development and 
essential for differentiation BMDMs in vitro. In brief, L929 cells were cultured in D10 
medium until monolayers reached confluence and were expanded in several culture 
flasks. If cells reached confluence in 162 cm² culture flasks (Corning), L929 cells were 
harvested and combined in a 10-STACK culture flask (Corning). The volume is 
approximately 1300 ml. The L929 culture was again allowed to gain confluence upon 
which another 500 ml D10 medium was added (total volume in 10-STACK: ~1800 ml). 
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The culture was continued for another 10 days during which the L929 cells secreted M-
CSF into the supernatant. Subsequently, the conditioned medium was sterile filtered 
and aliquots were stored at -80°C until usage. As the exact concentration of M-CSF in 
the medium is unknown, bone marrow-derived macrophage cultures were started (see 
2.5.5) to determine an appropriate amount of L929 as supplement. A range of 
concentrations (5%, 10%, 15%, 25%) of L929-conditioned medium were tested. At day 
8 of the culture, BMDMs were replated, allowed to attach for 4h, and stimulated with 
LPS at 0, 1, 10, 100 ng/ml. Subsequently, the cultured cells were assayed for nitric 
oxide (NO) production (see 2.5.7) and analyzed for macrophage marker expression to 
determine the appropriate amount of L929 as supplement to induce macrophage 
differentiation. 
2.5.5 Bone marrow-derived macrophages 
Bone marrow cells were flushed from tibia and femur with cold RPMI 1640 medium 
(Life Technologies) and subjected to red blood cell lysis as described above. The cells 
were resuspended in macrophage differentiation medium (see 2.9). On day 3 of the 
culture, fresh macrophage differentiation medium was added without removing the old 
medium. At day 6 the medium was exchanged by fresh medium. At day 8 the cells 
were detached by incubating 5 min at 37°C in 10 ml citrate saline buffer. After washing, 
the cells were counted and plated or used for additional assays. 
When stated the cells were cultured with 50 µg/ml oxLDL for 24-48 h on day 8. 
Consecutively, cells were labeled with propidium iodide (PI) (Biolegend) and Annexin V 
(Biolegend) for 15 min according to the manufacturer’s protocol. The percentage of live 
(Annexin V-/PI-), apoptotic (Annexin V+/PI-), and necrotic (Annexin V+/PI+) cells was 
analyzed using a BD FACS Canto II (BD Biosciences). 
2.5.6 Metabolic analysis 
At day 8 of the BMDM culture 50000 cells were seeded per well in an XFe96 cell 
culture microplate in 100 µl culture medium. 24 h after plating the cells extracellular 
acidification rates (ECAR) and oxygen consumption rates (OCR) were measured in 
real-time in an XF-96 Flux Analyzer (Seahorse Bioscience, Agilent Technologies) as 
described in detail previously.100 ECAR changes in response to glucose and oligomycin 
(OM) injections were used to assess glycolysis and OCR changes in response to OM, 
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) and rotenone + 
antimycin A injections were used to assess mitochondrial oxidative phosphorylation 
(OXPHOS) characteristics. After completion of the extracellular flux analysis, DNA 
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content was measured with CyQuant (Thermo Scientific) using a spectrophotometer at 
508 nm excitation and 527 emission to normalize ECAR and OCR data. 
2.5.7 Nitric oxide production 
At day 8 of BMDM culture the supernatant was collected and 50 µl transferred to a 96-
well plate. A standard dilution series was made with sodium nitrite. 50 µl Griess reagent 
(Sigma Aldrich) was added to each sample and the absorption was read using a 
spectrophotometer at 550 nm wavelength.  
2.5.8 Reactive oxygen species production 
At day 8 of BMDM culture cells were exposed to 10 ng/ml LPS (Sigma Aldrich) for 24 h. 
Subsequently, the supernatant was removed and 100 µl 5 µM CM-H2DCFDA (Life 
Technologies) in serum-free RPMI medium were added, followed by 30 min incubation 
at 37°C. The attached BMDMs were washed with PBS and detached using citrate 
buffer. Following another washing step, the BMDMs were analyzed using a BD FACS 
Canto II (BD Biosciences). 
2.5.9 Uptake of fluorescent E. coli particle 
At day 8 of BMDM culture, the culture medium was removed and replaced by culture 
medium containing 1 mg/ml bioparticle suspension (pHrodo Green E. coli BioParticles, 
Thermo Scientific). After incubation (1 h) the cells were washed, detached using citrate 
buffer and analyzed for fluorescence resembling bioparticle uptake with a BD FACS 
Canto II (BD Biosciences).  
2.5.10 Uptake of Dil-conjugated oxLDL 
At day 8 of BMDM culture, the culture medium was removed and replaced by culture 
medium containing 50 µg/ml Dil-oxLDL (Biotrend, Cologne, Germany). Subsequent 
incubation (4 h) the cells were washed, detached using citrate buffer, and analyzed 
with a BD FACS Canto II (BD Biosciences).  
2.5.11 Cholesterol efflux analysis 
At day 7 of the BMDM culture, 0.5x106 cells were replated per well in a 24-well plate 
and allowed to adhere overnight in culture medium. The next day the culture medium 
was replaced by culture medium containing tritium (3H)-cholesterol (1 µCi/well; 
PerkinElmer, Waltham, MA, USA) and oxLDL (50 µg/ml, Biotrend) for 24 h. After 
loading the cells were equilibrated for 2 h in RPMI medium containing 0.2% BSA (both 
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Life Technologies). The equilibrated BMDM were subsequently incubated for 6 h with 
RPMI medium containing 0.2% BSA and ApoA1 (15 µg/ml, Sigma Aldrich) or HDL (50 
µg/ml, Sigma Aldrich) or received no further treatment. The medium was removed, 
collected, and the cells were lysed at 37°C with 0.3 M sodium hydroxide (NaOH) 
solution for 15 min. The cell lysate was collected and both, the lysate and the 
supernatant were transferred to scintillation medium (Zinsser Analytic, Frankfurt, 
Germany) and radioactivity measured with a scintillator (PerkinElmer). Counts from 
cellular lysate added with counts from supernatant represent total cholesterol uptake 
whereas counts only for supernatant represent cholesterol efflux.  
2.6 Biomolecular methods 
2.6.1 RNA isolation 
All reagents were obtained from Qiagen if not stated otherwise. Total ribonucleic acid 
(RNA) was isolated from tissue stored in RNAlater (Ambion, Thermo Scientific) at -
80°C according to the protocol of Qiagen RNeasy Mini Kit II. The entire procedure was 
performed under RNase-free conditions and partly on ice. The tissue samples were 
thawed and the amount of tissue was determined to use a maximum of 100 mg per 
sample. A stainless steel bead (7 mm diameter) was added along with the tissue 
sample removed from RNAlater to a 2 ml tube and kept on ice. Before placing the tube 
in the TissueLyser with a 12-Tube LT Adapter 1 ml Qiazol Lyses Reagent was added. 
Lysis was performed for 5 min at 50 Hz. The lysate was transferred to a new 
microcentrifuge tube and incubated at room temperature for 5 min so nucleoprotein 
complexes were able to dissociate. After incubation 200 µl Roti® - Phenol/C I (Roth, 
Karlsruhe, Germany) was added and the tube was shaken vigorously for 15 s. Another 
incubation step for 3 min. at room temperature was performed and thereafter all 
samples were centrifuged at 12,000 x g for 15 min at 4°C. After centrifugation 3 (or 4) 
Phases appeared in the tube: a) an upper, colorless, aqueous phase containing RNA 
b) a white interphase c) a lower, red, organic phase and d) a clear phase below the red 
phase (only in tissues with high fat content).  
The upper, aqueous phase was transferred gently to a new tube without interfering with 
DNA- and protein-containing phases. One volume of 70% ethanol was added to the 
transferred RNA-containing phase and the tube was vortexed. Up to 700 µl of sample 
was transferred to an RNeasy Mini spin column placed in a supplied 2 ml tube. After 
closing the lid, the sample was centrifuged for 15 sec at 8,000 x g at room temperature. 
The flow-through was discarded. This procedure was repeated until the entire 
remainder of the sample was used. For digestion of potentially contaminating genomic 
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DNA the ribonuclease (RNase)-Free DNase set supplied with DNase I, buffer RDD and 
RNase-free water was used. Lyophilized DNase I was dissolved in 550 µl of RNase-
free water to prepare a DNase I stock solution. After adding 350 µl of buffer RW1 to the 
RNeasy spin column the column was centrifuged at 5000 x g for 15 sec at room 
temperature. For each sample 10 µl DNase I stock solution were added to 70 µl buffer 
RDD. Subsequently, 80 µl of DNase I incubation mix was directly added to the middle 
of the RNeasy spin column membrane and incubated for 15 min at room temperature. 
Following incubation 350 µl RW1 buffer was applied to the RNeasy spin column and 
the column centrifuged for 15 sec at 8000 x g. The obtained flow-through was 
discarded. The membrane of the RNeasy spin column was washed twice with 500 µl 
buffer RPE supplied with 96% Ethanol. Following centrifuging the column for 15 sec at 
8000 x g, a second drying step at 8000 x g for 2 min was performed. All flow-through 
was discarded. For elution of the RNA the RNeasy spin column was placed in a new 
1.5 ml collection tube and 50 µl of RNase-free water was added to the membrane. The 
column was centrifuged for 1 min at 8000 x g. 
Purity and yield of total RNA of each preparation were assessed spectrophotometrically 
at OD260/OD280 employing a nanodrop (Peqlab). A value of OD260/OD280 lower than 1.7 
led to the disqualification of these samples. Samples were stored at -80°C until further 
use. 
2.6.2 cDNA synthesis 
RNA isolated from aortas was reverse transcribed with the SuperScript® VILO™ 
complimentary DNA (cDNA) Synthesis Kit (Invitrogen) according to the manufacturer’s 
instructions. In brief, 4 µl 5X VILO™ Reaction Mix and 2 µl 10X SuperScriptR Enzyme 
Mix were added on ice. The concentration of RNA adjusted to the sample with the 
lowest concentration with DNAse-/RNAse-free water (Sigma Aldrich) for equal amounts 
of starting material, and 14 µl of RNA were added. The total reaction volume was 20 µl. 
The content of the tubes was mixed gently and incubated at 25°C for 10 min. 
Subsequently, the mixture was incubated at 42°C for 1 h and the reaction stopped at 
85°C for 5 min.  
2.6.3 Real-time polymerase chain reaction 
Quantitative PCR (qPCR) was performed with a SYBR Green Fast Master mix (Life 
Technologies) on a ViiA7 real-time PCR system (Life Technologies). Primers were 
obtained from Sigma Aldrich. Primer sequences are listed below (see 2.6.4). 
 
For a single real-time PCR reaction the following reagents were mixed on ice. 
2 MATERIALS AND METHODS 
 
43 
2 µl   2 ng/µl cDNA, 
4 µl   Sybr Green Fast Master mix, 
1.84 µl  DEPC-treated H2O, 
0.08 µl  300 nM forward primer, and 
0.08 µl  300 nM reverse primer 
 
If higher sample numbers were processed a master mix was prepared in a tube on ice 
and kept in the dark. Each PCR reaction was pipetted in duplicate. The PCR program 
was composed of an initial step at 95°C for 20 sec followed by 40 cycles of each 1 sec 
at 95°C and 20 sec at 60°C. Subsequently, a dissociation cycle was performed with 15 
sec at 95°C, 1 min at 60°C, and followed by 15 sec at 95°C with a 2% ramp rate. The 
obtained data from real-time PCR for the respective genes and tissues was analyzed 
by applying the 2−∆∆𝐶𝑇 method.210 -actin expression was considered to be equal in a 
respective tissue upon administration of atherogenic diet and therefore was used as 
reference. 
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2.6.4  Table 5: List of genes and primer sequences applied for gene expression 
analysis 
Gene 
Forward primer sequence 
5' → 3' 
Reverse primer sequence 
5' → 3' 
IL-1 AAAGAATCTATACCTGTCCTGTGTAATGAAA GGTATTGCTTGGGATCCACACT 
ICAM-1 CTACCATCACCGTGTATTCGTTTC CGGTGCTCCACCATCCA 
Gata3 CAGCTCATGTGGAACCTCTG TGCACCTGATACTTGAGGCACTCT 
IL-6 GCTACCAAACTGGATATAATCAGGAAA CTTGTTATCTTTTAAGTTGTTCTTCATGTACTC 
VCAM-1 GTGTTGAGCTCTGTGGGTTTTG TTAATTACTGGATCTTCAGGGAATGAG 
CCL1 ATGGGCTCCTCCTGTCCTGAT CCACGTTTTGTTAGTTGAGGCG 
IL-12p35 GGAACTACACAAGAACGAGAG AAGTCCTCATAGATGCTACCA 
STAT6 TTTCTGCCAAAGACCTGTCC TCTGTTCGGGCTTATAGTGAC 
CCL5 GGAGTATTTCTACACCAGCAGCAA GCGGTTCCTTCGAGTGACA 
Rort ACAGCCACTGCATTCCCAGTTT TCTCGGAAGGACTTGCAGACAT 
MCP1 CTTCTGGGCCTGCTGTTCA CCAGCCTACTCATTGGGATCA 
IL-12p40 GGTGCAAAGAAACATGGACTTG CACATGTCACTGCCCGAGAGT 
IL-23p19 GGATTCCCGTCCCTCGGTCTC GGGCCAAGGCGCTTGGCACAG 
IRF4 CAGCTCATGTGGAACCTCTG CACTCTTGGATGGAAGAATGAC 
CXCL10 CTGCCCACGTGTTGAGATCA TGGTCTTAGATTCCGGATTCAGA 
IL-2 TGCGGCATGTTCTGGATTTG TGGCACTCAAATGTGTTGTCAG 
Foxp3 CCCAGGAAAGACAGCAACCTT TTCTCACAACCAGGCCACTTG 
T-Bet GCCAGGGAACCGCTTATATG GACGATCATCTGGGTCACATTGT 
STAT3 CTTCGAGACTGAGGTGTACCACC TACCACAGGATTGATGCCCAA 
IL-17 TCCCTCTGTGATCTGGGAAG CTCGACCCTGAAAGTGAAGG 
IFN TGGCTGTTTCTGGCTGTTACTG GCTCTGCAGGATTTTCATGTCA 
-actin GACAGGATGCAGAAGGAGATTACTG CCACCGATCCACACAGAGTACTT 
2.7 Statistical analysis 
Data is presented as average ± standard error mean (SEM) or standard deviation (SD). 
Student’s t test was used to analyze data for statistical significance with GraphPad 
Prism v.5 software (GraphPad Software Inc., La Jolla, USA). A p value of <0.05 was 
considered statistical significant.  
For gene expression analysis, a false discovery rate approach (FDR set to 10%) was 
applied to control for type I errors6 and a 2-tailed p value of <0.1 was considered 
statistical significant. 
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2.8 Buffers 
Tissue lysis buffer 
10 mM Tris 
10 mM EDTA 
10 mM Sodium chloride (NaCl) 
0.5% Sarcosyl (N-Lauroylsarcosine sodium salt) 
adjusted to 0.5 Liter with distilled H2O. 
 
Erythrocyte lysis buffer 
10 mM Potassium hydrogen carbonate (KHCO3) 
150 mM Ammonium chloride (NH4Cl) 
0.1 mM EDTA 
adjusted to 1 Liter with distilled H2O and pH 7.2-7.4. 
 
FACS buffer 
1x PBS 
0.5% BSA 
0.01% Sodium azide (NaN3) 
 
Westen Blot blocking buffer 
Tris-buffered saline  
0.1% Tween 20  
3-5% skim milk. 
 
Fixation/Permeabilization working solution (from Foxp3 staining set, 
eBioscience) 
1 part of fixation/permeabilization concentrate was diluted with 3 parts of 
fixation/permeabilization diluent. 
 
Permeabilization buffer (from Foxp3 staining set, eBioscience) 
Dilute the 10x Permeabilization Buffer (00-8333-56) 10 times in distilled water. 
 
Dynal isolation buffer 
1x PBS 
0.1% BSA 
2 mM EDTA 
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CFSE label buffer 
1x PBS 
0.1% BSA 
 
Citrate saline buffer  
135 mM Potassium chloride 
15 mM Sodium citrate 
In distilled H2O. Autoclave before usage. 
 
Antigen retrieval buffer 
1M Tris 
0.1 M EDTA 
pH 8 in distilled H2O 
 
Oil Red O-stock solution 
1 g Oil Red O (Sigma Aldrich) 
200 ml 99% 2-propanol 
 
RIPA buffer 
50 mM Tris, pH 7.2-7.4 
150 mM NaCl 
0.1% SDS 
0.5% sodium deoxycholate 
1% Triton X 100 
2.9 Media 
T cell medium 
All reagents were obtained from (A) Thermo Scientific and (B) Sigma Aldrich. 
RPMI1640 with Glutamax (A) 
10% FCBS (A) 
100 U/ml Penicillin (A)  
100 µg/ml Streptomycin (A) 
10 mM Hepes (B) 
1x MEM non-essential amino acids (B) 
1 mM Sodium pyruvate (B) 
50 µM 2-Mercaptoethanol (B) 
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D10 medium 
DMEM (Dulbecco’s Modified Eagle Medium) with 4,5 g/L glucose and pyruvate (Life 
Technologies) 
10% FBS 
100 U/ml Penicillin  
100 µg/ml Streptomycin  
 
Macrophage differentiation medium 
All reagents were obtained from Thermo Scientific, except the L929-conditioned 
medium which was self-made, see 2.5.4 
RPMI1640 
2mM L-Glutamine 
10% FBS 
100 U/ml Penicillin  
100 µg/ml Streptomycin  
20 % filtered L-929 cell (ATCC,CCL-1)-conditioned medium containing M-CSF 
 
Bone marrow freeze medium 
RPMI1640 
10% FBS 
10% DMSO 
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3 RESULTS 
3.1 CD27 co-localizes with T lymphocytes and associates with 
ruptured human atherosclerotic lesions. 
Human carotid atherosclerotic plaques, histologically classified as ruptured, display a 
higher CD27 expression compared to stable carotid atherosclerotic plaques (Figure 3 
A). CD27 is almost exclusively expressed on CD3+ T cells in human atherosclerotic 
lesions (Figure 3 B). 
 
 
Figure 3. CD27 expression is increased in ruptured human atheroma and associates with T cells. 
(A) CD27 mRNA expression in stable and ruptured human atherosclerotic lesion analyzed by gene array 
(n=20). (B) Adjacent sections of human atherosclerotic lesions stained for (left) CD3 (red) and 
counterstained with hematoxylin (nuclei; blue); (middle) for CD27 (blue) and counterstained with Nuclear 
Red (red); (right) for CD3 (red) and CD27 (blue). Arrows indicate CD3
+
, CD27
+
, or CD3
+
CD27
+ 
cells, 
respectively; Scale bar = 25 µm. Data are mean ± SD. 
 
Immunohistochemistry demonstrated specific staining of CD27 colocalizing with CD4+ 
T cells in murine atheroma (Figure 4 A-C). 
 
Figure 4. CD27 colocalizes with CD4 T cells.  
(A-C) Immunofluorescent images for CD4 and 
CD27 staining (A), CD4 combined with a CD27 
isotype-specific antibody (B) microscopy in cross-
sections of the aortic root of a 28-week-old  
Cd27
+/+
Apoe
-/-
 mouse and CD4 and CD27 
colocalization staining on aortic sections of a 28-
week-old Cd27
-/-
Apoe
-/- 
mouse (C). Scale bar = 20 
µm. 
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Additionally, CD8+ T cells and Foxp3+ cells, which per definition are a subset of CD4+ T 
cells, are positive for CD27. Non-lymphoid cells of atherosclerotic lesions as 
macrophages and SMC did not express CD27 (Figure 5). 
 
Figure 5. CD27 colocalizes exclusively 
with T cells in atherosclerotic lesions of 
murine aortas. Immunofluorescent 
images for CD8, Foxp3, Mac3, ASMA, and 
CD27 obtained by confocal microscopy in 
cross-sections of the aortic root of a 28-
week-old Apoe
-/-
 mouse; Scale bar = 20 
µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow cytometry of aortic suspensions of hyperlipidemic Apoe-/- mice demonstrated high 
abundance of T cells, B cells, and macrophages whereas T cells were only a 
minority (Figure 6 A). Among aortic T cells, CD4+ and CD8+ T cells were equally 
distributed. As expected, CD4+ Treg were only minor fraction of aortic leukocytes 
(Figure 6 D). Further analysis of the respective leukocyte and lymphocyte subsets 
revealed exclusive and specific CD27 expression on T cells and subsets thereof, 
whereas myeloid and B cells did not express CD27. CD27 deficient mice do not harbor 
CD27 expression on aortic T cells (Figure 6 B,C,E,F). Interestingly, CD27 expression 
was similar between T cell subsets (Figure 6 E,F). A significant reduction in aortic Treg 
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was observed in hyperlipidemic Cd27-/-Apoe-/- compared to Cd27+/+Apoe-/- mice (Figure 
6 D). A mechanistic explanation will follow below. 
 
Figure 6. Aortic T cells exclusively express CD27.  
Flow cytometry was applied to determine (A,D) leukocyte abundance and CD27 expression (B,E) on the 
respective subset in the aorta of hyperlipidemic Cd27
+/+
Apoe
-/-
 (solid line with grey fill) or Cd27
-/-
Apoe
-/-
 
(dashed line) mice (age=28 weeks; n=3). (C,F) Representative histograms are displayed. An isotype 
control (red line) and fluorescence minus one (FMO) control (blue line) were included. Data is presented 
as mean±SD.  
 
3.2 Hematopoietic CD27 deficiency increases atherosclerosis 
and promotes a pro-inflammatory plaque phenotype. 
Cd27-/-Apoe-/- bone marrow was transplanted into lethally-irradiated Apoe-/- recipient 
mice. Upon recovery for 6 weeks recipient mice consumed a cholesterol-rich diet for 7 
weeks until assessment of atherosclerosis. Absolute and relative lesion size in the 
aortic root increased 2.2-fold in Cd27-/-Apoe-/- bone marrow chimeras compared 
Cd27+/+Apoe-/- bone marrow chimeras (Figure 7 A-C).  
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Figure 7. Lack of hematopoietic CD27 aggravates atherosclerosis.  
(A) Atherosclerotic plaque area in cross-sections at indicated positions of the aortic root from irradiated 
Apoe
-/-
 mice reconstituted with Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 bone marrow. (n=10-14 (Donor: 
Cd27
+/+
Apoe
-/-
); n=13-18 (Donor: Cd27
-/-
Apoe
-/-
)) (B) Average of lesion area in stages 312-518 as 
percentage of total vessel area. (C) Representative photomicrographs showing Oil Red O-stained 
sections; Scale bar = 200 µm. Data is presented as mean±SD. 
 
This exacerbation of plaque area was accompanied by an increase in necrotic core 
area (Figure 8 A), reflecting accelerated plaque progression. Indeed, phenotypic 
classification according to Virmani guidelines208 revealed more advanced lesion 
characteristics in Cd27-/-Apoe-/- bone marrow chimeras corroborating aggravated 
atherosclerosis (Figure 8 B). 
 
 
Figure 8. Lack of hematopoietic CD27 increases necrotic core area and causes advanced lesions. 
(A) Relative lesional necrotic core area in atherosclerotic lesions of the ascending aorta from irradiated 
Apoe
-/-
 mice reconstituted with Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 bone marrow. (B) Phenotypic 
characterization of lesions. FCA, fibrous cap atheroma; IX, intimal xanthoma; PIT, pathologic intimal 
thickening; n=10-14 (Donor: Cd27
+/+
Apoe
-/-
); n=13-18 (Donor: Cd27
-/-
Apoe
-/-
)). Data is presented as 
mean±SD. 
 
Interestingly, the deficiency of CD27 in hematopoietic cells led to significantly increased 
macrophage content accompanied by decreased lesional Treg numbers assayed by 
immunohistochemistry staining for CD68 and Foxp3, respectively (Figure 9 A,C). 
Although lesional abundance of Treg was reduced, abundance of the entire parental 
CD4+ T cell population was only mildly affected by hematopoietic CD27 deficiency 
(Figure 9 B). The content of SMC (Figure 9 D) and collagen (Figure 9 F) did not change 
between groups. However, endothelial expression of the adhesion molecule ICAM-1 
significantly increased (Figure 9 E). These data suggest a pro-inflammatory plaque 
milieu with less anti-inflammatory Tregs present in atherosclerotic lesions of 
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hyperlipidemic CD27-deficient bone marrow-transplanted mice resulting in potentially 
enhanced leukocyte recruitment and subsequently accelerated plaque progression.  
 
 
Figure 9. Lack of hematopoietic CD27 affects cellular plaque composition and increases 
endothelial adhesion molecule expression. 
Quantifications (left) and representative photomicrographs (right) are displayed for each staining. The 
dashed line separates the atherosclerotic lesion from the lumen (L). (A-E) Immunofluorescent staining in 
cross-sections of the aortic root from irradiated Apoe
-/-
 mice reconstituted with Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 bone marrow analyzed for (A) CD68
+
 area, (B) CD4
+
 T cells, (C) Foxp3
+
 T cells (Treg), (D) -SMA; 
A-D scale bar = 100 µm. (E) ICAM-1
+
 area was quantified on the lesions endothelial area and further 
correlated to endothelial length; Scale bar= 25 µm. (F) Percentage of sirius red positive stained area in 
aortic lesions; Scale bar = 200 µm. Data is presented as mean±SD.  
 
3.3 Hematopoietic CD27 deficiency decreases systemic Treg 
abundance and promotes vascular inflammation. 
Cd27-/-Apoe-/- bone marrow chimeras showed reduced abundance of Tregs in the 
spleen and aorta (Figure 10 A,B, and data not shown). Of note, splenic Tregs of Cd27-/-
Apoe-/- bone marrow chimeras proliferated less as assayed by Ki-67 staining whereas 
aortic Tregs did not differ compared to control (Figure 10 C-E). 
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Figure 10. Hematopoietic CD27 deficiency decreases splenic and aortic Treg abundance. 
Flow cytometric analysis of splenic (A,C) and aortic suspensions (B,D) of irradiated Apoe
-/-
 mice 
reconstituted with Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 bone marrow for (A,B) Foxp3
+
 Treg and (C,D) Ki-67 
expression of Treg. (E) Representative flow cytometric histograms depicting Ki-67 expression on splenic 
Treg. Data is presented as mean±SD. 
 
Gene expression analysis of abdominal aortae from mice transplanted with Cd27-/-
Apoe-/- bone marrow revealed a significant increase in pro-inflammatory genes. The 
Th2–associated marker Gata-3 was significantly increased in the aorta, whereas Rort 
and Foxp3 were only mildly reduced displaying a potential shifting of T cell subsets in 
the aorta compared to Cd27+/+Apoe-/--transplanted controls (Figure 11 A,B). 
Furthermore, the pro-inflammatory chemokines Ccl1 and the adhesion molecules 
Icam1 and Vcam1 were significantly increased potentially promoting leukocyte influx 
into the lesion, leading to macrophage accumulation and perpetuating atherosclerosis 
(Figure 11 A). Indeed, CD27-deficient transplanted mice displayed a higher ICAM-1 
staining on the plaque endothelium as demonstrated by immunohistochemistry (Figure 
9 E). In addition, the pro-inflammatory cytokines Il1b, Il6, and Il12p35 were significantly 
increased (Figure 11 A). These data indicate the presence of a persistent inflammatory 
reaction in the arterial wall of Cd27-/-Apoe-/- bone marrow chimeras likely due to 
reduced abundance of Tregs.  
 
 
Figure 11. Hematopoietic CD27 deficiency causes vascular inflammation. 
Relative mRNA expression analyzed by quantitative PCR in murine aortas, (A) q value after FDR 
correction < 0.1 for all genes presented. (B) Relative mRNA expression of genes that did not reach 
statistical significance but were included in a multiple testing approach. n=5 (Donor: Cd27
+/+
Apoe
-/-
), n=9 
(Donor: Cd27
-/-
Apoe
-/-
). A table displaying probability values for comparisons of differences in mRNA 
expression levels can be found in the appendix (Table VIII). Data is presented as mean±SD. 
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To investigate whether systemic reduction of Treg numbers also causes changes in 
plasma cytokine expression, multiplex-bead based assays and ELISA were applied. 
Since Tregs are potent source for TGFβ, decreased Treg numbers may account for 
systemically lower concentrations of this anti-inflammatory cytokine. Indeed, plasma 
TGFβ was reduced (Figure 12 A). The plasma abundance of other cytokines was not 
affected (Figure 12 B). 
 
 
Figure 12. Hematopoietic CD27 deficiency decreases plasma TGFβ concentration. 
(A) Plasma cytokine concentration of TGFβ measured by ELISA of irradiated Apoe
-/-
 mice reconstituted 
with Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/- 
bone marrow. (B) Plasma cytokine expression levels analyzed by 
multiplex bead-based technology. (n=8 (Donor: Cd27
+/+
Apoe
-/-
), n=7-8 (Donor: Cd27
-/-
Apoe
-/-
)). Data is 
presented as mean±SD. 
 
3.4 CD27 deficiency increases nTreg apoptosis but does not 
affect their migratory or suppressive capacity. 
Reduced abundance of Tregs in lymphoid organs may be a consequence of reduced 
CCR7 expression leading to decreased sensitivity of Tregs to the lymph node-homing 
chemokines CCL19 and CCL21. Interestingly, CCL19 seemed not to affect Treg 
migration in transwell assays at any concentration (Figure 13 A), however, caused total 
CD4+ cell migration (data not shown). In contrast, CCL21 promoted migration of Treg 
although the migratory capacity was not different between genotypes (Figure 13 B) 
thus excluding altered migratory capacity as a potential mechanism for reduced 
lesional and systemic Treg abundance. 
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Figure 13. CD27 deficiency does not affect Treg chemotaxis towards CCL19 and CCL21.  
Migration of CD4
+
 T cells isolated from spleens of Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 mice through a transwell 
plate towards various concentrations of murine (A) CCL19 and (B) CCL21 during a 2h culture. Migrated 
cells were counted, analyzed for their CD25 expression by flow cytometry and displayed as ratio of the 
cellular input. Data is representative for two individual experiments. Data is presented as mean±SD. 
 
Next, we addressed whether the mild pro-inflammatory and pro-atherosclerotic 
phenotype relates to an overall reduction of Treg frequency or whether the suppressive 
capacity per single Treg differs. Co-culture of CFSE-labeled and anti-CD3/CD28-
stimulated CD4+ T cells with varying numbers of Tregs from Cd27+/+Apoe-/- or Cd27-/-
Apoe-/- mice did not show any difference in the fraction of divided conventional T cells 
indicating similar suppressive capacity between wildtype- and CD27-deficient Tregs 
(Figure 14 A,B).  
 
 
Figure 14. CD27 deficiency does not influence the suppressive capacity of Treg.  
(A) Varying numbers of Tregs isolated from spleens of Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 mice were co-
cultured with CFSE-labeled CD4
+
CD25
−
 conventional responder T cells (Tconv) from Cd27
+/+
Apoe
-/-
 mice 
and anti-CD3/CD28 stimulatory beads for 3 days. CFSE dilution was measured and frequency of divided 
responder T cells is displayed. n=3 (Cd27
+/+
Apoe
-/-
), n=4 (Cd27
-/-
Apoe
-/-
) (B) Representative histograms for 
CFSE dilution of Cd27
+/+
Apoe
-/-
 effector T cells. Data is presented as mean±SD. 
 
Recent studies demonstrated impaired Treg survival upon disruption of CD27 
signaling156, 196 prompting us to investigate whether Cd27-/-Apoe-/- mice show a similar 
phenotype in this hyperlipidemic mouse model. Indeed, flow cytometric analysis of the 
thymus revealed a significant reduction in CD4+CD25+ cells (Figure 15 A) whereas the 
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fraction of Foxp3+ cells among those cells was 50% and remained unchanged between 
genotypes (data not shown). This was accompanied by increased Annexin-V staining 
demonstrating increased apoptosis of thymic but not splenic CD4+CD25high Treg from 
Cd27-/-Apoe-/- mice (Figure 15 B,C). Moreover, splenic Tregs in the bone marrow 
transplantation model displayed significantly reduced Ki-67 staining indicating less 
proliferation of these cells (Figure 10 C). Thus, our observation of increased 
atherosclerosis in Cd27-/-Apoe-/- mice may stem from overall limited numbers of Treg 
caused by reduced survival in the thymus and impaired proliferation in the periphery. 
 
 
Figure 15. CD27 deficiency reduces thymic Treg abundance by increasing their apoptosis.  
(A) Abundance of thymic CD4
+
CD25
+
 cells in Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 mice assayed by flow 
cytometry. Tregs (CD4
+
CD25
+
) of (B) thymic and (C) splenic suspensions
 
from were analyzed by flow 
cytometry for apoptosis by Annexin-V binding and live/dead fixable staining exclusion. Representative 
plots gated on CD4
+
CD25
+
 cells are displayed. Data is presented as mean±SD. 
 
3.5 Systemic CD27 deficiency aggravates early 
atherogenesis, but does not affect advanced atherosclerosis. 
Absolute and relative lesion area was increased in Cd27-/-Apoe-/- mice compared to 
littermate controls at the age of 18 weeks (Figure 16 A-D). 
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Figure 16. Early atherosclerosis is accelerated in Cd27
-/-
Apoe
-/-
 compound-deficient mice. 
(A) Atherosclerotic plaque area in cross-sections at indicated positions of the aortic root at different stages 
from 18-week-old, male Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 mice. n=15-17 (Cd27
+/+
Apoe
-/-
), n=16-21 (Cd27
-/-
Apoe
-/-
). (B) Average lesion area in stages 312-520 as percentage of total vessel area. (C) Representative 
photomicrographs of Oil Red O-stained sections; Scale bar = 200 µm. (D) Phenotypic characterization of 
lesions. Data is presented as mean±SD. 
 
CD3+ T cells and CD4+ T cells appeared less frequent in atherosclerotic lesions of 
CD27 deficient compared to littermate control mice (Figure 17 A,B). In addition, 
increased macrophage content was observed corroborating the phenotype observed in 
the bone marrow chimeras (Figure 17 C). Furthermore, the collagen content in 
atherosclerotic lesions did not change among groups while lesions seemed 
phenotypically more advanced in accordance with increased lesion size (Figure 17 D). 
 
 
Figure 17. Macrophage area is increased in atherosclerotic lesions of young Cd27
-/-
Apoe
-/-
 
compound-deficient mice. 
Immunofluorescent staining in cross-sections of the aortic root for (A) CD3
+ 
T cells, (B) CD4
+
 T cells, (C) 
CD68
+
 macrophage area. Quantifications (left) and respective representative photomicrographs (right) are 
displayed for each staining. Arrows indicate positive stained cells, the dashed line separates the 
atherosclerotic lesion from the lumen (L) Scale bar = 100 µm. (H) Percentage of sirius red-positive stained 
area in aortic root lesions; Scale bar = 200 µm. Data is presented as mean±SD.  
 
Although at this early stage of plaque development no Tregs could be detected 
histologically, flow cytometry of splenic and aortic suspensions, lymph nodes, and 
blood (Figure 18 A-D) demonstrated a significant decrease of Treg abundance in Cd27-
/-Apoe-/- mice. 
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Figure 18. CD27 deficiency decreases systemic Treg abundance in young hypercholesterolemic 
mice. 
Flow cytometric analysis of Foxp3
+
 Treg of (A) splenic, (B) lymph node, (C) aortic suspensions, (D) and in 
blood of 18-week-old Cd27
+/+
Apoe
-/-
 and Cd27
-/-
Apoe
-/-
 mice. Data is presented as mean±SD.  
 
In contrast, 28-week-old Cd27+/+Apoe-/- and Cd27-/-Apoe-/- did not display alteration in 
absolute and relative plaque size (Figure 19 A-C). In addition, the classification of 
atherosclerotic lesions of 28-week-old Cd27-/-Apoe-/- and control mice did not yield any 
relevant differences (Figure 19 D). 
 
 
Figure 19 CD27 deficiency does not influence advanced atherosclerosis. 
(A) Atherosclerotic plaque area in cross-sections at indicated positions of the aortic root at different stages 
from 28-week-old, male Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/-
 mice. n=10-11 (Cd27
+/+
Apoe
-/-
), n=9-11 (Cd27
-/-
Apoe
-/-
) (B) Average lesion area in stages 312-520 as percentage of total vessel area. (C) Representative 
photomicrographs of Oil Red O-stained sections; Scale bar = 200 µm. (D) Phenotypic characterization of 
lesions. Data is presented as mean±SD. 
 
Besides lesion size and phenotype, the content of lesional CD3+ T cells, CD4+ T cells, 
Tregs, macrophages, or collagen did not change between 28-week-old Cd27-/-Apoe-/- 
and control mice (Figure 20 A-E).  
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Figure 20. CD27 deficiency does not influence cellular composition in aged hypercholesterolemic 
mice. 
(A-D) Immunofluorescent staining in cross-sections of the aortic root of 28-week-old, male Cd27+/+Apoe-/- 
or Cd27
-/-
Apoe
-/-
 mice for (A) CD3
+ 
T cells, (B) CD4
+
 T cells, (C) Foxp3
+
 Treg cells, and (D) CD68
+
 
macrophage area. (E) Percentage of sirius red positive stained area in aortic root lesions. Data is 
presented as mean±SD. 
 
Concomitantly, flow cytometry demonstrated similar abundance of Tregs in spleen, 
lymph nodes, and in circulation between groups (Figure 21).  
 
 
Figure 21. CD27 deficiency does not affect systemic Treg abundance in aged hypercholesterolemic 
mice. 
Flow cytometric analysis of Foxp3
+
 Treg of (A) splenic, and (B) lymph node suspensions and in (C) blood 
of 28-week-old Cd27
+/+
Apoe
-/-
 and Cd27
-/-
Apoe
-/-
 mice. Data is presented as mean±SD. 
 
The transplantation of CD27-deficient bone marrow leads to leukocytosis which we can 
confirm in our model (Table 6).211 Since leukocytosis promotes atherosclerosis212, we 
could not determine whether either leukocytosis or reduced Treg frequency are the 
underlying causes for exacerbated atherosclerosis. To exclude leukocytosis we applied 
a milder model of atherosclerosis without the need for bone marrow transplantation 
using Cd27+/+Apoe-/- and Cd27-/-Apoe-/- compound-mutant mice consuming a chow diet. 
Indeed, neither 18-week-old nor 28-week-old Cd27-/-Apoe-/- mice displayed relevant 
changes in hematological parameters (Table 6). 
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Of note, CD27 deficiency did neither change body weight nor total plasma cholesterol 
or distribution among lipoprotein fractions in CD27-compund deficient mice or bone 
marrow chimeras (Table 6 and Figure 22). 
 
 
Figure 22. CD27 deficiency does not affect plasma lipoprotein cholesterol distribution. 
Cholesterol distribution in different lipoprotein fractions separated by ultracentrifugation. Plasma from (A) 
18-week-old Cd27
+/+
Apoe
-/-
 and Cd27
-/-
Apoe
-/-
 mice (n=6/group) and from (B) Apoe
-/-
 mice reconstituted 
with Cd27
+/+
Apoe
-/-
 or Cd27
-/-
Apoe
-/- 
bone marrow (n=4/group) was analyzed. Data is presented as 
mean±SD. 
 
In sum, deficiency of the co-stimulatory receptor CD27 exacerbates atherosclerosis 
preferentially in early stages of disease by reducing thymic T cell survival and 
development. However, data describing the function of CD70, the ligand of CD27, is 
missing. We thus we sought to investigate the role of CD70 in atherosclerosis. 
  
p p p
n
Body weight [g] 30.94 ± 1.31 29.94 ± 3.62 n.s. 33.45 ± 1.92 32.92 ± 1.38 n.s. 29.09 ± 1.57 29.58 ± 1.27 n.s.
Platelets [10³/µl] 1306 ± 338 1401 ± 431 n.s. 1702 ± 366 1854 ± 528 n.s. 382 ± 165 481 ± 85 n.s.
Erythrocytes [10
6
/µl] 8.44 ± 0.94 8.60 ± 1.10 n.s. 8.43 ± 0.52 8.28 ± 0.46 n.s. 14.78 ± 2.19 17.16 ± 0.64 n.s.
Leukocytes [10³/µl] 3.79 ± 1.98 3.51 ± 1.60 n.s. 3.62 ± 1.04 2.83 ± 0.70 n.s. 5.30 ± 2.30 10.89 ± 5.08 0.0003
Lymphocytes [%] 68.07 ± 7.67 70.63 ± 10.74 n.s. 68.00 ± 10.88 71.08 ± 7.38 n.s. 60.83 ± 12.90 59.65 ± 15.60 n.s.
Monocytes [%] 6.22 ± 1.98 6.01 ± 1.79 n.s. 6.78 ± 3.32 6.08 ± 2.19 n.s. 5.51 ± 2.08 5.29 ± 1.61 n.s.
Granulocytes [%] 25.71 ± 6.67 23.37 ± 9.37 n.s. 25.22 ± 7.90 22.84 ± 5.89 n.s. 33.66 ± 11.14 35.03 ± 14.22 n.s.
Lymphocytes [10³/µl] 2.49 ± 1.31 2.37 ± 1.01 n.s. 2.40 ± 0.75 1.95 ± 0.43 n.s. 3.34 ± 1.86 6.61 ± 3.83 0.004
Monocytes [10³/µl] 0.17 ± 0.14 0.16 ± 0.12 n.s. 0.20 ± 0.15 0.13 ± 0.08 n.s. 0.21 ± 0.10 0.49 ± 0.22 < 0.0001
Granulocytes [10³/µl] 1.13 ± 0.63 0.99 ± 0.68 n.s. 1.02 ± 0.43 0.75 ± 0.33 n.s. 1.74 ± 0.64 3.79 ± 2.12 0.0008
Plasma Cholesterol [mM] 5.61 ± 1.45 6.28 ± 1.21 n.s. 7.56 ± 1.64 6.36 ± 0.80 n.s. 11.73 ± 6.86 10.32 ± 2.17 n.s.
11 12
Mean ± SD. Statistical significance was calculated for groups pairwise by 2-tailed t test. ***p  < 0.001, ****p  < 0.0001
Cd27
+/+
Apoe
-/- Cd27
+/+
Apoe
-
/-
Table 6. Body weight, hematological parameters, and plasma cholesterol content in CD27 deficient mice 
and bone marrow chimeras.
16 18
Bone marrow transplant28 weeks18 weeks
Cd27
-/-
Apoe
-/-
Cd27
+/+
Apoe
-/-
Cd27
-/-
Apoe
-/- Cd27
-/- 
Apoe
-/-
→ Apoe
-/-
18 16
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3.6 CD70 is predominantly expressed on macrophages in 
human and murine atherosclerotic lesions. 
Transcriptional profiling revealed that ruptured human carotid atherosclerotic plaques 
display higher CD70 expression compared to stable plaques (Figure 23) suggesting 
participation of this molecule in the inflammatory process in atherosclerosis. 
 
Figure 23. Increased CD70 expression in ruptured human atheroma.  
CD70 mRNA expression in stable and ruptured human atherosclerotic 
lesions analyzed by gene array (n=20). Data is presented as mean±SEM. 
*p < 0.05 
 
 
 
 
 
 
 
 
Furthermore, flow cytometric analysis of atherosclerotic aortas of Apoe-/- mice identified 
macrophages as the predominant CD70-expressing immune cells whereas T cells are 
only expressing little amounts of CD70, if any (Figure 24). 
 
Figure 24. Macrophages are the 
predominant CD70 expressing 
cells in the murine aorta of 
atherosclerotic mice. 
CD70 expression determined by flow 
cytometry on leukocyte subsets in 
the aorta of Apoe
-/-
 mice (age=28 
weeks; n=3). Representative 
histograms (left) and quantifications 
(right). Myeloid cells are live CD11b
+
 
cells. Macrophages are live 
CD11b
+
F4/80
+
 cells. Data is 
presented as mean±SEM. 
 
 
 
 
Immunohistochemistry corroborated that CD70 localized primarily to macrophages in 
atherosclerotic lesions of the ascending aorta of hyperlipidemic Apoe-/- mice (Figure 
25). Notably, splenic and aortic T cells of hyperlipidemic mice did not express CD70. 
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Figure 25. CD70 colocalizes predominantly with macrophages in murine atherosclerotic plaques. 
Immunofluorescent staining (maximum intensity projections) for CD68 and CD70 recorded by confocal 
microscopy in cross-sections of the aortic root of a 28-week-old Apoe
-/-
 mouse; Scale bar = 20 µm. L = 
lumen. 
 
3.7 CD70-deficient macrophages are less inflammatory and 
metabolically active. 
The macrophage-dominant expression of CD70 led us to investigate its function in this 
cell type. Flow cytometry revealed that on an Apoe-/- background, CD70-deficient 
BMDM had increased expression of M1 macrophage markers CD64 and MHCII 
compared to littermate control CD70-proficient BMDM. However, they also expressed 
more CD301 and produced more IL-10, both characteristics of M2 macrophages 
(Figure 26 A-D). 
 
 
Figure 26. CD70-deficient macrophages harbor M1 and M2 marker expression. 
BMDM were derived from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. Flow cytometric analysis for (A) CD64, (B) 
CD301, and (C) MHCII. (D) IL-10 concentration in culture supernatant. Data is presented as mean±SEM 
(n=3). *p < 0.05, **p < 0.01, ****p < 0.0001 
 
Furthermore, CD70-deficiency led to reduced production of ROS and NO by BMDM, 
pointing towards a diminished inflammatory capacity and an impaired M1 macrophage 
functionality (Figure 27 A,B). In general, CD70-deficient BMDM displayed a higher rate 
of apoptosis (Figure 27 C). 
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Figure 27. CD70-deficient macrophages are less inflammatory and prone to apoptosis 
BMDM were derived from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. (A) ROS production was assayed by 
production of the fluorescent adduct of CM-H2DCFDA by flow cytometry. (B) NO production was assayed 
by enzymatic assay. (C) Cell viability assayed by Annexin-V and PI staining by flow cytometry. Data is 
presented as mean±SEM (n=3). *p < 0.05 
 
Interestingly, Cd70-/- BMDM showed impaired mitochondrial function as demonstrated 
by the reduced basal respiration, OM-sensitive mitochondrial ATP synthesis, and 
FCCP-induced maximal respiration in Cd70-/- BMDM (Figure 28 A). Cd70-/- BMDM 
displayed similar glycolysis as evident from the recorded ECAR (Figure 28 B). 
Glycolysis is rather associated with M1 macrophages whereas M2 macrophages are 
considered to depend more on oxidative phosphorylation. 
 
 
Figure 28. CD70-deficient macrophages are less inflammatory and metabolically active. 
BMDM were derived from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice and subsequently treated with (A) 
Oligomycin, FCCP, and rotenone (Rot) and antimycin (AA) or (B) glucose and OM. Vertical dotted lines 
indicate application of respective reagent. Bioenergetic profiles were assessed by (A) mito-stress test and 
(B) glycolysis stress test and are presented as (A) OCR and (B) ECAR, respectively. Data is presented as 
mean±SEM (n=3).  
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3.8 CD70-deficiency reduces scavenging and cholesterol 
efflux capacities of macrophages. 
Next, we examined whether metabolic impairment of CD70-deficient BMDM also led to 
functional deficits. Indeed, CD70-deficient BMDM scavenged less fluorescently-labeled 
E.coli and oxLDL particles suggesting reduced phagocytic activity in absence of CD70 
(Figure 29 A,B). Supporting this finding, CD70-deficient BMDMs expressed lower levels 
of the scavenger receptor CD36 and transformed less efficiently into foam cells 
reflecting their reduced cholesterol uptake capacity (Figure 29 C,D). 
 
 
Figure 29. CD70-deficient macrophages display reduced particle uptake and foam cell formation 
capacity.  
BMDM from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice were incubated with (A) fluorescently-conjugated E. coli 
particles or (B) Dil-oxLDL. Uptake of aforementioned agents and (C) CD36 expression was analyzed by 
flow cytometry. (D) BMDMs were incubated with oxLDL and intracellular accumulation of neutral lipids was 
analyzed by LipidTox staining applying flow cytometry. Data is presented as mean±SEM (n=3). *p < 0.05, 
***p < 0.001 
 
Furthermore, lack of CD70 led to reduced cholesterol efflux towards HDL whereas 
ApoA1-directed efflux remained unchanged (Figure 30 A). Of note, cholesterol efflux to 
ApoA1 is mediated by ABCA1 whereas efflux to HDL relies mainly on ABCG1. In line 
with the functional data, western blot analysis of cellular lysates revealed a reduced 
expression of ABCG1 while ABCA1 expression in oxLDL-treated CD70-deficient 
BMDMs remained unchanged (Figure 30 B). Flow cytometry corroborated reduced 
ABCG1 expression on macrophages lacking CD70, further substantiating impaired 
HDL-mediated cholesterol efflux of CD70-deficient BMDM (Figure 30 C,D). 
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Figure 30. CD70-deficient macrophages display reduced cholesterol efflux capacity by reduced 
ABCG-1 expression.  
BMDM were generated from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. (A) Cholesterol efflux to ApoA1 and 
HDL of BMDMs preloaded with [
3
H]cholesterol. (B) Western blot analysis of protein extracts from BMDMs 
either non-treated or incubated with oxLDL for 48h. Immunoblots were probed for ABCA1, ABCG1, or 
GAPDH. Representative blots (left) and quantitative analysis (right) expressed as fold change oxLDL vs. 
untreated cells. Flow cytometric analysis for (C) ABCA1 and (D) ABCG1 expression of BMDMs. Data is 
presented as mean±SEM (n=3). *p < 0.05, **p < 0.01 
 
3.9 CD70 deficiency aggravates atherosclerosis in bone 
marrow transplanted mice. 
To gauge the contribution of CD70 on hematopoietic cells to atherosclerosis, we 
transplanted Cd70+/+Apoe-/- or Cd70-/-Apoe-/-
 
BM into lethally-irradiated Apoe-/- recipient 
mice. Following administration of cholesterol-rich diet for 7 weeks atherosclerotic 
plaque size was increased 2-fold in the ascending aorta of Apoe-/- mice receiving 
CD70-deficient BM compared to controls (Figure 31 A,B). 
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Figure 31. Hematopoietic CD70 deficiency aggravates atherosclerosis.  
Irradiated Apoe
-/-
 mice were reconstituted with bone-marrow from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. (A) 
Atherosclerotic plaque area in cross-sections at indicated positions of the ascending aorta. (B) 
Quantification of average lesion area in stages 312-520 as percentage of total vessel area (left) and 
representative photomicrographs showing Oil Red O-stained sections (right); Scale bar = 200 µm. Data is 
presented as mean±SEM (n=12-15). *p < 0.05, **p < 0.01, ***p < 0.001 
 
Increased lesion size was accompanied by a larger necrotic core (Figure 32 A). 
Phenotypic classification according to Virmani guidelines208 demonstrated advanced 
lesion characteristics in CD70-deficient BM chimeras confirming exacerbated 
atherosclerosis (Figure 32 B). 
 
Figure 32. Hematopoietic CD70 deficiency 
aggravates atherosclerosis.  
Irradiated Apoe
-/-
 mice were reconstituted with bone-
marrow from Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. 
(A) Relative lesional necrotic core area. (B) 
Phenotypic characterization of lesions. Data is 
presented as mean±SEM (n=12-15). **p < 0.01 
 
 
 
 
In agreement, lesional macrophage content was increased when CD70 was absent on 
hematopoietic cells (Figure 33 F). Of note, the content of collagen, SMC, CD4+ T cells 
in the lesions, as well as expression of ICAM-1 and VCAM-1 on EC in lesions did not 
differ between the two experimental groups (Figure 33 A-E).  
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Figure 33. Lack of hematopoietic CD70 increases lesional macrophage area. 
Irradiated Apoe
-/-
 mice were reconstituted with Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 bone marrow (n=10-14 
(Donor: Cd70
+/+
Apoe
-/-
), n=12-15 (Donor: Cd70
-/-
Apoe
-/-
)). (A) Percentage of sirius red positive stained 
area in lesions of the ascending aorta. (B-F) Immunofluorescent staining for (B) -SMA, (C) CD4, 
quantification (left) and representative photomicrographs (right), (D) ICAM-1, (E) VCAM-1, and (F) CD68
+
 
macrophage area, quantification (left) and representative photomicrographs (right) in cross-sections of the 
ascending aorta. (D,E) ICAM-1
+
 and VCAM-1
+
 area was quantified on the lesions endothelial area and 
further correlated to endothelial length. Data is presented as mean±SEM. **p < 0.01. Scale bar = 100 
 
3.10 CD70 deficiency only mildly affects systemic Treg 
abundance in bone marrow-transplanted mice. 
CD70 and CD27 are exclusive interaction partner. As CD27 deficiency impairs Treg 
development and increases atherosclerosis (see aforementioned data) systemic Treg 
abundance was investigated in CD70-deficient bone marrow-chimeric mice 
hypothesizing that CD70 deficiency reduces Treg content contributing to exacerbated 
atherosclerosis. In our study, we only observed a moderate decrease in splenic Tregs 
in mice transplanted with Cd70-/-Apoe-/- BM compared to mice receiving Cd70+/+Apoe-/- 
BM (Figure 34 B). Concomitantly, Treg in CD70-deficient bone marrow chimeric mice 
displayed lower expression of proliferative and anti-apoptotic markers, Ki67 and BCL-2, 
respectively (Figure 34 D,F) which might explain the mild reduction in splenic Treg 
abundance. However, aortic Treg abundance and Treg Ki67 and BCL-2 expression on 
Treg was not affected by lack of hematopoietic CD70 (Figure 34 A,C,E). Furthermore, 
Treg abundance in atherosclerotic lesions did not change in mice transplanted with 
Cd70-/-Apoe-/- BM (Figure 34 G) suggesting CD70 in Treg development and function 
appears negligible in our model of atherosclerosis and altered Treg numbers are 
unlikely to underlie those effects caused by CD70-deficiency observed here. Indeed, in 
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the BM transplantation set-up, CD70 is not expressed by thymic DC but still expressed 
on mTECs and thus Treg development is only mildly affected. 
 
 
Figure 34. CD70 deficiency reduces splenic but not aortic Treg abundance. 
(A-G) Irradiated Apoe
-/-
 mice were reconstituted with Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 bone marrow. Flow 
cytometric analysis of (A) aortic and (B) splenic suspensions for Foxp3
+
 Treg. Ki-67 expression of (C) 
aortic and (D) splenic Treg. Representative flow cytometric histograms depicting Ki-67 expression on 
splenic Treg (right). BCL-2 expression of (E) aortic and (F) splenic (middle) Treg. Representative flow 
cytometric histograms depicting BCL-2 expression on splenic Treg (right). (G) Immunofluorescent staining 
for Foxp3 in cross-sections of the ascending aorta. Quantifications (left) and representative 
photomicrographs (right) are displayed. Arrows indicate positive stained cells; Scale bar = 100 µm (n=7-
10). Data is presented as mean±SEM. *p < 0.05, **p < 0.01. 
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To further investigate the systemic inflammatory status of hyperlipidemic mice lacking 
hematopoietic CD70 we assessed changes in plasma cytokine expression by immuno-
assays. Paralleling a slight reduction in Tregs caused by lack of hematopoietic CD70 
we observed only a mild reduction in TGFβ plasma (Figure 35 A). Interestingly, plasma 
levels of lL-18 were increased in CD70-deficient bone marrow chimeras (Figure 35 B). 
The abundance of other cytokines in plasma was not affected (Figure 35 C). 
 
 
Figure 35. Hematopoietic CD70 deficiency increases plasma IL-18 concentration in hyperlipidemic 
mice. 
Irradiated Apoe
-/-
 mice were reconstituted with Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 bone marrow. (A) Plasma 
cytokine concentration of TGFβ measured by ELISA. (B,C) Plasma cytokine expression levels of analyzed 
by multiplex bead-based technology. (n=7 (Donor: Cd70
+/+
Apoe
-/-
), n=7-8 (Donor: Cd70
-/-
Apoe
-/-
)). Data is 
presented as mean±SEM. *p < 0.05 
 
Although CD70-deficient macrophages displayed reduced phagocytic capacity and 
reduced cholesterol efflux plasma lipid levels were comparable in Apoe-/- mice that 
were transplanted with Cd70+/+Apoe-/- or Cd70-/-Apoe-/-
 
BM (Table 7). Additionally, body 
weight and further hematologic parameters remained unchanged (Table 7). We only 
observed a mild increase in circulating monocytes of Apoe-/- mice transplanted with 
Cd70-/-Apoe-/- bone marrow (Table 7), which may also contribute to enhanced 
atherosclerosis. 
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3.11 Systemic CD70 deficiency aggravates atherosclerosis in 
young mice. 
In a second model of mild hypercholesterolemia comparing compound-mutant CD70-
proficient or deficient Apoe-/- mice that had consumed a chow diet for 18 weeks we also 
did not observe any changes in body weight, hematological parameters, or plasma 
cholesterol content (Table 7). However, absolute and relative lesion area increased 
significantly in the ascending aorta of Cd70-/-Apoe-/- mice compared to littermate 
controls (Figure 36 A,B). 
 
 
Figure 36. CD70 deficiency aggravates atherosclerosis in young hyperlipidemic mice.  
(A) Atherosclerotic plaque area in cross-sections at indicated positions of the ascending aorta at different 
stages from 18-week-old, male Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. (B) Average of lesion area in stages 
312-520 as percentage of total vessel area (left) and representative photomicrographs showing Oil Red O-
stained sections (right); Scale bar = 200 µm. Data is presented as mean±SEM (n=12-15). *p < 0.05 
 
Although none of the rather initial plaques in these mice featured necrotic cores, 
lesions in Cd70-/-Apoe-/- mice had decreased cellularity as compared to controls (Figure 
37 A). In addition, a larger proportion of lesions were classified as PIT, which are 
characterized by accumulation of extracellular lipids (Figure 37 B). The decrease in 
cellularity and the increase in extracellular lipid pools support the previous in vitro data 
p p p
n
Body weight [g] 27.60 ± 1.01 28.75 ± 0.53 n.s. 31.40 ± 0.45 29.92 ± 0.71 n.s. 29.13 ± 0.42 30.17 ± 0.51 n.s.
Platelets [10³/µl] 1087 ± 140 1239 ± 100 n.s. 1844 ± 71 1548 ± 110 n.s. 397 ± 65 535 ± 73 n.s.
Erythrocytes [10
6
/µl] 9.32 ± 0.21 8.52 ± 0.27 n.s. 8.26 ± 0.26 8.41 ± 0.29 n.s. 14.78 ± 0.83 16.16 ± 0.65 n.s.
Leukocytes [10³/µl] 6.02 ± 1.01 4.59 ± 0.45 n.s. 3.53 ± 0.54 3.51 ± 0.41 n.s. 5.28 ± 0.61 7.67 ± 0.98 n.s.
Lymphocytes [%] 70.24 ± 3.65 75.74 ± 1.16 n.s. 69.01 ± 2.06 71.71 ± 4.14 n.s. 60.17 ± 3.37 63.31 ± 2.78 n.s.
Monocytes [%] 5.62 ± 1.03 5.00 ± 0.41 n.s. 7.13 ± 0.83 4.95 ± 0.54 * 5.71 ± 0.51 5.34 ± 0.40 n.s.
Granulocytes [%] 23.98 ± 2.61 19.26 ± 0.98 n.s. 23.86 ± 1.47 23.35 ± 3.92 n.s. 34.13 ± 2.94 31.36 ± 2.51 n.s.
Lymphocytes [10³/µl] 4.16 ± 0.74 3.45 ± 0.36 n.s. 2.43 ± 0.40 2.26 ± 0.29 n.s. 3.30 ± 0.49 4.91 ± 0.73 n.s.
Monocytes [10³/µl] 0.28 ± 0.07 0.18 ± 0.03 n.s. 0.16 ± 0.02 0.12 ± 0.03 n.s. 0.22 ± 0.02 0.34 ± 0.04 *
Granulocytes [10³/µl] 1.59 ± 0.28 0.97 ± 0.09 n.s. 0.94 ± 0.13 1.02 ± 0.28 n.s. 1.75 ± 0.17 2.43 ± 0.32 n.s.
Plasma Cholesterol [mM] 8.35 ± 0.76 10.63 ± 1.40 n.s. 7.56 ± 0.62 6.36 ± 0.27 n.s. 11.73 ± 2.42 8.45 ± 1.14 n.s.
10 13
Mean ± SEM. Statistical significance was calculated for groups pairwise by 2-tailed t test. ***p  < 0.001, ****p  < 0.0001
Cd70
+/+
Apoe
-/- Cd70
+/+
Apoe
-/-
→ Apoe
-/-
Table 7. Body weight, plasma cholesterol content, and hematological parameters in CD70 deficient mice 
and bone marrow chimeras.
15 18
Bone marrow into Apoe
-/-28 weeks18 weeks
Cd70
-/-
Apoe
-/-
Cd70
+/+
Apoe
-/-
Cd70
-/-
Apoe
-/- Cd70
-/- 
Apoe
-/-
→ Apoe
-/-
10 16
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detailing dysfunctional lipid uptake and efflux by CD70-deficient macrophages. 
Although the absolute lesion area was increased in Cd70-/-Apoe-/- mice, neither 
absolute macrophage infiltrate nor content of collagen, SMC, or CD4+ T cells was 
different from controls (Figure 37 C-E). These data further support the notion that 
enhanced extracellular lipid accumulation, reflecting the deficient lipid handling of the 
CD70-deficient macrophages in vitro, causes enhanced atherosclerotic burden in 
Cd70-/-Apoe-/- mice.  
 
 
Figure 37. CD70 deficiency aggravates atherosclerosis and reduces cellular content in 
atherosclerotic lesions.  
(A) Quantification of nuclei in cross-sections of the aortic root 18-week-old, male Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. (B) Phenotypic characterization of lesions. (C) Percentage of sirius red positive stained area 
in aortic lesions. Immunofluorescent stainings were analyzed for (D) -SMAand (E) CD4 in cross-sections 
of the ascending aorta. Data is presented as mean±SEM (n=12-15). *p < 0.05 
 
To further investigate the systemic inflammatory status of hyperlipidemic CD70-
compoun-mutant mice in plasma cytokine expression was assessed by multiplex-bead 
based assays. No significant changes were observed between groups (Figure 38) 
which could be explained once by the mild chronic inflammatory nature of our 
atherosclerosis model and again highlights dysfunctional macrophages as underlying 
cause for aggravated atherosclerosis in Cd70-/-Apoe-/- mice. 
 
Figure 38. CD70 deficiency does not affect 
plasma cytokine concentration in young 
hyperlipidemic mice. 
Plasma cytokine levels/concentrations of 18-week-
old, male Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice 
analyzed by multiplex bead-based technology. 
Data is presented as mean±SEM (n=14-16). 
 
 
 
 
 
CD70 is expressed by thymic DC and mTECs. Thus, a global CD70 deficiency might 
affect Treg development as these cells need to receive signals via CD27 during their 
development. Indeed, CD70-compound-mutant mice demonstrate a mild reduction in 
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splenic Treg abundance which further might contribute to exacerbated atherosclerosis 
(Figure 39 A). 
 
Figure 39. CD70 deficiency reduces splenic Treg 
abundance in 18- and 28-week-old mice. 
Flow cytometric analysis Foxp3
+
 Treg of splenic 
suspensions for (A) 18-week-old (n=7-10) and (B) 28-
week-old (n=11-13), male Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 
mice Data is presented as mean±SEM. *p < 0.05, **p < 
0.01. 
 
 
 
 
 
3.12 Systemic CD70 deficiency does only mildly affect 
systemic B cell abundance but increases titers of oxLDL-
reactive Ig. 
B cells are important immune cells and pivotal in establishing a humoral immune 
response. Furthermore, B cells and subsets are implicated in atherogenesis.213 
Activated B cells express CD70 and previous reports demonstrated a reduction in B 
cell responses and germinal center formation when CD70 was constitutively expressed 
on T cells.214 Similarly, constitutive CD70 expression in B cells mediated a strong IFN 
response by T cells promoting B cell death in germinal centers thus reducing the 
humoral immune response.153 The mere abundance of B cells and subsets thereof 
might influence the amount and subtype of Ig produced. However, we did not detect 
any changes in B cell abundance in blood, spleen, lymph nodes, or the peritoneum. We 
only observed increased abundance of circulating B1b cells and peritoneal B1a cells 
(Figure 40 A-D) which are considered to produce natural IgM antibodies that confer 
protection against atherosclerosis. 
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Figure 40. CD70 deficiency does not alter general B cell abundance and only mildly affects B cell 
composition at various sites. 
Flow cytometric analysis for CD19
+
 B cells, CD11b
+
CD5
+ 
B1a and CD11b
+
CD5
-
 B1b of (A) blood, (B) 
lymph node suspensions, (C) splenic suspensions, and peritoneal exsudates of 18-week-old (male 
Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice Data is presented as mean±SEM. *p < 0.05 
 
Blocking CD27/CD70 interaction employing a monoclonal anti-CD70 antibody after 
infection with LCMV enhanced the expression of neutralizing antibodies.175 This led us 
to investigate how global CD70 deficiency would alter plasma Ig abundance in the 
atherosclerotic mice with a multiplex bead-based assay. Indeed, CD70-deficient 
hyperlipidemic mice had increased abundance of IgA, IgG3, and IgG2a in plasma 
(Figure 41). Yet, the assay did not detect IgG1.  
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Figure 41. CD70 deficiency increases IgG2a plasma abundance in young hyperlipidemic mice. 
Plasma expression levels for respective Ig of 18-week-old, male and female Cd70
+/+
Apoe
-/-
 (n=14) or 
Cd70
-/-
Apoe
-/-
 (n=17) mice analyzed by multiplex bead-based technology. Data is presented as 
mean±SEM. *p < 0.05 
 
The general abundance of Ig and subclasses does not allow for extrapolation about 
reactivity and abundance of Ig specifically binding atherosclerosis-relevant antigens, 
such as oxLDL. Accordingly, we performed an oxLDL-specific ELISA detecting oxLDL 
binding Ig in plasma of hyperlipidemic Cd70+/+Apoe-/- and Cd70-/-Apoe-/- mice. Indeed, 
plasma of CD70-deficient mice harbored more oxLDL-specific total IgG, IgG1, and 
IgG2b whereas levels of IgM remained unchanged (Figure 42). These data indicate 
increased abundance of Ig subsets considered pro-atherogenic potentially contributing 
to exacerbated atherosclerosis. The assay failed to detect levels of oxLDL-specific 
IgG2a and IgG3. 
 
 
Figure 42. CD70 deficiency increases plasma abundance of Ig binding oxLDL in young 
hyperlipidemic mice. 
Plasma abundance of antibodies detecting oxLDL of 18-week-old, male Cd70
+/+
Apoe
-/-
 (n=15) or Cd70
-/-
Apoe
-/-
 (n=17) mice. Antibody abundance was analyzed by ELISA and respective murine detection 
antibodies. Quantifications for optic density acquired at 450 nm wavelength of 1:20 diluted plasma is 
displayed in a bar graph (right), dilution series (1:20, 1:100, 1:1000) of plasma and respective ODs are 
displayed for each antibody (left). Data is presented as mean±SEM. *p < 0.05 
 
To address the impact of CD70 deficiency on advanced atherosclerosis we sacrificed 
28-week-old Cd70+/+Apoe-/- and Cd70-/-Apoe-/ mice. Although exacerbation in young 
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CD70-compound deficient mice and bone marrow chimeric mice was observed, 28-
week-old Cd70-/-Apoe-/ mice did not display alterations in absolute and relative plaque 
area compared to littermate controls (Figure 43 A,B). We did not observe any changes 
in body weight, hematological parameters, or plasma cholesterol content (Table 2). 
However, the relative abundance in circulating monocytes was reduced which would 
argue for reduced atherosclerotic burden.  
3.13 Advanced atherosclerosis is not altered by global CD70 
deficiency. 
 
Figure 43. CD70 deficiency does not alter atherosclerotic burden in aged hyperlipidemic mice.  
(A) Atherosclerotic plaque area in cross-sections at indicated positions of the ascending aorta at indicated 
stages from 28-week-old, male Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice. (B) Average of lesion area in stages 
312-520 as percentage of total vessel area (left) and representative photomicrographs showing Oil Red O-
stained sections (right); Scale bar = 200 µm. Data is presented as mean±SEM (n=10-12). *p < 0.05 
 
Besides lesion size and phenotype, neither the content of CD68+ macrophage area, 
CD4+ T cells, Foxp3+ Tregs, SMC, nor collagen was altered between 28-week-old 
Cd70-/-Apoe-/- and littermate control mice (Figure 44 A-E).  
 
 
Figure 44. CD70 deficiency does not affect atherosclerotic plaque composition in aged 
hyperlipidemic mice. 
Immunofluorescent stainings of cross-sections of the ascending aorta from 28-week-old, male 
Cd70
+/+
Apoe
-/-
 or Cd70
-/-
Apoe
-/-
 mice were analyzed for (A) CD68
+
 macrophage area, (B) CD4, (C) Foxp3
+
 
cells, and (D) -SMA. (E) Percentage of sirius red positive stained area in lesions of the ascending aorta. 
Data is presented as mean±SEM (n=10-12). 
 
Although flow cytometry revealed a significantly reduced abundance of Tregs in blood, 
spleen, and lymph nodes of 28-week-old hyperlipidemic CD70-deficient mice (Figure 
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39 B, Appendix Table IV), atherosclerosis was unchanged. However, phenotypic and 
inflammatory changes in secondary lymphoid organs not necessarily reflect the 
inflammatory status of atherosclerotic lesions.  
A comprehensive overview of immune cell abundance in Cd27-/-Apoe-/- mice and Cd70-
/-Apoe-/- mice can be found in the Appendix (Appendix Tables I-IV). CD27 and CD70 
interactions are indispensable for T cell memory formation and are needed for the 
fulminant induction of a T cell response. Indeed, we could observe reduced abundance 
of effector memory CD8+ T cells in blood and spleen of 18-week-old Cd27-/-Apoe-/- mice 
and in lymph nodes of young Cd70-/-Apoe-/- mice (Appendix Tables I, III). However, 
during aging these changes were not apparent anymore (Appendix Tables I, IV). Cd70-
/- and Cd27-/- bone marrow chimeric mice also displayed reduced effector memory T 
cell abundance in the spleen (Appendix Tables VII), whereas only Cd27-/-bone marrow 
chimeric mice also demonstrated less central memory CD8+ T cells in lymph nodes and 
spleen (Appendix Tables VI, VII). Of note, CD27 and CD70 deficiency did not influence 
CD4+ T cell memory formation (Appendix Tables I-VII).  
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4 DISCUSSION 
Human atherosclerotic lesions harbor a substantial amount of T cells expressing CD27 
and lesions classified as ruptured display increased expression of CD27 and CD70 
compared to stable lesions thereby implicating this co-stimulatory dyad in 
atherogenesis. However, it is also possible that increased CD27 and CD70 transcript 
simply reflects an increased influx of activated immune cells or activation of lesional 
immune cells expressing those molecules. Hypercholesterolemia induces the infiltration 
of leukocytes such as T cells and monocytes in the arterial wall, which perpetuates 
inflammation. Monocytes will subsequently transform into macrophages. In models of 
murine atherosclerotic plaques CD27 colocalizes with T cells and subsets thereof 
whereas CD70 was highly expressed in macrophages. 
4.1 Reduced Treg abundance in CD27-deficient mice causes 
exacerbated atherosclerosis. 
The present study indicates that in atherosclerosis CD27 co-stimulation increases Treg 
responses, which is associated with reduced disease symptoms. In a model of bone 
marrow transplantation, CD27 deficiency caused a substantial increase in 
atherosclerotic lesion size accompanied by less Tregs and more macrophages in these 
lesions. Moreover, the majority of plaques displayed an advanced phenotype. In 
addition, CD27-deficiency in hematopoietic cells promoted inflammation in 
atherosclerotic lesions as also demonstrated by increased expression of pro-
inflammatory chemokines, cytokines, and adhesion molecules in the murine aorta. This 
pronounced inflammatory phenotype is likely evoked by a systemic decrease in Treg 
abundance. However, the transplantation of CD27-deficient bone marrow cells induces 
leukocytosis and causes activation of stem cells which might further perpetuate aortic 
inflammation. Nonetheless, hyperlipidemic CD27-deficient mice display similar 
increment in atherosclerotic burden compared to mice transplanted with CD27-deficient 
bone marrow, however, do not develop leukocytosis, as also reported previously.211, 212 
Accordingly, our data suggest that systemic reduction of Tregs caused by CD27 
deficiency majorly contributes to exacerbated atherogenesis. Indeed, Tregs are known 
to counter-balance inflammation and control peripheral immune homeostasis and their 
anti-inflammatory features in atherosclerosis are well-established.56, 62, 215 Tregs exert 
their suppressive function in various ways. In particular, they are potent sources of the 
anti-inflammatory cytokines IL-10 and TGFβ and disruption of IL-10- and TGFβ-
signaling on T cells and DC aggravated atherosclerosis.74, 75, 216 
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TGFβ can suppress MHCII expression on APC, stimulate SMC proliferation, collagen 
synthesis, and decrease matrix metalloproteinase expression, thus stabilizing the 
collagen content and the phenotype of the atherosclerotic lesion.5 A decrease in 
plasma levels of TGFβ may be attributable to a systemic decrease of Tregs as the 
potential source and explain the increased pro-inflammatory status of Cd27-/- mice. 
Since Tregs are in a balance with Th17 cells it is tempting to speculate that a decrease 
of Tregs could lead to a more pronounced Th17 response. Indeed, in experimental 
autoimmune encephalomyelitis, a murine model of multiple sclerosis, CD27 signaling 
decreased Th17 function and disease severity by suppressing IL-17 production and 
CCR6 expression in already committed Th17 cells.190 However, plasma levels of IL-17 
and the expression of the lineage-specific marker Rort in the aorta were unchanged in 
mice reconstituted with Cd27-/-Apoe-/- bone marrow, indicating that changes in Th17 
cell activity are unlikely to contribute to the increased inflammation. 
Thus, decreased Treg numbers are the most likely cause of increased atherosclerosis 
in mice reconstituted with Cd27-/-Apoe-/- bone marrow. Concomitantly, aortic expression 
of the IL-12p35 subunit increased, suggesting increased abundance of IL-12 whereas 
expression of the IL-23p19 subunit tended to decrease in mice transplanted with CD27-
deficient bone marrow. This argues for a shift towards a Th1-dominated T cell 
response and a reduced Th17 response since IL-23 is needed for maintenance of Th17 
cells.217 Furthermore, the expression of GATA-3 is substantially increased. Yet, GATA-
3 is expressed by Th2 T cells and M2 macrophages and its origin here remains elusive. 
The drastically elevated expression of IL-1 coinciding with increased macrophage 
content in aortae of mice receiving Cd27-/-Apoe-/- bone marrow is not surprising 
considering that macrophages are potent sources for this pro-atherogenic cytokine.98, 
101 
Although the abundance of aortic Tregs was diminished in mice reconstituted with 
Cd27-/- bone marrow we were only able to detect a trend in reduced expression of the 
lineage transcription factor Foxp3. This discrepancy may derive from the analysis of 
whole tissue lysates which contain cells not only from the plaque but also from 
additional layers of the vessel, namely media and adventitia, thus diluting the 
abundance of Foxp3 mRNA.  
IL-2 is an autocrine T cell survival factor important for peripheral Treg maintenance 
since Tregs are not able to synthetize IL-2 themselves.218 Plasma IL-2 levels did not 
differ in Cd27-/- chimeric mice of the present study. However, systemic IL-2 levels 
require careful interpretation with regard to local Treg prevalence since a recent study 
demonstrated a necessity for IL-2 abundance in the micro-milieu for Treg 
maintenance.219 Nonetheless, we propose that in the chronic inflammatory condition of 
4 DISCUSSION 
 
81 
atherosclerosis, reduced production of IL-2 by activated conventional Cd27-/- T cells 
might lead to a reduced abundance of IL-2 in the atherosclerotic lesion.160 This would 
impair Treg maintenance and the conversion of conventional T cells into iTregs further 
perpetuating lesional inflammation.220 
A second pathway that most likely contributes to the pronounced inflammation in 
plaques of Cd27-/- mice in the present study is the systemic decrease in nTregs 
resulting from increased apoptosis of developing nTregs in the thymus. Indeed, ligation 
of CD27 by CD70 expressed on mTECs or DC was found to promote thymic output of 
nTregs during T cell development in wild-type mice.156 The low though relevant 
abundance of Tregs in the atherosclerotic lesion complicates to delineate whether they 
originate from converted conventional T cells or underwent thymic development. Thus, 
it is not clear which of the two aforementioned mechanisms prevails and requires 
clarification in the future. 
4.2 Tregs are anti-atherogenic and are reduced during 
atherogenesis. 
Interestingly, patients suffering from non-ST-segment-elevated myocardial infarction 
harbor lower numbers of circulating Treg accompanied by enhanced apoptosis allowing 
for speculation regarding the clinical potential of counterbalancing Treg apoptosis.221 
Tregs have a distinct kinetic in atherosclerosis as recently demonstrated in Ldlr-/- 
mice.80 Their presence in atherosclerotic lesions peaked upon 4 weeks of cholesterol-
enriched diet. Sustained hyperlipidemia reduced their frequency accompanied by an 
increase in lesion size and inflammation. However, the underlying mechanisms remain 
undefined. Besides reduced survival other pathways might limit Treg abundance. One 
mechanism may be the conversion of Tregs into T cells lacking Foxp3 expression, 
which cannot be detected by the classical assays for this conventional lineage marker. 
Additionally, Tregs might actively egress from the atherosclerotic lesion during the 
progression of atherosclerosis. Recently, an elegant study demonstrated homing of 
peripheral Tregs to the thymus where they suppressed development of further 
progeny.222 None of the aforementioned mechanisms has been formally demonstrated 
during the course of atherosclerosis. Apoe-/- mice were used in the present study and it 
seems likely that Tregs show similar kinetics as observed in Ldlr-/- mice. Thus, Tregs 
might play an essential and protective role particularly during early stages of 
atherosclerosis. However, upon progression of atherosclerosis other immune cells 
predominate and the influence of Treg becomes negligible, corroborating our finding of 
similar atherosclerotic burden yet continuously suppressed Treg numbers in 28-week-
old mice. Direct comparison of results obtained by Maganto-Garcia et al. with this study 
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requires cautious interpretation as different hyperlipidemic mouse models were 
applied.80 
This is the first study demonstrating the involvement of CD27 in atherosclerosis 
ascribing this co-stimulatory molecule a rather anti-inflammatory and athero-protective 
role by enhancing Treg survival and development.  
4.3 Cd70-/- macrophages are metabolically less active and 
prone to apoptosis. 
CD70-deficiency in Apoe-/- mice induces a unique macrophage phenotype including 
markers of M1- (CD64, MHCII) and M2- (CD301, IL-10) differentiation. During in vitro 
experiments, M1 macrophages are induced by LPS whereas M2 macrophages are 
induced by IL-4. Furthermore, CD70-deficient BMDM from Apoe-/- mice produce less 
ROS and NO. Of note, ROS production is usually associated with function and 
activation of M1 macrophages, and both ROS and NO are key components of the 
antimicrobial machinery of M1 macrophages.223 Interestingly, NO production can inhibit 
oxidative metabolism which is pivotal for M2 macrophage survival and function.224 
Typically, lower ROS production would constitute a characteristic situation of M2 
macrophages featuring an increased oxidative consumption rate. These features again 
reflect a unique phenotype of CD70-deficient BMDM which are not clearly classifiable 
solely as M1 or M2 macrophages. Of note, M1 macrophages conduct an increased 
glycolytic metabolism and reduced mitochondrial respiratory activity, whereas M2 
macrophages are typically characterized by a high mitochondrial oxidative 
phosphorylation and enhanced spare respiratory capacity. Whereas glycolytic 
metabolism induces a pro-inflammatory M1 macrophage phenotype, inhibition of 
glycolysis by applying 2-desoxyglucose reduces inflammatory cytokine production.225, 
226 Inhibition of fatty acid oxidation prevents M2 macrophage polarization thus 
suggesting that macrophage polarization is linked to their metabolism and influencing 
each other.227 In our model, we observed similar glycolytic capacity but reduced OCR 
of CD70-deficient BMDM supporting their unique identity as observed by phenotypic 
marker expression. Their lowered metabolic fitness is paralleled by increased apoptotic 
potential.  
4.4 Cd70-/- macrophages harbor reduced lipid clearing 
capacity leading to pronounced atherosclerosis. 
Additionally, CD70-deficient BMDMs harbored reduced capacity to scavenge bacterial 
and modified lipid particles, probably due to reduced CD36 expression, an important 
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scavenger receptor mediating phagocytosis. This is accompanied by reduced 
expression of the cholesterol transporter ABCG1. Hence, CD70-deficient macrophages 
display reduced cholesterol efflux towards HDL, which is the main cholesterol acceptor 
interacting with ABCG1. Interestingly, CD70 deficiency did not alter ABCA1 expression 
and ABCA1-mediated cholesterol efflux to its acceptor ApoA1. 
The role of ABCG1 in atherosclerosis is controversially discussed and can exert anti- or 
pro-atherogenic functions depending on the mouse model and the disease stage 
assessed. Reports demonstrated increased or unchanged susceptibility towards 
atherosclerosis in ABCG-1 deficient (Abcg1-/-) mice in different mouse models.228, 229 
This appears stage-dependent since administering HFD to Abcg1-/-Ldlr-/- mice for 10 
weeks increases atherosclerosis whereas 12 weeks causes reduction in atherosclerotic 
burden.230 Transplantation of Abcg1-/- bone marrow into Apoe-/-- or Ldlr-/--recipient mice 
decreased atherosclerotic burden by enhanced apoptosis of macrophages.231 
Furthermore, macrophages from Abcg1-/- mice produce more ApoE which is paralleled 
by an increase in circulating ApoE in Abcg1-/-Ldlr-/- bone marrow chimeric mice 
compared to controls.232 These controversial findings seem only be partially applying to 
the macrophage phenotype observed in the present study, since the here described 
mice lack ApoE and reduced ABCG1 expression does not protect against 
atherosclerosis. However, the exact underlying mechanism why CD70 deficiency 
influences ABCG1 expression and ABCG1-mediated cholesterol efflux remains to be 
further investigated. 
Reduced metabolic activity cannot be excluded to further negatively influence 
phagocytic activity of macrophages upon CD70 deficiency. A plethora of work attributes 
macrophages a major role in atherosclerosis.233 Accordingly, reduced fitness or 
function of macrophages likely contributes to exacerbated atherosclerosis.  
The aforementioned features of Cd70-/- macrophages suggest an impaired capacity 
disburdening the arterial wall from lipid deposits thus fostering atherosclerotic lesion 
formation. Indeed, in two models of atherosclerosis we corroborate the anti-atherogenic 
role of CD70. Mice receiving Cd70-/- bone marrow display a substantial increase in 
atherosclerotic lesion size and the majority of plaques are of an advanced phenotype. 
Similar results were obtained in 18-week-old Cd70-/-Apoe-/- mice supporting the anti-
atherogenic role of CD70. Furthermore, lesions from Cd70-/-Apoe-/- mice are bigger, 
display lower cellularity and were scored as PIT being characterized by the 
accumulation of extracellular lipids recapitulating the reduced lipid handling capacity of 
macrophages observed in vitro. However, during the progression of atherosclerosis 
CD70-deficiency does not affect atherosclerotic burden in hyperlipidemic Apoe-/- mice 
anymore. It seems likely that during advanced stages of atherosclerosis macrophages 
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from Cd70+/+Apoe-/- and Cd70-/-Apoe-/- mice are equally dysfunctional in clearing lipid 
depositions in the arterial wall thus explaining similar atherosclerotic burden. 
4.5 Tregs are moderately affected by CD70 deficiency 
depending on the mouse model. 
Another important function of CD70 pertains to Treg development in the thymus. CD70 
on mTECs or DC in the thymus ligates CD27 on developing Tregs and thus fosters 
generation of natural Tregs as demonstrated by aforementioned data and suggested 
by others.156 In our study, we only observed a moderate decrease in splenic Tregs in 
hyperlipidemic Cd70-/-Apoe-/- bone marrow chimeric mice. Moreover, these Tregs 
displayed lower expression of proliferative and anti-apoptotic markers, Ki67 and BCL-2, 
respectively. In the BM transplantation set-up, CD70 is not expressed by thymic DC but 
still expressed on mTECs and thus Treg development is only mildly if at all affected as 
shown by unchanged numbers of aortic Tregs compared to control mice. Thus, the role 
of CD70 in Treg development and function appears negligible in this model of 
atherosclerosis and altered Treg numbers are unlikely to underlie those effects of 
CD70-deficiency observed in the bone marrow transplantation model. However, global 
CD70 deficiency reduces Treg frequencies in the spleen at early and advanced stages 
of atherosclerosis. As we did not assess aortic Treg abundance in those mice, we 
cannot exclude reduced frequency of aortic Treg contributing to pronounced 
atherosclerosis in Cd70-/-Apoe-/- mice.  
4.6 CD70 deficiency fosters oxLDL-IgG production by B cells. 
Besides the aforementioned immune cells, B cells might be affected by CD70 
deficiency as they express CD70 upon activation and maturation.141 Furthermore, B 
cells and subsets are implicated in atherogenesis.213 Previous reports demonstrated a 
reduction in B cell responses and germinal center formation when CD70 was 
constitutively expressed on T cells or B cells.153, 214 B cell frequencies influence Ig 
expression. However, we did not observe any profound changes in B cell abundance at 
various sites in Cd70-/-Apoe-/- mice. However, blocking CD27/CD70 interactions with a 
monoclonal anti-CD70 antibody after infection with LCMV enhanced the expression of 
virus-neutralizing antibodies.175 Indeed, CD70-deficient hyperlipidemic mice showed 
increased IgG2a concentrations which is elicited by Th1 cytokine responses and 
considered pro-atherogenic.113 However, data from this experiment requires careful 
interpretation. The analyzed mouse models are derived from a C57BL6/J background 
which harbors expression of the Igh1-b allele thus not bearing the genetic information 
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for IgG2a (which rather pertains to Balb/c mice). C57BL6/J mice instead express the 
IgG2c isotype which has a 16% amino acid difference compared to the IgG2a 
subtype.234 Thus, the here used commercially available bead assay detecting IgG2a 
might inadequately cross-react with the IgG2c subtype underestimating the actual 
abundance. Overall increased abundance of immunoglobulins is not necessarily 
affecting the presence of antigen-specific immunoglobulins. Indeed, oxLDL-reactive 
IgG, IgG1, and IgG2b subclasses were increased whereas levels of IgM remained 
unchanged in plasma of hyperlipidemic Cd70-/-Apoe-/- compared to littermate control 
mice. IgG, IgG1 and, IgG2b are considered pro-atherogenic and produced by B2 cells. 
Depletion of B2 cells reduced the aforementioned athero-reactive Ig subclasses and 
mice were protected from atherosclerosis.113 Natural B cells, such as B1a cells, are 
potent sources of the IgM subclass which is encoded in the germ line and not 
generated by Ig class switching and affinity maturation such as IgG subclasses. Mice 
deficient for IgM display exacerbated atherogenesis.235 Overall, CD70 deficiency 
increases the abundance of circulating pro-atherogenic Ig subclasses which potentially 
contribute to exacerbated atherosclerosis. However, future studies need to address the 
exact contribution of increased atherosclerotic antigen-specific antibodies to increased 
atherosclerosis in Cd70-/-Apoe-/- mice. 
4.7 CD27/CD70 interactions moderately influence T cell 
memory. 
Although CD27/CD70 interactions are pivotal for T cell memory generation, the 
reduction in memory T cells was age-dependent and affected only CD8 T cells. 
However, the general population might not reflect the behavior of antigen-specific T 
cells overall influenced by CD27 or CD70 deficiency. Only recently, potential antigens 
in atherosclerosis were identified being derived from peptides of ApoB-100 or LDL.236, 
237 These peptides could also be used to load tetramers or dextramers to identify 
antigen-specific T cells in atherosclerosis, which will help to further investigate the 
timing and interplay of factors expressed by athero-reactive T cells. Furthermore, the 
application of tetramers that are consisting of a Streptavidin-core complex to which up 
to 4 biotinylated MHCII-complexes displaying the antigen of interest will bind to, may 
help to unravel the fate of antigen-specific T cells in atherosclerosis. However, these 
experiments are beyond the scope of this thesis and currently exerted at collaborative 
partner sites.  
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4.8 Why does this work contribute to novelty to the 
understanding of CD27/CD70 in atherosclerosis? 
So far, this is the first study addressing the implications of CD27 and CD70 signaling in 
atherosclerosis. Previous work demonstrated that transgenic expression of CD70 on B 
cells led to a CD27-driven increase in the pro-atherogenic Th1 subset.206 Nevertheless, 
amelioration of atherosclerosis in that model was likely caused by increased apoptosis 
of pro-atherogenic Ly6C+ monocytes and chronic stimulation of CD27 on T cells which 
ultimately led to a gradual loss of the naïve T cell pool and a profound reduction of B 
cells. Although pioneering in its approach, this study employed a very non-physiological 
B cell-restricted overexpression of CD70 which led to a severe patho-inflammatory 
phenotype. This transgenic system emphasizes a potential consequence of chronic 
and systemic CD27/CD70 engagement, but cannot predict the consequence of natural 
CD27/CD70 interactions in atherosclerosis.206  
Currently only CD27 is known as interaction partner of CD70. Although this study 
demonstrates CD27 expression only on T cells in atherosclerotic aortas and CD70 
expression mainly on macrophages the exact cell types and subsets interacting via 
CD27/CD70 with each other remain unidentified. Furthermore, intrinsic CD70 signaling 
has been described153 and future studies have to address the requirement and cellular 
origin of a putative CD27 signal interacting with macrophage CD70. Hematopoietic 
stem cells express CD27 thus potentially representing the cellular source for 
interactions with CD70 on developing macrophages in the BMDM culture. In addition, 
the absence of CD70 might also alter the CD27 expressing cell which in turn affects 
functionality of the interaction partner. 
4.9 Future perspectives 
The role of the co-stimulatory dyad CD27/CD70 remained so far elusive. In the present 
work, we were able to demonstrate CD27 expression by T cells in atherosclerotic 
lesions whereas CD70 was predominantly expressed by macrophages. This is the first 
study comprehensively demonstrating the effects caused by CD27 or CD70 on 
atherosclerosis. Young mice deficient for either CD27 or CD70 developed aggravated 
atherosclerosis whereas established atherosclerotic lesions remained unaffected. Of 
note, deficiency of hematopoietic CD27 or CD70 promoted most significantly 
atherosclerosis suggesting leukocytes causing the underlying changes. However, 
different mechanisms were observed in CD27- or CD70-compound mutant mice.  
CD27-deficient mice display promoted progression of atherosclerosis accompanied by 
increased macrophage content and larger necrotic cores. Furthermore, the 
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endothelium covering atherosclerotic lesions and atherosclerotic aortas from CD27 
bone marrow chimeric mice displayed increased expression of pro-inflammatory 
cytokines (IL-1, IL-6), adhesion molecules (ICAM-1, VCAM-1), and chemokines 
(CCL1), thus, further fueling atherosclerosis. Interestingly, the pronounced pro-
atherogenic phenotype was accompanied by systemic and local reduction of anti-
inflammatory Tregs. CD27-deficent Tregs were not impaired in their suppressive 
capacity suggesting the mere reduction in abundance being responsible for 
pronounced atherosclerosis in CD27-deficient mice. The reduced systemic abundance 
of Tregs in CD27-deficient mice is caused by enhanced apoptosis of developing Tregs 
in the thymus where Tregs need to receive signals via CD27 and CD70 expressed by 
DCs and mTECs.  
Although CD70 bone marrow chimeric mice displayed aggravated atherosclerosis, the 
abundance of Tregs was only mildly affected, as mTECs still covered CD70 
expression. Thus, other mechanisms are coming into play. Indeed, CD70-deficient 
mice harbor a substantial increase in oxLDL-specific antibodies that might contribute to 
atheroprogression. However, it is likely that the pro-atherosclerotic effect is caused by 
the phenotype of the CD70-deficient macrophages. These macrophages are 
metabolically less active, less inflammatory, and prone to cell death. Furthermore, they 
exhibit reduced scavenging capacity, turn less into foam cells, and possess reduced 
cholesterol efflux capacity. This all further substantiates the pro-inflammatory plaque 
environment based on the substantially reduced capacity to clear lipids from the 
atherosclerotic vessel wall.  
Considering all these pro-inflammatory effects in atherosclerosis based on either CD27 
or CD70 deficiency, it appears desirable to promote function of these molecules, 
particularly during the early stages of disease development. However, we observed 
increased expression of CD27 and CD70 in human atherosclerotic lesions classified as 
ruptured, possibly reflecting and anti-inflammatory response, or the mere presence of 
T-effector cells and macrophages which bear expression of CD27 and CD70. Ongoing 
clinical studies are targeting CD27 or CD70 in patients suffering from tumors using 
biologicals. A broad range of tumor cells express high levels of CD70, thus a 
neutralizing antibody might proof successful in patients with advanced malignancies.238 
CD70-expressing Tregs are contributing to tumor immune evasion and thus blocking 
them might be beneficial for the patient. 238 Furthermore, agonistic CD27 antibodies 
were designed to promote anti-tumor immunity by enhancing a cytotoxic CD8 T cell 
response.203 However, therapeutic intervention agonistically modulating CD27 might 
also enhance the suppressive capacity of tumor-resident Tregs. Although this might 
enhance tumor immune evasion, the data available indicates a successful anti-tumor 
4 DISCUSSION 
 
88 
immune reaction after CD27 stimulation overweighing the potential negative effects. 
Nonetheless, the present work demonstrates potential side-effects on the 
cardiovascular system by modulating CD27 and CD70. So far, no study addressed the 
potential cardiovascular side effects of these therapeutical antibodies. Additionally, 
these antibodies should be tested in animal models under hyperlipidemic conditions. 
Furthermore, the progression of other inflammatory diseases should be investigated in 
animal models that were systemically treated with CD70 blocking or agonistic CD27 
antibodies. Overall, the philosophical question arises, whether a patient suffering from 
advanced tumor malignancies could gain expanded lifetime when undergoing a 
modifying CD27-CD70 therapy on the cost of accepting a higher risk for cardiovascular 
complications. 
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5 SUMMARY 
Atherosclerosis is a chronic patho-inflammatory condition of the arterial vessel wall. 
Hypercholesterolemia is a major risk factor and lipid depositions in the vessel wall drive 
formation of the nascent atherosclerotic lesion. During pathogenesis innate and 
adaptive immune cells play distinct roles. Depending on their general function these 
cells either contribute to disease progression or counterbalance atherogenesis. T cells 
are part of the adaptive immune system and contribute to atherosclerosis in a subset-
dependent manner. T cells need to receive proper T cell receptor stimulation and co-
stimulatory signals provided by antigen presenting cells for full activation. The present 
thesis summarizes the first studies elucidating implications of the costimulatory 
CD27/CD70 dyad in atherosclerosis.  
Expression of both co-stimulatory molecules is increased in human atherosclerotic 
lesions classified as ruptured, suggesting implicating of this dyad in this patho-
inflammatory process. Whereas CD27 colocalizes with T cells in aortae of 
hyperlipidemic mice macrophages display highest CD70 expression suggesting 
interactions between both cell types via the CD27/CD70 axis in atherosclerotic lesions. 
However, deficiency for either molecule causes enhanced atherosclerosis in bone 
marrow chimeric mice and in young compound-mutant mice via different pathways. 
Mice transplanted with CD27-deficient bone marrow display increased atherosclerotic 
lesion size and accelerated disease progression. Besides an increase in necrotic core 
and macrophage area, we observed that endothelial cells covering atherosclerotic 
lesions expressed more intercellular adhesion molecule 1 (ICAM-1) in absence of 
hematopoietic CD27. Concomitantly, aortae from CD27 bone marrow chimeric mice 
displayed increased expression of pro-inflammatory cytokines (interleukin-1, 
interleukin-6), adhesion molecules (ICAM-1, vascular adhesion molecule 1), and 
chemokines (chemokine C-C motif ligand 1). This pro-inflammatory milieu further fuels 
inflammation in the atherosclerotic lesion and leads to pronounced atheroprogression. 
Similar results were observed in young CD27/Apoe-compound-deficient mice. In both 
mouse models of atherosclerosis, Treg frequencies were diminished systemically and 
locally in atheroma. CD27-deficent Tregs were not impaired in their suppressive 
capacity suggesting the mere reduction in abundance responsible for aggravated 
atherosclerosis in CD27-deficient mice. The reduced systemic abundance of Tregs in 
CD27-deficient mice is caused by enhanced apoptosis of developing Tregs in the 
thymus where Tregs need to receive signals via CD27 and CD70 expressed by 
dendritic cells and thymic medullary epithelial cells. At later stages of atherosclerosis, 
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effects mediated by CD27-deficiency appear negligible since neither atherosclerotic 
burden nor systemic Treg abundance changed compared to littermate control mice. 
Multiple pathways seem to contribute to enhanced atherosclerosis in CD70 deficient 
mice. Macrophages derived from CD70-deficient mice are metabolically less active and 
prone to apoptosis. Furthermore, they are less competent in the uptake and efflux of 
oxidized lipoproteins. The reduced lipid clearance capacity contributes to exacerbated 
atherosclerotic lesion development. Indeed, CD70 bone marrow chimeric mice and 
young CD70/Apoe-compound mutant mice display larger and more advanced 
atherosclerotic lesions. Concomitant to an increase in necrotic core formation, the 
overall cellularity in atherosclerotic lesions is reduced suggesting that also increased 
lipid deposition accounts for increased lesion size. In CD70 bone marrow chimeric 
mice, Treg abundance is only mildly affected since developing Tregs can still receive 
CD27 signals via CD70 expressed on radioresistant medullary thymic epithelial cells. 
Thus, exacerbated atherosclerotic lesion formation in CD70-apoecompound-deficient 
mice is also affected by reduced Treg frequencies as observed in the spleen. 
Furthermore, increased abundance of oxidized low-density lipoprotein-reactive Ig 
subclasses might further lead to enhanced atheroprogression. However, at later stages 
of atherosclerosis effects mediated by CD70 become less important and CD70-
deficient mice have similar atherosclerotic lesion size and phenotype compared to 
littermate controls. 
In sum, CD27 and CD70 exert atheroprotective effects, especially during early phases 
of atherosclerosis.  
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6 ZUSAMMENFASSUNG 
Atherosklerose ist durch eine chronische pathologische Entzündung in der arteriellen 
Gefäßwand charakterisiert. Hypercholesterinämie ist hierbei ein entscheidender 
Risikofaktor und die auftretenden Lipidablagerungen in der Gefäßwand fördern die 
Entstehung und Progression atherosklerotischer Läsionen. Immunzellen des 
angeborenen und adaptiven Immunsystems üben während der Pathogenese der 
Atherosklerose distinkte Funktionen aus. T Zellen als Protagonisten des adaptiven 
Immunsystems tragen entsprechend ihrer charakteristischen Eigenschaften positiv 
oder negativ zum Fortschreiten der Atherosklerose bei. Zur vollständigen Aktivierung 
benötigen T-Zellen Signale, welche durch den T-Zellrezeptor und kostimulatorische 
Moleküle vermittelt werden. Die hier vorliegende Arbeit beschreibt erstmalig die 
Auswirkung von Interaktionen der kostimulatorischen CD27/CD70 Achse auf 
Atherosklerose. 
Sowohl CD27 als auch CD70 Expression sind erhöht in rupturierten humanen, 
atherosklerotischen Läsionen, was für eine entscheidende Rolle in diesem Prozess 
spricht. Das Fehlen von CD27 oder CD70 verschlimmert die Atherogenese in 
knochenmarkstransplantierten oder jungen, gendefizienten Mäusen, wobei jeweils 
unterschiedliche Mechanismen zu greifen scheinen. 
Die Transplantation von CD27-defizientem Knochenmark vergrößert atherosklerotische 
Läsionen und führt zu einem fortgeschrittenen Plaque-Phänotyp im Vergleich mit 
Wildtyp-transplantierten Apoe-/- Empfängermäusen. Ebenso findet sich eine vermehrte 
Nekrose in den atherosklerotischen Läsionen, welche mit einer erhöhten Ansammlung 
von Makrophagen einhergeht. Weiterhin exprimieren die Endothelzellen der 
atherosklerotischen Läsion mehr intercellular adhesion molecule 1 (ICAM-1), was auf 
eine erhöhte Infiltration von inflammatorischen Leukozyten in den atherosklerotischen 
Plaques hindeutet. Aorten von CD27-defizienten Knochenmarkschimären weisen 
zudem gesteigerte Expression der pro-inflammatorischen Zytokine Interleukin-1, 
Interleukin-6, der Adhäsionsmoleküle ICAM-1, vascular adhesion molecule 1, und des 
Chemokins chemokine C-C motif ligand 1 auf. Dieses pro-inflammatorische Milieu 
fördert die Rekrutierung von Immunzellen in die atherosklerotische Läsion und trägt zur 
verstärkten Pathogenese bei. Ähnliche Prozesse konnten in jungen CD27-defizienten 
Mäusen beobachtet werden. Hyperlipidämische Mäuse, denen CD27-defizientes 
Knochenmark transplantiert wurde oder die global CD27-defizient sind, weisen nicht 
nur eine systemische, sondern auch eine lokale Reduktion von regulatorischen T 
Zellen (Treg) auf. Diese CD27-defiziente Tregs besitzen dabei jedoch dieselbe 
suppressive Kapazität wie solche aus Wildtyp-Mäusen. Daher scheint die erhöhte 
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Atherogenese durch CD27 Defizienz eher in der systemischen und lokalen Reduktion 
der Anzahl von Tregs begründet zu sein. Fehlende Interaktion von CD27 auf den sich 
entwickelnden Tregs im Thymus mit dendritischen Zellen und medullären thymischen 
Epithelzellen, welche CD70 exprimieren, führt zu einer gesteigerten Apoptose der sich 
entwickelnden Tregs. Diese vermehrte Apoptose führt zur systemischen Treg 
Reduktion. In späteren Stadien der Atherosklerose scheinen die durch CD27-Defizienz 
vermittelten Effekte eine vernachlässigbare Rolle zu spielen, da sich weder Ausmaß 
der Atherosklerose noch systemische Abundanz der Tregs ändern. 
Multiple Mechanismen tragen zur erhöhten Atheroprogression CD70-defizienter Mäuse 
bei. Makrophagen, denen CD70 fehlt, sind metabolisch weniger aktiv und weisen eine 
erhöhte Tendenz zur Apoptose auf. Überdies nehmen CD70-defiziente Makrophagen 
weniger oxidierte Lipoproteine auf und zeigen ein verringertes Potential Lipide 
auszuschleusen. Die reduzierte Kapazität Lipide aus der Gefäßwand zu entfernen 
kann zur erhöhten Atherogenese beitragen. Tatsächlich weisen CD70-defiziente 
Knochenmarkschimären und junge, CD70-defiziente Mäuse größere und 
fortgeschrittene atherosklerotische Plaques auf. Dies geht mit vermehrter Bildung eines 
nekrotischen Kerns einher, welcher eine erhebliche Reduktion der Zelldichte aufweist. 
Das Fortschreiten der atherosklerotischen Läsion in CD70-defizienten Mäusen scheint 
durch eine vermehrte Lipidablagerung verursacht zu sein und nicht durch einen 
erhöhten Kollagengehalt, welcher unverändert bleibt. 
Mäuse, denen CD70-defizientes Knochenmark transplantiert wurde, weisen nur eine 
geringfügige systemische Reduktion der Tregs auf. Von den CD70-exprimierenden 
Zellen im Thymus tötet die Bestrahlung zwar dendritische Zellen ab, jedoch überleben 
bestrahlungs-resistente medulläre Epithelzellen. Diese können so nach wie vor ein 
CD70 Signal zur Verfügung stellen, wodurch, trotz CD70 Gendefizienz in 
hämatopoetischen Zellen, über CD27-CD70 Interaktionen wichtige Überlebenssignale 
an die sich entwickelnden Tregs vermittelt werden. Daher ist die verstärkte 
Atheroprogression in globalen CD70-defizienten Mäusen – neben den beschriebenen 
Effekten auf Makrophagen - auch einer Beeinträchtigung der Treg Entwicklung 
zuzuschreiben, welche sich in einer systemischen Reduktion dieser Zellen 
niederschlägt. Überdies führt die globale Defizienz an CD70 zu einer erhöhten 
Konzentration oxidierter low-density lipoprotein Partikel-reaktiver Antikörper im Plasma, 
welche als pro-atherogen gelten. Fortgeschrittene Stadien der Atherosklerose scheinen 
weder durch CD27- noch durch CD70-Defizienz beeinflusst zu sein. 
Zusammenfassend weisen CD27 und CD70 atheroprotektive Mechanismen auf, die 
besonders in der frühen Phase der Atherosklerose von Bedeutung sind. In späteren 
6 ZUSAMMENFASSUNG 
 
93 
Phasen scheinen andere Mechanismen zu greifen und die Rolle von CD27 und CD70 
rückt in den Hintergrund. 
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schneiden. Lieber Tobi, liebe Geli, ich bin immer noch froh nach unserem Ski-Ausflug 
ohne Tobi nach Hause gegangen zu sein . Die Zeit mit euch beiden war großartig, 
weil wir mehr oder weniger zur selben Zeit hier losgelegt haben und zusammen 
„erwachsen“ geworden sind. Danke euch beiden für alles. Im Speziellen hier auch 
nochmal ein großes Dankeschön an Svenja, mit der ich viele Projekte, lustige 
Momente, großartige Konversationen und auch Leidenszeiten in München und 
Amsterdam geteilt habe. Ich bin froh, dass du zu der CD27/CD70/GITR Truppe 
gestoßen bist. Ein großes Dankeschön natürlich auch für das Korrekturlesen dieser 
Arbeit. 
 
Next, I would like to thank all the current and past members of Esther’s group in 
Amsterdam and in Maastricht (especially Linda, Tom, Esther S., Anett, Myrthe, and 
Erwin) and Jan from Menno’s group. Without you this work would not have been fully 
accomplishable. Thank you for working with me on all these long-lasting projects. 
Linda, you have been a great help through all these years. Thank you so much, 
especially trying to rescue those flattened arches . Erwin, it has been sometime that 
you introduced flow cytometry to me in a 2-week intense course. During this period, I 
think my head was on fire and my liver on heavy duty. By now, I can’t even tell how 
many hours of my life I spent in front of our Canto. 
 
Dear Dirk, lustiger Holzhackerbub, the time I spend working with you was absolutely 
fantastic. It all started in Aachen with a memorable first impression in your fancy 
sweater and red chinos. Only a few years later, you are dressed in leather chaps 
“performing” Mr. Boombastic. Who could tell would have happened without my 
backup? Too bad you left too early for a “serious” job. I will never forget our skiing trip 
where pure confidence met ignorance (“Move b****”). We had absolutely fantastic times 
at our Stammtisch and especially in the football stadium a couple of years ago. Some 
of the most used expressions and idioms at our Abendbrotzeit stem from you (Plataten, 
Bonobonen; Aaaaabahhh, This is so bad, you can’t even clean a window with it; Life is 
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a…). Thank you for all the support, friendship, extensive nights on the roof terrace, and 
the good memories through all the years. 
 
This brings me to the next person I would like to mention. Dear Remco, thank you very 
much for all the support and friendship in the past years. Although we only recently 
shared projects, we always had great moments of nonsense conversations and 
laughter together. Thank you for teaching me a lot of Dutch expressions and idioms I 
never heard of, starting by the monkey and the sleeve, 3 kilo klopfend paars…. I will 
truly miss the outstanding conversations with you, Norbert, Martin and Dirk spanning 
private life and future, but also including the more inappropriate and censored topics. 
Certainly, I am grateful that I could learn a lot about microscopy techniques and 
technical background regarding our equipment. Furthermore, you helped Mr. Mullet for 
a comeback not only by founding the mullets on tour competition but also proudly 
wearing the wig at a lot of occasions. But this passion about mullets is not very 
surprising since you are originating from New Kids land, Junge. And one of the biggest 
achievements, of course besides our Karoake performance, is seeing you being a 
bigger Christian Steiffen Fan than Martin, Norbert and I am by now. 
 
Lieber David, alten Schalker, dir möchte ich auch einen kleinen Abschnitt widmen. 
Vielen Dank für die großartige Zeit, die wir im und nach dem Labor verbracht haben. 
Mit dir hatte ich ein paar intensive Laborwochen, gekrönt von einem der intensivsten 
Oktoberfestbesuche. Wer hätte gedacht, dass der Besitzer des Slayermobils 
gleichzeitig alle Heino Songs auswendig kennen würde? Ich habe es immer noch in 
meinem Hinterkopf als du in Aachen mal sagtest: „Egal was du tust, nimm bloß nicht 
das CD27/CD70 Projekt oder GITR, die sind verflucht!!!!“ Haha, daran habe ich öfters 
während der letzten 5 Jahre denken müssen, obwohl ich als Wissenschaftler 
NATÜRLICH nicht an Flüche glaube. Dennoch bin ich sehr froh über die Entscheidung 
an den drei Projekten gearbeitet zu haben und: Ende gut, Alles gut!. Auch wenn wir 
uns über die Jahre immer nur kurz und manchmal unbewusst gesehen haben (wie z.B. 
bei Rock am Ring) werde ich die Zeit nicht vergessen.  
 
Lieber Schmitti, nach dem ich jetzt schon die ganze Bande erwähnt habe, darfst du 
natürlich nicht fehlen. Seit 6 Jahren bist du nun vorwiegend Freund und dann Kollege. 
Ich weiß gar nicht, wo ich all die tollen Momente aufzählen soll, die wir erlebt haben. 
Ich fang trotzdem mal an. Neben dem besten Büro aller Zeiten in Aachen haben wir 
uns auch außerhalb vom Labor ordentlich rumgetrieben. Karneval, der Chiemsee rockt, 
Boschek ist verliebt (in Hamburg, und zwar nicht nur ins Dosenbier), die 
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Scherbenpolka, diverse Oktober/Herbst/Frühjahrs/Starkbierfestbesuche, Grillen bei 
euch daheim, Dropkick Murphys… Eine der größten Herausforderungen, die wir 
zusammen gemeistert haben, war die Gordon Konferenz 2015. Selten war eine 
Konferenz anspruchsvoller für Gehirn und Leber. Das anschließende Wochenende in 
Boston werde ich auch nicht vergessen, vor allem stillose Menschen im Beacon Hill 
Pub. Ich weiß nicht, wo ich mich nur bei dir und Yvonne bedanken soll für alles, was ihr 
für mich getan habt, innerhalb und außerhalb des Labors. Vielen Dank für eure 
Freundschaft. 
 
Liebe Helene, dein Weggehen nach Amsterdam hat schon eine große Lücke hier 
zurückgelassen. Wir haben viel erlebt in der Zeit in Aachen und München, nicht nur 
während der Arbeit, aber überwiegend auch danach. Ich bin froh um jede einzelne 
Geschichte, die ich mit dir erleben durfte (Junggesellenabschied der Engländer fällt mir 
da spontan ein). Umso schöner fand ich es, dass ich dich regelmäßig in Amsterdam 
besuchen konnte und immer einen Schlafplatz auf deiner Couch hatte. Danke für alles, 
deine Unterstützung und Hilfe, aber vor allem für deine Freundschaft, die mir wirklich 
viel bedeutet. Und natürlich hier auch lieben Dank für das Korrekturlesen! 
 
An dieser Stelle möchte ich mich bei allen anderen Kollegen und Kolleginnen am 
Institut bedanken, welche meinen Alltag und Erfahrungsschatz bereichert haben und 
für eine angenehme Arbeitsatmosphäre gesorgt haben. Ich habe sowohl 
wissenschaftlich als auch persönlich viel von euch gelernt. Bitte seht es mir nach, wenn 
ich euch nicht alle persönlich erwähne (stellvertretend seien hier genannt: die ganze 
AG Söhnlein, AG Döring….). Ein besonderes Dankeschön an alle Gartenhäusler 
(Verena, Sabine, He, Julian, Veit, Kathrin, Mariam, Yuanfang, Zhe, Markus, Sarajo, 
Chanyung) und speziell an Nada, Ann, Johan, Mariaelvy, Philipp, Janina, Carlos N., 
Carlos SR., Quinte, Petteri, Michael, Donato, Martina, Patti, Yvonne J., Larisa, Virginia, 
Mariam, Tanja, Michael und Zhen. Einige von euch kenne ich noch aus Aachener 
Zeiten, Amsterdam oder von den ersten Tagen in München. Ihr alle habt definitiv 
meinen Alltag hier bereichert und ich bin dankbar für alles, was ich mit euch während 
der Arbeit und auch außerhalb erleben durfte. Auch hier seien mal wieder diverse 
Oktoberfest- und Starkbierfestausflüge erwähnt. Vielen Dank, Michael, für die vielen 
Stunden mit mir am Sorter. 
 
Liebe Manu, ich muss immer wieder an die Illertaler Inzester, Kool Savas und die 
anfängliche Kellerzeit zurückdenken, als Jürgen und Klaus noch neben uns saßen. 
Klaus, Danke für deine Weisheit/en (wie versprochen), they made my day. Du warst 
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hier in München neben Helene eine Konstante und diverse Wochenenden/Wochentage 
musste die Feierwut kuriert werden. Passend dazu fällt mir gerade der Tag ein, an dem 
ich in 2011 meinen Vertrag hier unterschieben habe. 
 
Liebe Janina, ich hoffe du findest demnächst auch ohne mich die richtigen 
Tastenkombinationen (und mal einen anderen Klingelton). Vielen Dank für all die 
Gespräche mit dir und deine positive Ausstrahlung, ich habe oft herzhaft gelacht.  
 
Lieber Xavier, mittlerweile kannst du so gut Deutsch, da brauche ich den Abschnitt gar 
nicht zu übersetzen. Vielen Dank für die vielen Serien und die vielen großartigen 
Unterhaltungen über politische, alltägliche, zensierte aber auch wissenschaftliche 
Themen. Du hast ein großartiges biochemisches Wissen und bist immer hilfsbereit. 
Man kennt dich auch als wandelndes Inventar des Gartenhauses und ohne dich wäre 
wohl nicht nur ich manchmal Stunden damit beschäftigt gewesen, diverse Chemikalien 
zu suchen. Vielen lieben Dank für das Durcharbeiten meiner Doktorarbeit und das 
auch noch unter etwas Zeitdruck. Du magst genauso wie ich etwas härtere 
Gitarrenmusik, wobei ein Großteil deiner Lieblingsmusik bzw. Albumcover mir eher 
etwas Angst einflößen . 
 
Weiterhin möchte ich bei unserem Sekretariat (Frau Bretzke, Frau Stöger und Frau 
Herrle) für die Unterstützung bei der Bewältigung der Bürokratie bedanken. Ein 
herzliches Dankeschön an das Personal der zentralen Versuchstierhaltung, welche 
einen wichtigen Beitrag zu dem tierexperimentellen Teilen dieser Arbeit beigetragen 
haben.  
 
Ein großes Dankeschön geht an Thomas Brocker, Ludger Klein und allen anderen 
Mitgliedern des SFB1054, welcher mich und meine Arbeit finanziell unterstützt hat und 
es mir ermöglichte an diversen Kongressen teilzunehmen. Als Mitglied des SFB1054, 
der implementierten IRTG und als deren Sprecher war es mir möglich an vielen 
Retreats, Vorlesungen, Symposia und Seminaren teilzunehmen. Weiterhin habe ich 
dadurch sehr viele Wissenschaftler mit unterschiedlichsten Forschungsfeldern aus der 
ganzen Welt kennenlernen dürfen, wodurch sich mein berufliches aber auch privates 
Umfeld vergrößert hat. 
 
An dieser Stelle vielen Dank an alle aktiven und ehemaligen Mitglieder der IRTG, 
besonders aber an dreimal Julia (Winnewisser, von Rohrscheidt, Maul), Christopher, 
Tobi, Maria, Valentin, Fabi, Domi, Isabel und Torben. 
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Im Speziellen bin ich aber dankbar Markus, Julia, Steffi und Andrea kennengelernt zu 
haben und zu meinen Freunden zählen zu dürfen. Ohne euch wäre mein Leben in 
München eindeutig langweiliger and farbloser gewesen. Danke, dass ich durch euch 
die Leute der Steinheil-WG und alle assoziierten „Mitbewohner“ (Holger, Vroni, Steffi, 
Domi, Joost, Andi, und so viele mehr) kennengelernt habe. Die Partys bei euch waren 
legendär. Ich glaub, daher war ich auch immer einer der letzten der gegangen 
ist/gehen musste . Aber neben euren Partys zur vorgerückten Stunde in Oldschool 
HipHop Sessions hosted by Andi und Holger geendet sind gab es noch so viele tolle 
und unvergessliche gemeinsame Abende, Oktoberfestbesuche und natürlich 
Klangtherapiestunden. Vroni, ich hoffe du kannst auch ohne mich/Keile die Band 
weiterführen . 
Markus, ich bin mehr als froh, dass du mich mal zur Bergkichweih mitgenommen hast. 
Gut, dass wir zur Erinnerung ein Video dort gedreht haben, welches schon 
internationalen Bekanntheitsgrad hat. 
Andrea, you old, Italian Viking. Rockavaria (YEAH \m/) with you was awesome and I 
am looking forward to the Boss and Highfield with you. The time I spent with you, 
Markus (and of course everyone else of the Steinis) was absolutely fantastic, 
particularly the boys out nights. 
Ich werde euch und das Drumherum sehr vermissen. 
 
I am deeply grateful to Prof. Ulrich von Andrian and his group in Boston for the 
outstanding lab exchange. Dear Uli, Mario, Aude, Carmen Ira, Scott, David, Susi, 
Lauren, and Guiying, thank you so much for the great experience I had staying in your 
lab. I learned so much from and working with you in this extraordinary environment. It 
definitely broadened my horizon. Furthermore, I am absolutely thankful for getting to 
know other members of the immunology department, especially Pete and Jennifer, 
Amy, Jernej, Virkam, Dimitry, Jon, and Dan, which absolutely contributed to my 
wonderful experience in Boston. I am still accounting 2nd place for the best costume at 
my first Halloween party at the immunology department’s beer hour a major 
achievement. It was great having some of you visiting me in Munich. Hope to see you 
guys soon again. I would also like to thank Gunilla, Jimmy, Flavio, Mike and the 
German bunch of Bostonians (Nadja, Ryan, Thomas, Lary, Christian and Juhee). I 
really appreciated living with you, Gunilla and Jimmy, in the most unusual and anti-
posh/establishment household in Brookline. I can’t even remember how many funny 
conversations I witnessed and participated in and how often Jimmy had to cool his jets. 
It was absolutely fantastic.  
8 ACKNOWLEDGEMENTS 
 
114 
Thank you, Flavio and Mike for all the time we spend together not only in Boston, but 
also in Munich. It was absolutely great having you here and I am blessed having you as 
friends. Thank you all so much for everything, these were memorable and for me 
unforgettable times.  
 
Lieben Dank für die großartige Zeit, Lisa und Loll, nicht nur auf dem Chiemsee 
Festival. Ohne euch hätte ich Tobi, Katja und Tanja nie kennengelernt, keinen 
Donnerstags-Stammtisch gehabt und das IPEK wäre wohl um eine unvergessliche 
Weihnachtsfeier in Tobis Küche ärmer. 
 
Liebe/r Timo, Thomas, Pati, Elke und Anette, ich bin sehr froh euch kennengelernt zu 
haben. Auch wenn wir uns während all der Jahre immer wieder nur sporadisch 
getroffen haben und das durch die halbe Welt verstreut, war es jedes Mal großartig. Ich 
hoffe sehr, dass wir das beibehalten. 
 
Liebe Henny, vielen Dank für alles, was du für mich getan hast. Ich bin dankbar, dass 
du Teil meines Lebens bist, auch wenn die Zeiten nicht immer einfach und geradeaus 
waren. Ich habe viel von dir und durch dich für mein Leben und auch über mich gelernt. 
An dieser Stelle gilt mein Dank euch, liebe/r Ingo, Mat, Claus, Peter und Silke. Danke 
für die gute Zeit, die wir gemeinsam hatten. 
 
Fast zum Schluss möchte ich all meinen Freunden aus Aachener Zeiten (unter 
Anderem Boschek, Calculon, Pöpe, Sunshine, Alex H., Fahri, Zutter, Eileen, Dave, 
Präsident, Tobi, Andrea, Eve, Aline, Jule, Marianne, Sonja, Anne) und dem Gillrather 
Jugendheim (Tööf, Kathrin, Pietisch, Niki, Hausi, Alyssa, Michael und Verena, Stiff, und 
viele, viele mehr) danken. Wir haben unfassbar viel erlebt (Zandvoort, unseren 
Stammtisch, den Keller des Todes, Breslau, Karneval in Köln, Karnevalsumzüge mit 
eigenem Wagen, Oktoberfest, Hochzeiten, Geburten, Rock am Ring, Rocco del 
Schlacco, Mainacht, die Vorbereitungen zur Mainacht, Tööf Rock, 30ste Geburtstage, 
Jaya the Cat Konzerte, WM, EM, Alemannia-Spiele in der ersten Liga, Biopartys, 
Fussballauswärtsspiele, Mayonnaise im Haar, …) alles hier aufzuführen würde 
sicherlich den Rahmen sprengen und ein eigenes Buch füllen. Leider muss ich euch 
etwas enttäuschen, ich habe nie an einem Zombie-Killer-Virus geforscht. Der 
Rasenmäher kann noch im Schuppen bleiben. 
Danke, dass ihr all die Jahre für mich da wart. Kurzum, ich bin euch für jeden einzelnen 
Moment dankbar und ich bin froh solche Freunde wie euch in meinem Leben zu haben. 
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Die letzten Zeilen möchte ich meinem Bruder Torsten und meinen Eltern, Heinz-Josef 
und Annette, widmen. Diesen Abschnitt zu schreiben ist mir besonders schwer 
gefallen, weil ich nicht weiß, wo ich überhaupt anfangen soll. Ihr habt mich immer 
bedingungslos unterstützt und aufbauende, aufmunternde Worte gefunden, wenn es 
gerade bei der Doktorarbeit oder auch so mal nicht lief. Wenn nötig habt ihr den langen 
Weg auf euch genommen und seid mir zur Hilfe nach München geeilt. Viel schöner 
aber war es euch hier einfach so zu Besuch zu haben. Ohne euch, eure Fürsorge und 
Unterstützung wäre mein derzeitiger und zukünftiger Werdegang nicht möglich. Bald 
wird ein weiteres Kapitel aufgeschlagen und das wird mich noch etwas weiter weg 
führen. Dennoch werde ich eins sicherlich nicht vergessen: eure Tür hat schon immer 
für mich immer offen gestanden und bei euch ist zu Hause. Home is where the heart is! 
Euch gebührt mein größter Dank!  
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